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ABSTRACT    
 
Background: The metabolic syndrome (MetS) is a cluster of risk factors associated with an increased risk of 
developing chronic diseases of lifestyle, and has more recently been associated with cancer risk. Currently, the 
pathophysiology of the MetS and cancer risk is still unknown; however it is proposed to involve several factors. These 
include the effects of body composition (android and gynoid shapes), and insulin resistance on the bioavailability of 
growth factors, inflammatory markers and sex hormone profiles. Various anthropometrical measurements have been 
used to investigate body composition, however, due to their limitations, a new metric namely a body shape index 
(ABSI) has been proposed to be a better measure of fat distribution and body shape. 
Aims: To determine the prevalence of the MetS, and the possible risks of developing cancer in relation to metabolic 
status, body composition, growth factors as well as inflammatory and sex hormone parameters. 
Methods: Female participants between the ages of 20-60 years were classified according to the International Diabetes 
Federation’s (IDF) definition of the MetS and according to body shape (android/gynoid) by photoscopic somatotyping. 
A series of tests and assessments were conducted; such as blood pressure assessments, anthropometric measurements, 
bioelectrical impedance analyses (BIA) and blood analyses. Blood analysis included fasting glucose, fasting insulin, 
lipid profile, insulin-like growth factor-1 (IGF-1), inflammatory marker (C-reactive protein (CRP)); and sex hormone 
parameters (oestrogen, female testosterone, sex hormone binding globulin; and free androgen index). 
Results: The prevalence of the MetS was found to be 57.5 %; with abdominal obesity (73.8 %), elevated blood 
pressure (BP, 68.8 %) and low high density lipoprotein-cholesterol (HDL-c) levels (68.8 %) being the more prevalent 
risk factors. Both metabolic status; and body shape alone were found to be predictors influencing anthropometric, BIA, 
physiological and biochemical blood parameters. Metabolic status was found to have an effect on several parameters in 
the gynoid body shape groups, i.e. body mass (BM) (p<0.001), hip circumference (HC) (p<0.01), body mass index 
(BMI) (p<0.001), fat mass (FM) (%) (p<0.01), fat free mass (FFM) (%) (p<0.01), waist circumference (WC) 
(p<0.001), HDL-c (p<0.001), triglycerides (TG) (p<0.05), systolic blood pressure (SBP) (p<0.05) and diastolic blood 
pressure (DBP) (p<0.01), while metabolic status showed an effect on BM (p<0.001), BMI (p<0.01), TG (p<0.05), SBP 
(p<0.01) and DBP (p<0.01) in the android body shape groups. Both metabolic status and body shape did not show any 
effect on ABSI, total cholesterol (TC), low density lipoprotein-cholesterol (LDL-c), fasting insulin, CRP and all sex 
hormone parameters. Correlation analyses revealed significant correlations for several anthropometric, BIA and blood 
parameters. 
Conclusion: This study showed that metabolic status, body shape and/or both could predict changes in various body 
composition, physiological and biochemical parameters in women. However, no effects were evident for any 
parameters linking the MetS to cancer risk. Thus, no accurate conclusion could be drawn regarding the 
pathophysiology. Our findings on ABSI, still warrants future investigation to substantiate the use of this metric in 
relation to the MetS, body shape and cancer risk. 
 
Key words: Metabolic syndrome, body shape, cancer 
 





Agtergrond: Die metaboliese sindroom (MetS), wat bestaan uit ‘n groep risiko faktore wat met ŉ toename in die 
ontwikkeling van chroniese lewenstyl siektes geassosieër word, is onlangs ook met kanker geassosieër. Tans, is die 
patofisiologie van die MetS en kanker risiko onbekend; hoewel dit moontlik verskeie faktore kan insluit. Hierdie 
faktore sluit onder andere in; liggaamsamestelling (androïede en genoïede vorme), asook insulienweerstandigheid en 
die biobeskikbaarheid van groei faktore, inflammatoriese merkers en geslagshormoon profiele. Verskeie 
antropometriese metings word gebruik om liggaamsamestelling te bepaal, maar as gevolg van beperkinge, word ŉ 
nuwe maatstaf, naamlik die liggaamsvorm indeks (LVI) voorgestel as ŉ beter meting om vet verspreiding en 
liggaamsvorm te beskryf. 
Doelwitte: Om die voorkoms van die MetS, en die moontlike risiko vir die ontwikkeling van kanker wat verwant is 
aan die MetS, liggaamsamestelling, groei faktore, asook inflammatoriese en geslagshormoon parameters te bepaal. 
Metodes: Vroulike deelnemers tussen die ouderdomme 20-60 jaar is volgens die MetS definisie van die Internasionale 
Diabetes Federasie (IDF), asook die liggaamsvorme (androïed/genoïed) deur middel van fotoskopiese somatotipering, 
geklassifiseer. ŉ Reeks ondersoeke is gedoen insluitend bloeddruk, antropometrie, bio-elektriese impedansie (BIA), en 
bloed analises. Bloed analises het vastende glukose, insulien, lipied profiel, insulien-agtige groeifaktor-1 (IGF-1), 
inflammatoriese merker (C-reaktiewe proteïen (CRP)); en geslagshormoon parameters (estrogeen, vroulike 
testosteroon, geslags hormoon bindings globulien; en vry-androgeen indeks) ingesluit. 
Resultate: Die voorkoms van die MetS was 57.5 %; waaronder abdominale vetsug (73.8 %), verhoogde bloeddruk 
(BP, 68.8 %), en hoë digtheids lipoproteïen cholesterol (HDL-c) vlakke (68.8 %) die mees prevalente risiko faktore 
was. Beide die metaboliese status; en liggaamsvorm alleen, is as moontlike voorspellers geïdentifiseer wat die 
antropometriese, BIA, fisiologiese en biochemiese parameters aanbetref. Die metaboliese status het verder ŉ effek op 
verskeie parameters in die genoïede liggaamsvorm groep getoon, i.e. liggaamsmassa (LM) (p<0.001), heup omtrek 
(HO) (p<0.01), liggaamsmassa indeks (LMI) (p<0.001), vet massa (VM) (%) (p<0.01), vetvrye massa (VVM) (%) 
(p<0.01), middellyf omtrek (MO) (p<0.001), HDL-c (p<0.001), trigliseriede (TG) (p<0.05), sistoliese bloeddruk 
(SBD) (p<0.05) en diastoliese bloeddruk (DBD) (p<0.01), terwyl die metaboliese status ŉ effek getoon het op LM 
(p<0.001), LMI (p<0.01), TG (p<0.05), SBD (p<0.01) en DBD (p<0.01) in die androïede liggaamsvorm groep. Beide 
die metaboliese status en liggaamsvorm het geen effek op die LVI, totale cholesterol (TC), lae digtheids lipoproteïen 
cholesterol (LDL-c), vastende insulien, CRP en alle geslagshormoon parameters getoon nie. Betekenisvolle korrelasie 
analises is verkry onder verskeie antropometriese, BIA en bloed parameters. 
Gevolgtrekking: Hierdie studie toon dat die metaboliese status, liggaamsvorm, en/of beide veranderinge in verskeie 
liggaamssamestelling, fisiologiese en biochemiese parameters in vroue kan voorspel. Geen effekte is waargeneem vir 
enige parameter wat die MetS met kanker risiko kan verbind nie. Dus, kan geen akkurate afleiding gemaak word oor 
die patofisiologie hiervan nie. Ons bevindinge oor die LVI noodsaak verdere ondersoek met betrekking tot die MetS, 
liggaamsvorm en kanker risiko. 
Sleutelwoorde: Metaboliese sindroom, liggaamsvorm, kanker 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW
 
1.1 Introduction 
1.1.1 Metabolic syndrome and cancer  
Following, and adapting to a westernized lifestyle (unhealthy eating habits, dietary changes (nutrition 
transition), and decreased physical activity) has increased significantly in both developed and 
developing countries worldwide (Oggioni et al., 2014; Vorster et al., 2011). This in turn has 
contributed to an increase in the incidence of lifestyle diseases such as cardiovascular disease (CVD), 
diabetes mellitus (DM), and cancer (Tachang et al., 2012; WHO, 2014). Annually, lifestyle diseases 
contribute to 38 million deaths globally, with CVD estimated at 17.5 million deaths per annum, cancer 
at 8.2 million, and diabetes at 1.5 million deaths (WHO, 2014). Sub-Saharan Africa is currently 
experiencing an epidemiological transition, characterized by both a high incidence of infectious 
diseases and increased incidence of lifestyle-related diseases (Statistics South Africa, 2013).  
The metabolic syndrome (MetS), regarded as a major risk factor for chronic diseases of lifestyle, 
shows a global increase in the prevalence of the MetS annually (Kaur, 2014; O’Neill & O’Driscoll, 
2015). The MetS, consisting of a cluster of metabolic, physiological and biochemical risk factors, is 
independently associated with CVD, type 2 diabetes mellitus (T2DM), and has also recently been 
associated with certain cancers (Beltrán-Sánchez et al., 2013). Scientific evidence also links the MetS 
and its components as important risk factors for the development of various lifestyle cancers (Agnoli 
et al., 2010; Stocks et al., 2015). However, the pathophysiology and molecular mechanisms 
underlying the MetS, and cancer are still poorly understood and remain to be elucidated. Currently, 
evidence on the pathophysiology of the MetS and cancer development involves several factors which 
include insulin resistance (IR), inflammation, sex hormones and growth factors, as well as fat 
distribution. Obesity, specifically abdominal obesity, is implicated as the underlying factor in the 
development of IR, MetS and also more recently to cancer development (Mendonça et al., 2015; 
Sinicrope & Dannenberg, 2011).  
1.1.2 Anthropometry and body composition  
Increased weight, obesity, and fat distribution patterns, i.e. android and gynoid body shape, have been 
associated with an increased risk for developing metabolic-related diseases and cancer, especially in 
women (Ronco et al., 2008). Various anthropometric measurements have been used to investigate 
obesity and fat distribution. These typically include body mass index (BMI), waist circumference 
(WC), waist-to hip-ratio (WHR), and total body fat percentage (TBF %) (Eston & Reilly, 2009; 
Stewart & Sutton, 2012). However, due to limitations and discrepancies of these anthropometric 
measurements, a new metric, a body shape index (ABSI), have been proposed to assess the association 
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between fat distribution (body shape), and the risk of developing metabolic diseases and certain cancer 
types (Krakauer & Krakauer, 2012). Therefore, the use of appropriate anthropometric measurements 
may be helpful in identifying individuals with an increased non-communicable disease risk. 
LITERATURE REVIEW 
1.2 The metabolic syndrome  
1.2.1 History 
The MetS is a concept that has been around for more than five decades (Okafor, 2012). Kylin (1923) 
observed an association between hyperglycaemia, increased arterial blood pressure and gout. In 1965, 
Avogaro and colleagues provided a similar description of the syndrome (Avogaro et al., 1965). 
Almost 20 years later, Jean Vague described these factors, and its association with visceral obesity, 
and linked this with metabolic abnormalities found in CVD and T2DM (Vague et al., 1989; Vague, 
1996). During the late 1980’s, Reaven gave the famous Banting lecture, and although it was proposed 
that IR was the underlying factor of these metabolic abnormalities (referred to as Syndrome X), 
abdominal obesity was not included in this concept (Reaven, 1988). Currently, this concept is known 
as the MetS, a clinical term which remains the most widely used (Kaur, 2014; Okafor, 2012; Thaman 
& Arora, 2013). 
1.2.2 The metabolic syndrome and components 
The MetS is clinically described as a cluster of metabolic, physiological and biochemical risk factors 
that functions in an interconnected manner. This cluster of risk factors has been shown to increase the 
risk of developing cardiovascular-related dysfunction, T2DM, as well as all-cause mortality, both as a 
unit (Kassi et al., 2011; Kaur, 2014), as well as independently (Beltrán-Sánchez et al., 2013). The 
MetS risk factors are typically described in terms of body dimensions, blood lipid profiles, blood 
pressure, blood glucose homeostasis, and can also include inflammatory and pro-thrombotic profiles 
depending on what definition of the syndrome is used (Kaur, 2014; Thaman & Arora, 2013). The main 
components of the MetS (Figure 1.1) includes, obesity (specifically abdominal obesity), dyslipidaemia 
(increased triglycerides (TG), low density lipoprotein cholesterol (LDL-c), Apo-lipoprotein and 
decreased high density lipoprotein-cholesterol (HDL-c)), increased arterial blood pressure (systolic 
and diastolic), IR and impaired blood glucose homeostasis (Alberti et al., 2009; Després et al., 2008; 
Kassi et al., 2011; Kaur, 2014; Okafor, 2012).  




Figure 1.1: Main components of the MetS. 
(Adapted from Després et al., 2008; Okafor, 2012)  
 
Other physiological factors such as pro-inflammatory markers, pro-thrombotic markers, sleep apnea, 
and non-alcoholic fatty liver disease, have also been considered, adding to the complexity of the MetS 
(Alberti et al., 2009, Kassi et al., 2011; Kaur, 2014; Okafor, 2012). Abdominal obesity and IR have 
been implicated as the primary factors in the development of the MetS. However, due to the 
complexity of the MetS, there is still no unifying definition which clearly defines the MetS and its 
diagnostic criteria (Kassi et al., 2011), since different definitions of the MetS exist.  
1.2.3 Definitions  
Table 1.1 summarizes the different definitions of the MetS available to date. During 1998, the World 
Health Organization (WHO) defined the MetS by including IR, impaired glucose tolerance, or the 
presence of T2DM in their definition (Alberti & Zimmet, 1998). This, in combination with two or 
more of the other defined criteria, finalized their definition of the MetS (Alberti & Zimmet, 1998). A 
year later, the European Group for the Study of Insulin Resistance (EGIR) discarded the use of micro-
albumin as criteria for the MetS, and instead added hyperinsulinaemia (Balkau & Charles, 1999). The 
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Table 1.1 Different metabolic status definitions and defined criteria 
Criteria  WHO EGIR NCEP-ATPIII AACE AHA/NHLBI IDF JIS 
Definition 
T2DM/ IFG/ 
IGT/IR and or     
≥ 2 of the other 
criteria 
T2DM/ IFG/ 
IGT/IR and or     
≥ 2 of the other 
criteria 




any 2 of the 
other criteria 
≥ 3 of 5 criteria, 
does not consider 
IR 
Central obesity 
plus ≥ 2 of the 
other criteria 
≥ 3 of 5 
criteria, does 
not consider IR 
Diabetes Yes No Yes No Yes Yes Yes 
Glucose 
measurements 
IGT, IFG or 
T2DM 
FPG: ≥ 6.1 
mmol/L 
FPG: ≥ 6.1 
mmol/L 
FPG: ≥ 6.1 
mmol/L 
FPG: ≥ 5.6 mmol/L 
or on diabetes 
treatment 
FPG: ≥ 5.6 mmol/L 
or T2DM diagnosis 
FPG: ≥ 5.6 








IR or Insulin 
levels > 75th 
percentile 
NA NA NA NA NA 
Anthropometry  
WHR: > 0.90 
men & > 0.85 
women  
BMI: ≥ 30 kg/m2 
men & women 
WC: ≥ 94cm 
men & ≥ 80 cm 
women 
WC: >102 cm 
men & > 88 cm 
women 
BMI: ≥ 25 
kg/m2 men & 
women 
WC: ≥ 102 cm 


















≥ 1.7 mmol/L 
and or HDL-c 
≥ 1.7 mmol/L 
and or HDL-c 
≥ 1.7 mmol/L 
and or HDL-c 
≥ 1.7 mmol/L 
and or HDL-c 
≥ 1.7 mmol/L and 
or HDL-c 
≥ 1.7 mmol/L or 
on TG treatment 
and or HDL-c 
≥ 1.7 mmol/L 
and or HDL-c 
HDL-c 
< 0.90 mmol/L 
men & < 1.00 
mmol/L women 
< 1.00 mmol/L 
men  & women 
< 1.03 mmol/L 
men & < 1.30 
mmol/L women 
< 1.03 mmol/L 
men & < 1.30 
mmol/L women 
< 1.03 mmol/L 
men & < 1.30 
mmol/L women 
< 1.03 mmol/L 
men &  
<1.30mmol/L 
women or on 
HDL-c treatment 
< 1.03 mmol/L 
men & < 1.30 
mmol/L women 




≥ SBP 140, DBP 
≥ 90 mmHg 
≥ SBP 140, 




≥ SBP 130, 
DBP ≥ 85 
mmHg 
≥ SBP 130, 
DBP ≥ 85 
mmHg 
≥ SBP 130, DBP 
≥ 85 mmHg 
≥ SBP 130, DBP 
≥ 85 mmHg or on 
hypertension 
treatment 
≥ SBP 130, 







20 μg/min or 
albumin creatine 
≥ 20 μg/min or 
NA NA 
Other feature of 
IR based on 
clinical 
judgment 
NA NA NA 
(Adapted from: Alberti & Zimmet, 1998; Alberti et al., 2009; Balkau & Charles, 1999; Einhorn et al., 2003; Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001; Ford et al., 2010; Grundy et al., 2004; IDF, 2006) 
 
During 2001, the National Cholesterol Education Program-Adult Treatment Panel (NCEP-ATPIII) 
proposed new cut-off values for WC, blood lipid profiles, arterial blood pressure, and fasting blood 
glucose (Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 
2001). In contrast to the WHO and EGIR, the NCEP-ATP III excluded IR as diagnostic criteria due to 
the cost and difficulty of implementing gold standard tests for IR in a clinical setting.   
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The American Association of Clinical Endocrinology (AACE) published a set of criteria (Einhorn et 
al., 2003), which was followed by a publication from the American Heart Association (AHA) and the 
National Heart, Lung, and Blood Institute (NHLBI) in 2004 (Grundy et al., 2004). In 2005, the 
International Diabetes Federation (IDF) published an updated set of criteria, in an effort to serve as a 
universal diagnostic tool in both a clinical and research setting (IDF, 2006). In this definition, 
abdominal obesity was included as the primary diagnostic criteria since body weight and WC 
differences exist between populations, different ethnic groups and individuals with different 
nationalities (IDF, 2006) (see Table 1.2). These differences therefore need to be taken into 
consideration when determining the presence of the MetS. 
Table 1.2: IDF: Ethnic-specific values for waist circumference 
Ethnic Background  Men Women 
Europeans  ≥ 94 cm ≥ 80 cm 
South-Asians ≥ 90 cm ≥ 80 cm 
Chinese  ≥ 90 cm ≥ 80 cm 
Japanese  ≥ 90 cm ≥ 80 cm 
South and Central Americans 
Use South- Asian values 
≥ 90 cm ≥ 80 cm 
Sub-Saharan Africans 
Use European values 
≥ 94 cm ≥ 80 cm 
Eastern Mediterranean and middle east 
populations  
Use European values 
≥ 94 cm ≥ 80 cm 
(Adapted from: Alberti et al., 2009; IDF, 2006)  
In 2009, a joint interim statement (JIS) was published by the IDF, AHA/NHBLI, World Heart 
Federation (WHF), International Atherosclerosis Society (IAS), and the International Association for 
the Study of Obesity (IASO) (Alberti et al., 2009). This definition still comprised of the main 
components of the MetS, but does not declare that any of the components are required for diagnostic 
properties of the MetS (Alberti et al., 2009). 
Therefore, although the different definitions agree on the core components of the MetS (obesity, IR, 
dyslipidaemia, hypertension and high blood glucose), there are several discrepancies between these 
definitions, which complicates the comparability of different studies, as well as to define cut-off 
values for different populations (Kaur, 2014). The most widely used definitions are those formulated 
by the IDF and NCEP-ATPIII, which include central obesity, while the AACE, WHO and EGIR’s 
definition focused more on IR (Huang, 2009).  
Definitions using IR as a criterion (WHO & EGIR) are criticized by the fact that the gold standard 
method (hyperinsulinaemia-eugycaemic clamp) to test for IR cannot be implemented as a routine test, 
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due to the fact that it is time consuming, costly, and labor intensive (Abdul-Ghani et al., 2007; Okafor, 
2012). Conversely, definitions that do not include IR (NCEP-ATPIII, ACCE, IDF and JIS) can be 
easily implemented in a routine clinical setting (Huang, 2009; Okafor, 2012). More specifically, a 
study showed that the use of the NCEP-ATPIII, IDF and ACCE definitions are more useful that those 
definitions which require IR, since more individuals are clinically identified with the MetS, IR and at 
risk for CVD (Can & Bersot, 2007). However, the use of the WHO and NCEP-ATPIII is problematic 
in terms of their applicability to different countries and ethnic groups especially in determining obesity 
cut-off values (Kassi et al., 2011). 
Although different definitions have been proposed which highlights some discrepancies, the MetS is 
still recognized as a global epidemiological health problem which is fueled by an increase in sedentary 
lifestyles and unhealthy diets (Tachang et al., 2012).  
 
1.2.4 Epidemiology  
The epidemiology of the MetS is topical due to a lack of consensus in defining the syndrome, the 
components of the syndrome itself, and the specific cut-off values for different countries and cultures 
(Kaur, 2014). In order to determine the prevalence of the MetS, the definition used, sample size, the 
region of interest, the population being studied (i.e. gender, age, and ethnicity), as well as the type of 
environment (i.e. urban or rural) should all be taken into consideration (Prasad et al., 2012). Other 
factors have also been proposed to play a role in the epidemiology of the MetS. This includes socio-
economic status, sedentary lifestyles, level of physical activity and genetic factors (Popkin et al., 
2012) 
Regardless of the MetS definition and cut-off values used, as well as the impact of various factors 
associated with the MetS, the prevalence of the MetS is significantly high and is on the rise in most 
populations around the world (Beltrán-Sánchez et al., 2013; Bhanushali et al., 2013; Cameron et al., 
2007; Emem-chioma & State, 2008; Erasmus et al., 2012; Hu et al., 2004; Lim et al., 2011; Motala et 
al., 2011; Prasad et al., 2012; Tran et al., 2011).  
1.2.4.1 Global prevalence of the MetS  
Globally, the prevalence of the MetS is estimated to range between less than ten percent to 62 % (see 
Table 1.3). This increase in the MetS prevalence has also been exacerbated by the increasing incidence 
of obesity (WHO, 2014). Epidemiological studies in the United States of America (USA) found that 
the prevalence of the MetS ranged between 20-40 % as a function of gender, and also depending on 
the definition used (Beltrán-Sánchez et al., 2013; Bhanushali et al., 2013). Bhanushali et al. (2013) 
found that the MetS was more prevalent in women compared to men (39.4 % vs 26.8 % respectively) 
using the NCEP-ATPIII definition. This higher prevalence amongst the women can be explained by 
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the fact that certain risk factors are more prevalent in women than men, such as abdominal obesity and 
HDL-c levels (Bhanushali et al., 2013). 
Beltrán-Sánchez et al. (2013) found that a fifth of the USA population remained at a high risk for 
cardio-metabolic diseases. Also, even though the MetS prevalence decreased significantly over time 
from 25.5 % between 1999-2000, to 22.9 % between 2009-2010 (p=0.024), a fifth of this population 
still presented with the MetS, since they still exhibited at least three to five of the MetS risk factors. 
Furthermore, this study found gender and racial differences, i.e. white men had a higher prevalence of 
abdominal obesity vs their other racial counterparts and black women had a higher prevalence of 
elevated blood pressure (Beltrán-Sánchez et al., 2013).  
A European study which included data from 11 European study cohorts (n=11507 individual data sets; 
n=6151 men and n=5351 women) reported an overall prevalence of between 6.3-29.9 % in women vs 
7.7-35.5 % in men depending on the definition used (Hu et al., 2004). However, when the authors 
used a modified version (hyperinsulinaemia was added, and micro-albumin was excluded) of the 
WHO definition for the MetS, they found that the prevalence increased in both men (15 %) and 
women (14.2 %) (Hu et al., 2004). This study further showed that the prevalence of the MetS changed 
with the addition of more risk factors to the definition. Additionally, Hu et al. (2004) also found that 
the prevalence of the MetS (as defined by the WHO) was associated with a 1.4 fold increase in the risk 
of all-cause mortality in both genders, as well as a 2.3 fold increase in the risk for CVD mortality in 
men, and 2.8 fold in women. A Korean study showed increased MetS prevalence from 24.9 % in 1998, 
to 31.3 % in 2007 (Lim et al., 2011). 
Similar results were observed in a study by Prasad et al. (2012), where 33.5 % of an Indian population 
presented with the MetS. The MetS in this population also differed in terms of gender, with a higher 
prevalence seen in women vs men (42.3 % vs 24.9 % respectively). In addition, those individuals 
classified as having the MetS, lead a sedentary lifestyle, had low fruit intake, were obese, presented 
with abdominal obesity and displayed increased TG and LDL-c levels (Prasad et al., 2012).   
An Australian study by Cameron et al. (2007) included the WHO, EGIR, NCEP-ATPIII and IDF 
definitions to determine the prevalence of the MetS (Cameron et al., 2007). They found that the 
prevalence of the MetS ranged between 13.4-30.7 % depending on the definition used, i.e. WHO (21.7 
%), EGIR (13.4 %), NCEP-ATPIII (22.1 %), and IDF (30.7 %) respectively. They also showed that 
the prevalence of the MetS increased with an increase in age for all the definitions used, and that the 
prevalence was greater in men than women irrespective of which definition was used (Cameron et al., 
2007). 
Irrespective of the definition used, and what region of the world the MetS is investigated in, the 
prevalence of MetS is high with distinct gender and ethnic differences. This is worrying, especially 
since the MetS may be well studied in some regions of the world, which is not the case for Africa. 
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This therefore indicates that more studies investigating the MetS, especially in the South African 
continent, are needed in order to fully understand the potential burden of the MetS and its associated 
health risks.  
1.2.4.2 African prevalence of the MetS  
Limited epidemiological data exists on the prevalence of the MetS on the African continent. This 
could largely be due to the lack of an African-applicable MetS definition (Okafor, 2012) and the fact 
that WC cut-off values, specific for African people have not yet been established (Motala et al., 2011). 
Most South African studies to date have been based on definitions and cut-off values derived from 
studies conducted in North-America, Europe and Asia (Miranda et al., 2005; Thaman & Arora, 2013; 
Tran et al., 2011). This in turn has implications of establishing a MetS definition that can be used in an 
African setting (Okafor, 2012). However, recent South African studies with a good representable 




The prevalence of the MetS in Africa is estimated to range between less than five percent and 18.5 % 
(see Table 1.3). Emem-chioma & State (2008) reported that approximately six percent of the 
participants presented with the MetS using the NCEP-ATPIII criteria. Furthermore, the men displayed 
a higher MetS prevalence when compared to women. In addition, abdominal obesity, hypertension and 
low HDL-c were all significant risk factors associated with the MetS in this population (Emem-chioma 
& State, 2008). Awosan and colleagues (2013) reported a third of the participants had central obesity 
or an increased WC. Additionally, although an overall 37.8 % had reduced HDL-c, 32.8 % had 
increased TG levels, and 31.9 % had high blood pressure, these percentages were higher in men. In 
this specific study, the overall prevalence of the MetS ranged between 17.8 and 18.5 % depending on 
the definition used. Furthermore, this study also highlighted the IDF definition as a much more 
sensitive definition of identifying the MetS in the included study participants (Awosan et al., 2013). 
An Ethiopian study found the overall prevalence of the MetS to be 12.5 % using the NCEP-ATPIII, 
and 17.9 % using the IDF definition (Tran et al., 2011). A significant increase in BMI and arterial 
blood pressure were more prominent in women than men, which suggests that women are at greater 
risk for the development of the MetS (16.2 vs 10.0 %, NCEP-ATPIII & 24.0 vs 14.0 %, IDF) (Tran et 
al., 2011).  
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Table 1.3: Prevalence of the MetS: Global to South Africa 
Author Country Total 
Metabolic syndrome definition 
MetS prevalence 
outcomes WHO EGIR 
NCEP-
ATPIII 
IDF JIS Other 
Bhanushali 
et al., 2013 
USA n= 1326   √    
More prevalent in women (39.43 








    √  Prevalence between 20-30 %. 





Modified     √ 
Prevalence between 7.7-35.5 % in 
men and 6.3-29.9 % in women, 
depending on definition used.  
Prasad et 
al., 2012 




Prevalence was high overall (33.5 
%), with a higher prevalence in 
women (42.3 %) vs men (24.9 %). 
Lim et al., 
2011 
Korea n= 6907   √    
Prevalence between 24.9-31.3 % 
from 1998-2007, thus a 6.4% 
increase in MetS. 
Cameron 
et al., 2007 
Australia n= 1326 √ √ √ √   
Prevalence between 13.4-30.7 % 




Nigeria n= 300   √    Prevalence of 6.3 %. 
Awosan et 
al., 2013 
Nigeria n= 270   √ √   
Prevalence between 17.8-18.5 % 
depending on definition. 
Tran et al., 
2011 
Ethiopia n= 1935   √ √   
Prevalence  between 12.5-17.9 % 
depending on definition 
Tachang et 
al., 2012 
Cameroon n= 147 √  √ √   
Prevalence between < 5-7.5 % 







n= 947   √ √ √  
Crude prevalence was 26.5% and 
age-adjusted prevalence between 







n= 588   √ √ √  
Prevalence between 55.4-62.0 % 
depending on definition. 








n= 1099     √  
Age-adjusted prevalence in women 
(44.9%) higher than men (17.3 %). 
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From all the studies cited in this section, the most prominent finding was that even though the 
African-based studies had smaller sample sizes in comparison to the international studies, the 
prevalence of the MetS was still considered relatively high. This is an important fact to consider, 
especially since the definitions and cut-off values used were derived from studies conducted in North-
America, Europe and Asia. In addition, the prevalence of individual components of the MetS was also 
high, suggesting that Africans may be at greater risk of developing the MetS and/or other metabolic 
related diseases in the future.  
1.2.4.3 South African prevalence of the MetS  
South Africa underwent several political changes, and with this came rapid and significant health 
transition. These changes were accompanied by lifestyle changes (nutrition transition, eating 
behaviour, changes in physical activity), all of which have been shown to significantly impact 
lifestyle diseases such as obesity and hypertension, and there for the MetS (Bourne et al., 2002; 
Erasmus et al., 2012; Steyn et al., 2012; van Zyl et al., 2012; Vorster et al., 2005; Vorster et al., 
2011). 
A study conducted in the Free-state province aimed to determine the risk profile of chronic lifestyle 
diseases and the MetS in an urban and rural setting (van Zyl et al., 2012). Here, a high prevalence of 
hypertension was reported in the rural community participants’, with fewer participants displaying a 
BMI higher than 25 kg/m
2 
in the urban community (53.0% vs 54.2 %) Obesity was also found to be a 
major problem in the women, particularly those from the rural community (57.6 % had a WC of  ≥ 
88cm and 43.1 % had a BMI of ≥ 30 kg/m2) (van Zyl et al., 2012). However, irrespective of whether 
the participants were from a rural/urban setting, a high prevalence of the individual MetS components 
were observed, especially in women. 
A cross-sectional study from the Ubombo district, KwaZulu Natal, determined the prevalence of the 
MetS in an apparently healthy rural African community (Motala et al., 2011). The overall prevalence 
of the MetS, depending on the definition used, differed, i.e. JIS (26.5 %), IDF (23.3%) and NCEP-
ATPIII (18.5 %), with an overall higher prevalence in women vs men. After adjusting for age, the 
prevalence was lower than that initially observed (JIS (22.1 %), IDF (19.2 %) and NCEP-ATPIII 
(15.0 %)). The JIS definition was also considered a more sensitive tool compared to the IDF and 
NCEP-ATPIII definitions respectively. Upon closer investigation of the individual MetS risk factors, 
approximately 65.2 % of women displayed low HDL-c levels, whereas 47.1% of men had elevated 
systolic blood pressure. The high prevalence of the MetS in the women of this study was proposed to 
be related to a higher prevalence of obesity (increased WC), a lack of physical activity as well as 
dietary-related factors (Motala et al., 2011). This study was also the first to suggest optimal WC cut-
off values for Africans (86 cm for men and 92 cm for women) (Motala et al., 2011).  
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A study completed in the Western-Cape reported that BMI, WC, arterial blood pressure, total 
cholesterol (TC) and HDL-c were significantly higher in women, while blood pressure and LDL-c 
were significantly higher in men (Erasmus et al., 2012). A similar pattern of the MetS prevalence was 
reported (depending on definition) to that of Motala et al. (2011). However, the overall prevalence of 
the MetS was significantly higher in this population; 62 % (JIS), 60.6 % (IDF) and 55.4% (NCEP-
ATPIII) respectively (Erasmus et al., 2012).  
More recently, a study by Peer et al. (2015
A
) found that the age-adjusted prevalence of the MetS in an 
urban black population in Cape Town was 44.9 % in women, and 17.3 % in men according to the JIS 
definition (Peer et al., 2015
A
). In addition, the most prevalent components of the MetS among women 
were central obesity (86 %) and low HDL-c (75 %), while in men, high blood pressure (51.4 %) was 
the main contributor overall. The prevalence found in this study was also much higher than that 
reported by Motala et al. (2011), which also made use of the JIS definition. They also showed that the 
prevalence of MetS increased with age. 
Another study by Peer et al. (2015
B
) reported optimal WC cut-off values based on a black population 
from Cape Town (83.9 cm men and 94 cm women) and verified the findings of Montala et al. (2011). 
However, these cut-off values differed from what was initially recommended for Africans (Alberti et 
al., 2009; IDF, 2006). The studies by Peer et al. (2015
B
) and Motala et al. (2011) therefore suggested 
that current WC cut-off values for Africans may require change or adaptations depending on the 
population used and the specific setting. The higher WC cut-off values in women highlights the 
importance of ethnic differences in body composition. Since, black women have less visceral adipose 
tissue (VAT) compared to white women, for a given WC (Sumner et al., 2011). In addition, South 
African studies have also shown that women have higher WC vs men (Erasmus et al., 2012; van Zyl 
et al., 2012). However, even though this may explain the higher WC cut-off values in women vs men; 
further investigation is required to support these findings. 
The studies considered in this section clearly emphasize the need for South Africans to recognize the 
burden of chronic lifestyle diseases. Evidence shows that the prevalence of the MetS is high in all 
regions of the world, including South Africa. Clear differences are seen with respect to different ages, 
ethnicity, gender, geographical area, as well as the MetS definition used. Furthermore, the prevalence 
of the MetS and its individual components are still high, especially in women. Previous evidence also 
shows that the MetS and its components increase the risk to not only develop CVD and T2DM, but 
also increases mortality (Kassi et al., 2011; Kaur, 2014).  
Experimental and cross-sectional studies now also link the MetS and its individual components to the 
development and progression of various lifestyle cancer types (Donohoe et al., 2011; O’Neill & 
O’Driscoll, 2015; Zhu et al., 2010). 
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1.3 Pathophysiology of the metabolic syndrome and the link to cancer 
1.3.1 Introduction  
Emerging evidence links the MetS and its components as important risk factors, in addition to 
traditional lifestyle risk factors, for the development of various cancer types (O'Neill & O'Driscoll, 
2015) (Figure 1.2). Traditional lifestyle-associated cancer risk factors include dietary factors, 
addictive substances, and low physical activity levels (WHO, 2009; WHO, 2014). Dietary 
components, for example increased fat, salt, refined sugar, and processed and red meat intake have all 
been strongly associated with an increased risk of developing cancer at different anatomical sites (Lee 
& Derakhshan, 2013). This is in contrast to a diet rich in fresh produce, fruit, vegetables, fibre and 
micronutrients, such as vitamin C and calcium, which are thought to be cancer protective (Esposito et 
al., 2014). 
In addition to changes in dietary patterns, the prevalence of sedentary behavior is increasing 
worldwide (Dias et al., 2014). Increased physical activity levels have been shown to reduce cancer 
risk; however, there is still a lack of evidence to support this association (Brown et al., 2012). Some 
evidence on addictive substance use exists. It has been shown that heavy, or regular alcohol 
consumption and tobacco use, are independent risk factors for cancer development in various 
physiological systems, including the respiratory, digestive and urinary systems (O'Neill  & O'Driscoll, 
2015; Touvier et al., 2014). However, the combination of regular or heavy alcohol consumption with 
tobacco use, contributes to an even greater cancer risk (Touvier et al., 2014). 
  
Figure 1.2: Traditional and other risk factors associated with the pathophysiology of cancer development.   
(Adapted from: Baan et al., 2007; de Haas et al., 2010; Weiderpass, 2010) 




Other traditional risk factors include, but are not limited to, age, air pollution, radiation exposure, and 
viral vectors (WHO, 2009), such as hepatitis B and C (liver cancer) and human papilloma virus 
(HPV) (cervical cancer) (Esposito et al., 2014). 
The MetS, and its components (hypertension, dyslipidaemia, IR, and abdominal obesity), are thought 
to be primary factors in the pathophysiology and risk for developing both CVD and lifestyle 
associated cancers (Arcidiacono et al., 2012; Bjørge et al., 2011; Donohoe et al., 2011).  
 
1.3.2 Evidence of the MetS and its link to specific (lifestyle) cancers 
The MetS as a single entity, and its components, has recently been implicated in cancer risk and 
development (Stocks et al., 2015; Ulmer et al., 2012). Numerous studies describes a link between the 
MetS and its components to an increased risk for various cancers such as colorectal, endometrial, 
ovarian, breast (post-menopausal), cervical and thyroid cancer (Agnoli et al., 2010; Mendonça et al., 
2015; Sinicrope & Dannenberg, 2010; Stocks et al., 2015). In addition, studies also indicated an 
increase in cancer incidence and mortality rates amongst MetS patients (Bjørge et al., 2011; Esposito 
et al., 2012). Table 1.4 provides scientific evidence linking the MetS to various types of cancer. Here, 
it is clearly indicated which MetS components is mostly associated with increased risk of cancer 
development.   
Bjørge et al. (2011) investigated the association between the MetS, and ovarian cancer, and found that 
increased levels of cholesterol (relative risk (RR) 1.52 (95 % confidence interval (CI) 1.01-2.29)) and 
systolic blood pressure (SBP) (RR 1.79 (95 % CI 1.12-2.86)) were positively associated with an 
increased risk for developing mucinous and endometrioid tumour sub-types, respectively. More 
interestingly, women younger than 50 years showed an increased risk of ovarian cancer mortality that 
was associated with the MetS (RR 1.52 (95 % CI 1.00- 2.30)), while an increased BMI conferred with 
an increased risk for ovarian cancer mortality in women older than 50 years (RR 1.71 (95 % CI 1.01-
1.37)) (Bjørge et al., 2011). Circulating sex hormones could partly explain the relationship with BMI, 
since BMI is associated with increased production of peripheral tissue oestrogen (post-menopausal) 
(Weinberg et al., 2006). 
In a study by Kim et al. (2007), the prevalence of the MetS was reported to be higher in colorectal 
adenoma cases (17 %) vs age-matched controls (11 %). The risk for colorectal adenoma was also 
significantly increased in participants with the MetS (odds ratio (OR) 1.51 (1.18-1.93); p=0.001)). In 
addition, abdominal obesity, as measured by WC, was found to be the only independent MetS risk 
factor for colorectal adenoma (OR 1.39 (1.15-1.68); p=0.001) (Kim et al., 2007). This is a definite 
possibility since WC is a surrogate measure of VAT deposition, and an increase in VAT is associated 
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with IR, as well as increased levels of insulin-like growth factor-1 (IGF-1) (Donohoe et al., 2011). 
Both IR and IGF-1 are major determinants of proliferation and apoptosis, and could possibly play a 
key role in carcinogenesis by increasing proliferation and decreasing apoptosis (Donohoe et al., 
2011). 
Zhang et al. (2010
B
) found that women who were classified as being overweight (RR 6.150 (3.976-
9.513); p<0.001), obese (RR 1.511 (1.262-18.809); p<0.001), and having diabetes (OR 2.207 (1.229-
3.964); p=0.0007) had an increased risk for endometrial cancer when, compared to women with a 
normal weight. This was found to be true for both endometrial cancer cases and healthy age-matched 
controls. In addition, TG, TC and LDL-c were positively correlated with endometrial cancer, while 
HDL-c showed a negative correlation (Zhang et al., 2010
B
). An association between IR and an 
increased risk for endometrial cancer have also been found (Friedenreich et al., 2012). 
Ulmer et al. (2012) showed that higher BMI, TG and blood pressure were positively associated with 
an increased risk for cervical cancer. Here, authors concluded that increased adipokine and 
inflammatory marker levels related to a high BMI and HPV infection may therefore be regarded as 
possible mechanisms for MetS-associated cervical cancer risk (Ulmer et al., 2012). 
One of the largest epidemiological studies to date, which included seven European cohorts, 
investigated the link between the MetS and the risk of various cancer types in both genders (Stocks et 
al., 2015). This cohort showed that BMI, blood pressure, blood glucose, TG and TC were positively 
associated with an increased risk of cancer incidence in both men and women. The MetS was also 
positively associated with an increased risk for overall cancer incidence and mortality in several 
cancers. Men displayed a stronger association for renal and liver cancer, compared to endometrial and 
pancreatic cancer in women. A positive association was also found for cancers involving the oral 
cavity in both genders. In addition, since some of the individual components of the MetS were also 
associated with cancer mortality, evidence suggests that the metabolic factors might be involved in 







Stellenbosch University  https://scholar.sun.ac.za
15 
 

















 High TG levels and 
reduced HDL-c 
associated with an 
increased risk for breast 
cancer. 
 Presence of the MetS 
associates with increased 
breast cancer risk. 









 Higher SBP, blood 
glucose, TG and reduced 
HDL-c levels found in 
breast cancer cases. 
 Association between 
increased TG levels and risk 
of breast cancer. 




n=287 320 women Ovarian 
 Increased levels of 
cholesterol and blood 
pressure conferred with 
an increased risk of 
tumour development. 
 Increased BMI conferred 
with an increased 
ovarian cancer mortality 
risk. 
 644 cases of epithelial 
ovarian cancer cases 
identified. 
 388 ovarian cancer deaths. 
 Increased levels of 
cholesterol and blood 









 IR associated with an 
increased risk for 
endometrial cancer. 
 Overall endometrial cancer 
cases had higher measures 
of IR vs age matched 
controls. 
 Age-adjusted analysis 
showed that increased levels 
of insulin, and IR were 
associated with an increased 
endometrial cancer risk. 







 High prevalence of the 
MetS and central obesity 
in women with post-
menopausal breast 
cancer. 
 Obesity and the MetS were 
associated with a larger 
tumour size, clinical and 
pathological breast cancer 
stage. 
Kim et al., 2007 Cross-sectional 
n=2531 men & 
women 
Colorectal 
 Higher prevalence of the 
MetS in colorectal 
adenoma case vs control 
group. 
 High WC associated 
with an increased risk for 
colorectal adenoma. 
 Overall association between 
MetS and colorectal 
adenoma cancer risk. 
Stocks et al., 2015 Pooled analysis 
n=564 596 
men and women 
Several cancer 
types 
 BMI, blood pressure, 
blood glucose, TG and 
TC associated with a risk 
of cancer incidence. 
 Blood pressure, blood 
glucose, and TG levels 
associated with cancer 
mortality. 
 MetS positively associated 
with a risk for overall 
cancer incidence and 
mortality in several cancer 
types. 






 High BMI, blood 
pressure and TG levels 
associated with an 
increased risk for 
cervical cancer. 
 425 cases of cervical cancer 
 Overall association between 
the MetS and cervical 
cancer risk. 












associated with an 
increased risk for 
endometrial cancer. 
 Metabolic abnormalities 
were associated with an 
increased endometrial 
cancer risk in the population 
overall. 
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An increase in breast cancer incidence has been observed in overweight and obese patients (Healy et 
al., 2010), as well as patients with T2DM (Onitilo et al., 2014), and the MetS (Agnoli et al., 2010; 
Healy et al., 2010). Agnoli et al. (2010) found that the presence of the MetS in post-menopausal 
women was directly associated with breast cancer risk (RR 1.58 (1.07-2.33)). This risk increased with 
the presence of three or more components of the MetS, even though some of the individual 
components of the MetS (TG and HDL-c) were also associated with an increased risk for breast 
cancer development (Agnoli et al., 2010; Alokail et al., 2013). Healy et al. (2010) on the other hand 
found that the overall prevalence of the MetS was approximately 40 %, and was more common in 
obese (61 %) vs non-obese patients (21 %). In addition, obesity was positively associated with a larger 
tumour size (> 2 cm; p=0.021), indicative of a later clinical and pathological breast cancer stage 
(Healy et al., 2010). This increased risk may be partly due to a change in sex hormone levels during 
menopause (decrease in oestrogen and an increase in androgens), which in turn, is associated with a 
change in fat distribution patterns, resulting in a more male-like body shape (android body shape and 
increased VAT). Other studies have also found an association between android body shape and an 
increase prevalence of the MetS, as well as all the components of the MetS (Noroozi et al., 2010; 
Pradhan, 2014; Sardinha et al, 2012).  
The role of the MetS as a single entity and/or its components in cancer development still needs to be 
elucidated, as no single component explains the full risk associated with cancer. A complex 
pathophysiology between cancer and the MetS and its components is proposed, which may include 
multiple pathways, as well as biochemical, physiological and genetic factors (Sinicrope & 
Dannenberg, 2010).  
 
Figure 1.3: A diagram illustrating the proposed pathophysiology of MetS, and the link to cancer. 
(Adapted from: Fuentes et al., 2013; Sinicrope & Dannenberg, 2011) 
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Although the aetiology and molecular mechanisms linking the MetS and cancer are still poorly 
understood, it was proposed that the effects of obesity and IR influence the bioavailability of sex 
hormones, growth factors and inflammatory markers (Figure 1.3) (Donohoe et al., 2011; Mendonça et 
al., 2015). 
Insulin resistance, characterized by hyperinsulinaemia, may predispose individuals with the MetS to 
develop cancer via direct effects of high insulin and increased IGF-1 levels (Arcidiacono et al., 2012). 
In addition, chronic low-grade inflammation, as a result of excess adipose tissue, causes a 
dysregulation in the synthesis of various adipokines and their actions which have been implicated in 
the development of cancer (Zhao & Liu, 2013).  
Several components of the MetS have also been shown to influence the synthesis and bioavailability 
of endogenous sex hormones (Lin et al., 2013). Adipose tissue distribution, especially android and 
gynoid body shape may be an underlying factor in the pathophysiology of the MetS and cancer 
development (Figure 1.3). For example, adipose tissue distribution plays a role in the development of 
IR, influences growth factor, sex hormones and inflammatory profiles, with android body shape often 
being associated with a more dysfunctional profile (Alwachi et al., 2013; Orbetzova et al., 2012; Preis 
et al., 2010; Weinberg et al., 2006). Sex hormones, growth factors and inflammatory markers regulate 
major pathways involved in angiogenesis, cell-proliferation and apoptosis, and thus have the ability to 
influence carcinogenesis. Therefore, these factors may play a role in the complex pathophysiology of 
the MetS and risk of cancer development (Sinicrope & Dannenberg, 2011). Some of these factors will 
be discussed in the following sections. 
 
1.3.3 Role of insulin and insulin-like growth factor-1 (IGF-1)  
1.3.3.1 Introduction 
Evidence linking growth factors such as insulin, IGF-1 with cancer development; have been proposed 
by several studies (Arcidiacono et al., 2012; Renehan et al., 2006; Vucenik & Stains, 2012). Such 
evidence points to the effect of increased insulin and IGF-1 levels on the activation of tyrosine kinase 
activity and its downstream signalling pathways (Arcidiacono et al., 2012). These growth factors are 
thought to be underlying factors in the multifaceted pathophysiology of the MetS and cancer 
development (Vucenik & Stains, 2012). 
1.3.3.2 Insulin-IGF axis 
The insulin-IGF axis is a complex molecular system that includes three ligands (insulin, IGF-1, and 
IGF- 2), each with its own receptors and six IGF-binding proteins (IGF-BP-1-6) (Djiogue et al., 2013; 
Roberts et al., 2010). 
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Insulin-like growth factor-1 is described as a peptide hormone that has hormonal and growth factor 
properties (Brahmkhatri et al., 2015; Djiogue et al., 2013). It plays a role in regulating cellular 
proliferation in response to available energy and nutrient status from diet and body reserves 
(Brahmkhatri et al., 2015; Djiogue et al., 2013). Furthermore, IGF-1 regulates growth, development 
and metabolism of various tissues (Hursting & Hursting, 2012; Hursting et al., 2012). Insulin-like 
growth factor-1 is produced by several tissue types, but is predominantly (70 %) produced by the liver 
(Friedrich et al., 2013; Hursting et al., 2012). The production of IGF-1 is subject to both hormonal 
and nutritional factors (Brahmkhatri et al., 2015), while, its secretion is dependent on growth hormone 
(GH) signalling, mediated by the GH-receptor (Hursting et al., 2012). Recently, hyperinsulinaemia 
and hyperglycaemia have been shown to stimulate IGF-1 production (Ramos-Nino, 2013). Of the two 
insulin growth factors, IGF-1 mediates GH functions, which in turns promotes cellular proliferation, 
differentiation and protein synthesis (Friedrich et al., 2013). Insulin-like growth factor-2 on the other 
hand, is a foetal growth factor, but it is also found in small amounts in adult tissues (Friedrich et al., 
2013). Insulin itself has a range of metabolic functions; however it also has the ability to function as a 
growth factor with strong mitogenic capacity (Suba, 2012). 
Insulin-like growth factor-1 and IGF-2 are both found in the circulation bound to IGF-BP (Renehan et 
al., 2006). Insulin-like growth factor-1 circulates at a high concentration (150-400 ng/ml) in plasma, 
but mostly in this bound state (Brahmkhatri et al., 2015). For example, only 0.5-1.0 % of IGF-1 is 
“free” in circulation, while the remaining 99 % is bound to IGF-BP (Friedrich et al., 2013). Insulin-
like growth factor-binding protein is predominately synthesised in the liver by hepatocytes to enhance 
half-life, regulate bioavailability and offer protection against degradation of IGF-1 and IGF-2 (Saydah 
et al., 2009). The synthesis of IGF-BP is inhibited by insulin and can be stimulated by glucagon, 
oestrogen and pro-inflammatory cytokines (Lewitt et al., 2014). Insulin-like growth factor-binding 
protein 3 is the most abundant form found in circulation, i.e. approximately 80 % of IGF-1 is bound to 
IGF-BP3 (Friedrich et al., 2013; Lewitt et al., 2014). Changes in the concentration of IGF-BP may 
therefore directly impact the concentration of IGF-1 in circulation (Saydah et al., 2009). 
1.3.3.3 Insulin-IGF axis and disease states 
The insulin-IGF axis has been implicated in the pathophysiology of obesity, IR, T2DM and the MetS 
(O’ Neill & O’Driscoll, 2015). Recently, this axis has been implicated in the development of cancer, 
as it regulates major pathways involved in proliferation and apoptosis, thus having the ability to 
influence carcinogenesis (Brahmkhatri et al., 2015; Lewitt et al., 2014).  
Obesity, specifically android body shape-associated obesity, is well-known to contribute to the 
development of IR, characterized by hyperinsulinaemia and impaired glucose tolerance, i.e. a high 
BMI, WC and WHR correlates with serum insulin levels, hyperglycaemia, hyperinsulinaemia and 
T2DM (Djiogue et al., 2013; Harvey et al., 2011; Orbetzova et al., 2012; Ramos-Nino, 2013). It is 
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proposed that hyperinsulinaemia may predispose individuals with the MetS to develop cancer via 
direct effects of high insulin levels (Westley & May, 2013).  
Substantial evidence links hyperinsulinaemia with cancer (Westley & May, 2013). For example, 
T2DM is associated with an increased risk for rectal, endometrium, pancreatic, breast and prostate 
cancer (Iyengar et al., 2015). Increased levels of plasma C-peptide, a marker of insulin secretion has 
also been associated with an increased risk for several cancer types (Michaud et al., 2007; Verheus et 
al., 2006). In addition, the risk for colorectal, liver, pancreatic and breast cancer has been shown to be 
even higher in patients who are IR (Arcidiacono et al., 2012).  
Multiple signalling pathways may be involved in chronic hyperinsulinaemia’s role in cancer 
progression, which can lead to mitogenic, anti-apoptotic and pro-angiogenic effects (Figure 1.4) 
(Arcidiacono et al., 2012). Several studies have shown that high levels of insulin are associated with 
an increased risk for endometrial, renal, colon and breast cancer (pre- and post-menopausal) (Hursting 
& Hursting, 2012; Hursting et al., 2012), and it is thought that insulin acts as a cancer promoter 
directly via its insulin receptor (ISR) (Roberts et al., 2010) (Figure 1.4). More specifically, the 
activating mitogen activated protein kinase (MAPK) and phosphoinositide-3-kinase (PI3K) pathways 
may play a role here (Harvey et al., 2011). Insulin also plays a role in IGF-1 production which has 
multiple effects on tumour growth and metastasis (Arcidiacono et al., 2012). 
 
Figure 1.4: Proposed mechanisms linking insulin and IGF-1 to cancer. 
(Adapted from Renehan et al., 2006; Roberts et al., 2010; Rowlands et al., 2012) 
 
It is hypothesised that hyperinsulinaemia leads to an increase in the bioavailability of IGF-1 mainly by 
two mechanisms (Figure 1.4). First, by directly up-regulating IGF-1 production in the liver (Hursting 
et al., 2012). Hyperinsulinaemia, in the hepatic portal circulation, leads to an increase in GH receptor 
expression, thereby leading to an increase in IGF-1 production (Westley & May, 2013). In addition, 
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insulin has a low binding affinity for Insulin-like growth factor-1-receptor (IGF-1R), however, high 
insulin levels found in obese (android obesity), hyperinsulinaemic and MetS individuals, might bind 
to and stimulate IGF-1R (Westley & May, 2013). The second mechanism involves indirectly down-
regulating the production of IGF-BP by reducing hepatic gene expression and protein synthesis of 
IGF-BP (Arcidiacono et al., 2012; Renehan et al., 2006). This leads to an increased bioavailability of 
IGF-1, which is then free to bind to IGF-1R (Mendonça et al., 2015; Ramos-Nino, 2013; Roberts et 
al., 2010).  
Insulin and IGF-1 binds to their respective cell surface receptors and thereby activates the PI3K (anti-
apoptotic) and/or the MAPK (mitogenic) pathway (Iyengar et al., 2015), both of which are primary 
regulators of cell growth and mitogenesis (Hursting et al., 2012). Overstimulation and the activation 
of MAPK and protein kinase B (PKB) pathways ultimately result in a cellular environment which 
leads to tumour development (Ramos-Nino, 2013; Roberts et al., 2010).  Thus, insulin can directly 
and indirectly stimulate tumour development, and this is likely mediated by IGF-1’s mitogenic and 
anti-apoptotic effects (Arcidiacono et al., 2012).  
Obesity and the MetS are associated with dysregulation of circulating insulin and IGF-1 levels 
(Friedrich et al., 2012; van Bunderen et al., 2013). Several studies found that IGF-1, IGF-2 and 
insulin levels are increased in the MetS (Friedrich et al., 2013; Renehan et al., 2006; Roberts et al., 
2011). Increased circulatory levels of IGF-1 have also been associated with an increased risk for 
various cancer types, i.e. colorectal, prostate and post-menopausal breast cancer, as well as a poor 
prognosis (Rowlands et al., 2012). In addition, calorie restriction reduces IGF-1 as well as insulin 
levels (Vucenik & Stains, 2012).  
It may be possible that an increase in both insulin and IGF-1 may activate the overstimulation of ISR 
and IGF-1R which leads to the activation of cell proliferation, an increase in protein synthesis and a 
decrease in apoptosis (Braun et al., 2011). Evidence also showed that the MetS is related to an 
overstimulation of ISR and IGF-1R (Arcidiacono et al., 2012). Although insulin and IGF-1 may play 
a role in cancer development and progression (Mendonça et al., 2015), other factors also need to be 
investigated for a clearer understanding of the complex interaction between the MetS and cancer.  
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1.3.4. The Role of adipose tissue and inflammatory biomarkers 
1.3.4.1 Introduction 
The role of inflammation as a primary factor in the pathophysiology of various disease states, i.e. IR, 
T2DM, CVD, obesity and cancer has been studied (Cefalu, 2009; Shrivastava et al., 2015). Recent 
evidence points to the fact that chronic low-grade inflammation, as a result of excess adipose tissue, 
might be implicated in the development of obesity-related metabolic diseases (Jung & Choi, 2014). 
1.3.4.2 Adipose tissue and inflammation 
As a metabolic active endocrine organ, adipose tissue secretes various bioactive substances known as 
adipokines, which have both pro- and anti-inflammatory properties (Mendonça et al., 2015; Zhao & 
Liu, 2013). These include, but are not limited to, C-reactive protein (CRP), leptin, adiponectin (Apn), 
tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), resistin and angiotensinogen (Gade et al., 
2010). These adipokines have diverse roles in food intake regulation, glucose and lipid metabolism, 
insulin sensitivity, adipocyte differentiation, inflammation, coagulation and blood pressure regulation 
(Fuentes et al., 2013). Dysregulation in the synthesis of these adipokines and their actions, in relation 
to obesity, have been linked to the development of various disease states, including the MetS, T2DM 
and cancer (Zhao & Liu, 2013).  
 
Acute inflammation is characterized by calor, dolor, erythema and leukocyte infiltration (Kushner et 
al., 2010). However, inflammation is also described as an increase in the concentration of pro- and 
anti-inflammatory cytokines, as well as acute phase proteins (Kushner et al., 2010). A poorly defined 
expression, low-grade inflammation, has been used in the literature to describe conditions in which 
the classical symptoms of inflammation are absent (Brenner et al., 2014). These include obesity, IR 
and the MetS (Kushner et al., 2010). Obesity is characterized by low-grade chronic inflammation due 
to a deregulated adipokine profile, and increased secretion of pro-inflammatory cytokines and their 
related signalling pathways (Jung & Choi, 2014). Adipose tissue of obese individuals is characterized 
by an infiltration of immune cells i.e. lymphocytes and macrophages. Furthermore, a phenotypic 
switch from anti-inflammatory (M2) to pro-inflammatory macrophages (M1) also occurs, which are 
all hallmarks of a pro-inflammatory state, thereby linking obesity to systemic inflammation (Figure 
1.5) (Fuentes et al., 2013).  




Figure 1.5: The proposed link between obesity and inflammation. 
(Adapted from: Donohoe et al., 2011) 
 
During a positive energy state, adipose tissue stores excess energy as TG in the lipid droplets of 
adipocytes, which leads to hyperplasia, as well as hypertrophy (Figure 1.5) (Bjørndal et al., 2011; 
Jung & Choi, 2014). The number of adipocytes has been genetically pre-determined, and an increase 
in fat mass in adulthood is thought to be mainly due to hypertrophy (Jung & Choi, 2014), resulting in 
the deregulated secretion of various adipokines (Lasselin et al., 2014). Adipocyte hypertrophy leads to 
an increased production of pro-inflammatory cytokines, namely TNF-α, IL-1β, IL-6, transforming 
growth factor beta (TGF-β), leptin, acute phase proteins (hepatic CRP) and a decrease in Apn, which 
has anti-inflammatory properties (Fain, 2006). In addition, adipose tissue itself can also secrete CRP 
(Ikeoka et al., 2010). As a result, a pro-and anti-inflammatory imbalance occurs, which leads to a low-
grade inflammatory state (Fuentes et al., 2013; Zhao & Liu, 2013). Additionally, adipose tissue 
hypertrophy leads to the redirection of fatty acids to the liver; promoting dyslipidaemia, (increased 
free fatty acids (FFA), TG and LDL-c and decreased HDL-c), and increased lipolysis, all of which 
contributes to the development of low-grade inflammation (Bjørndal et al., 2011; Jung & Choi, 2014).  
It is clear that the pathophysiology behind obesity-associated inflammation includes a network of 
cells, pathways and adipokines (Brenner et al., 2014). In addition to adipose tissue hyperplasia, 
hypertrophy, immune cell infiltration, other factors have also been proposed to play a role in low-
grade inflammation (Balistreri et al., 2010). These include the role of adipocyte differentiation, 
induced by increased levels of pro-inflammatory adipokines, which in turn leads to the secretion of 
more pro-inflammatory cytokines (Pérez-Hernández et al., 2014). In addition, hypoxia induced by the 
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rapid expansion of adipose tissue, also induces the release of inflammatory mediators, thus further 
contributing to inflammation (Trayhurn, 2013). Therefore, although adipose tissue remodelling, 
differentiation and hypoxia underline the complexity of obesity-associated inflammation, the exact 
mechanism still needs to be elucidated.  
1.3.4.3 Role of inflammatory markers  
Various adipokines, cytokines, chemokines, hormones and growth factors are thought to play a role in 
the MetS, and the association with lifestyle-associated cancer risk (Cefalu, 2009). Adipose tissues 
from patients that have the MetS display a deregulated adipokine and cytokine profile, which is 
shifted towards a chronic inflammatory state (Maury & Brichard, 2010).  
1.3.4.3.1 C-reactive protein (CRP)  
C-reactive protein forms part of the non-specific acute phase immunological response to 
inflammation, infection and tissue damage (Braun et al, 2011; Ingle & Patel, 2011). During the acute 
phase response, numerous proteins are rapidly synthesised by hepatocytes under the control of pro-
inflammatory cytokines, such as IL-1, IL-6 and TNF-α (Ingle & Patel, 2011; Pepys & Hirschfield, 
2003). C-reactive protein is a direct measurement of this acute phase, and is therefore considered as a 
measure of inflammation as its levels rapidly rise in response to it (Aguiar et al., 2013).  
C-reactive protein is the most studied and characterized systemic inflammatory biomarker used in 
epidemiological studies (Braun et al, 2011), which have shown that increased CRP levels are 
associated with a variety of metabolic (CVD and T2DM), inflammatory and chronic conditions 
(Brenner et al., 2014; Kushner et al., 2010; Pepys & Hirschfield, 2003). In addition, CRP is also 
related to obesity, since obesity is known as a low-grade chronic inflammatory condition (Braun et al, 
2011). 
The association between obesity and CRP has been extensively studied (Choi et al., 2013; Illán-
Gómez et al., 2012; Kao et al., 2009). One specific study showed that 35 % of men, and 60 % of 
women with a BMI of more than 30 kg/m
2
 showed increased CRP levels, indicating a possible 
correlation between CRP and the volume of adipose tissue in the body (Kao et al., 2009). Alwachi et 
al. (2013) specifically showed that the mean high sensitivity CRP (hsCRP) levels were significantly 
higher in post-menopausal women with an android body shape (5.39 mg/L) when compared to post-
menopausal women with a gynoid body shape (2.51 mg/L) (p< 0.05), suggesting that adipose tissue 
distribution may also be associated with increased CRP levels low-grade inflammation (Alwachi et 
al., 2013). More specifically related to the MetS, it was proposed to add as a component of the MetS 
definition (Ridker et al., 2004), since CRP has been shown to correlate with individual components of 
the MetS, such as abdominal obesity, hyperinsulinaemia, IR and dyslipidaemia (da Cruz et al., 2013). 
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An increase in CRP has been found in patients with the MetS (den Engelsen et al., 2012). The study 
by den Engelsen et al. (2012) found a higher median hsCRP of 2.2 mg/L (inter quartile range (IQR) 
1.2-4.0) in MetS participants when compared to participants without the MetS (1.7 mg/L (IQR 1.0-
3.4)). In addition, an increase in the number of the MetS components was associated with an increase 
in median hsCRP levels, and the presence of the MetS, WC, TG and HDL-c all showed a significant 
trends with increasing hsCRP categories (den Engelsen et al., 2012), implying that the MetS could 
play a role in low-grade inflammation. Similar results of higher CRP levels with more MetS 
components were evident in the studies by Mahajan et al. (2012), Sur et al. (2014) and Vidyasagar et 
al. (2013). 
Vidyasagar et al. (2013) also showed higher CRP levels in MetS patients with abdominal obesity 
compared to those without abdominal obesity (1.4 mg/L vs 0.8 mg/L), an effect which was age-
dependent. Different obesity indices (WHR, WC and TBF %) are also associated with higher CRP 
levels in both men and women with the MetS (Lin et al., 2010). After adjusting for hyperglycaemia, 
hypertension, hypertriglyceridemia and low HDL-c, only TBF % remained significant, which led to 
the conclusion that TBF % was a better predictor of inflammation when compared to WC, WHR and 
BMI. This study was however limited by its cross-sectional study design, as well as the population 
studied, which again highlights the need for different obesity cut-off values for different ethnic groups 
(Alberti et al., 2009; IDF, 2006).  
Although numerous studies have focussed on CRP and the MetS, the specific mechanism involved is 
still unknown; however, it is thought to be mediated by adipose tissue dysfunction predominantly (Lin 
et al., 2010). The role of CRP in the pathophysiology of the MetS may be due to one of the following 
mechanisms: Firstly, CRP may increase blood pressure by decreasing nitric oxide synthase and by 
triggering cardiac fibrosis which can cause vasoconstriction (Schwartz et al., 2007; Zhang et al., 
2010
A
). Secondly, increased CRP has also been associated with IR by increasing ISR substrate 
phosphorylation. This may lead to deregulated insulin-stimulated uptake and glucose transporter type 
four translocation, which can cause impaired insulin sensitivity (Devaraj et al., 2009). Lastly, CRP 
could also directly impair insulin synthesis via CRP-mediated inflammation and the production of 
reactive oxygen species (ROS) (Brenner et al., 2014).   
While clear evidence links CRP to the development of the MetS and/or its components, there remains 
little support linking CRP, the MetS and cancer development. Epidemiological studies have shown 
that CRP levels, measured by high sensitivity assays, do not only reflect the presence of cancer, but it 
may be associated with an increased risk for future development of cancer in apparently healthy 
individuals (Allin & Nordestgaard, 2011). Increased CRP levels have been observed in patients with 
pancreatic, oesophageal, colorectal, breast, lung, endometrium, ovarian and prostate cancer, and was 
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also associated with a poor prognosis (Allin & Nordestgaard, 2011; Brenner et al., 2014; Guo et al., 
2015).  
It is currently unknown whether increased CRP levels play a causal role in the pathophysiology of the 
MetS and its link to cancer, if it is just a biomarker to identify individuals with a greater risk, or if it is 
associated with the prognosis of several cancer types (Allin & Nordestgaard, 2011). However, 
although other inflammatory markers may potentially play a similar role in cancer development, 
which, include pro- and anti-inflammatory cytokines, as well as adipokines lepin and Apn, these 
markers were not the focus of this thesis. 
1.3.4.4 Proposed link between MetS, inflammation and cancer development 
Substantial evidence links chronic inflammation and the risk of cancer development (Figure 1.6) 
(Lumeng & Saltiel, 2011; Pérez-Hernández et al., 2014; Rodríguez et al., 2013). Obesity and the 
MetS is characterized by low-grade inflammation, primarily mediated by hypertrophy, hyperplasia 
and immune cell infiltration, ultimately leading to an deregulated synthesis of several adipokines 
(Cefalu, 2009; Lasselin et al., 2014; Maury & Brichard, 2010). This includes an increase in pro-
inflammatory cytokines and acute phase proteins, as well as a decrease in anti-inflammatory cytokines 
(Maury & Brichard, 2010).  
The first link between the MetS, inflammation and cancer development involves several inflammatory 
mediators (IL-6 and TNF-α) as they have been found to correlate to tumour development and 
progression (Pérez-Hernández et al., 2014), possibly as a result of the downstream effects they may 
have on major pathways involved in angiogenesis, cell-proliferation and apoptosis, thus having the 
ability to influence carcinogenesis (Braun et al., 2011; Guo et al., 2015) (Figure 1.6). In addition, 
other cancer-causing mechanisms which include loss of tumour suppressor function, increased cell 
cycling and stimulation of oncogenes, can also be related to cytokines and their sustained 
inflammatory signalling pathways (Landskron et al., 2014).  
 
Leptin and Apn also have a potential role in the risk of cancer development. Leptin has been shown to 
play a role in inflammation by increasing the synthesis of pro-inflammatory cytokines, and a role in 
cancer development by increasing cell proliferation and angiogenesis (Rodríguez et al., 2013). This is 
supported by elevated leptin levels found in cancer patients (Aleksandrova et al., 2012). 
Adiponectins’ role in the risk of cancer development can be explained by its ability to increase 
apoptosis (Mendonça et al., 2015). Adiponectin levels are decreased in patients with obesity, the 
MetS and cancer (Gnacińska et al., 2010; Otake et al., 2010; Zhao & Liu, 2013).  
 




Figure 1.6: The proposed link between metabolic syndrome, inflammation and cancer development. 
(Adapted from: Lumeng & Saltiel, 2011; Pérez-Hernández et al., 2014)  
 
Secondly, inflammation may be linked to cancer development via the insulin-IGF-axis (Figure 1.6). In 
addition to cytokines regulating CRP synthesis in the liver, cytokines also has effects on the synthesis 
of IGF-1 (Lumeng & Saltiel, 2011). It has been shown that cytokines regulate IGF-1 synthesis by 
either influencing GH synthesis or resistance (Lumeng & Saltiel, 2011). Thus, it may be possible that 
other inflammatory mediators, such as CRP, may also have an influence on IGF-1 synthesis, since it 
has been shown to potentially cause impaired insulin sensitivity, by affecting ISR substrate 
phosphorylation (Devaraj et al., 2009). For example, a study by Kaushal et al. (2004) found that 
participants with the MetS had lower IGF-1BP levels (14.4 μg/l vs 25.4 μg/l, p<0.001) and higher 
CRP (1.9 mg/L vs 1.0 mg/L, p<0.001) levels vs participants without the MetS. A negative correlation 
between CRP and IGF-1 (r=-0.11, p<0.001) was also evident (Kaushal et al., 2004), whereas 
Colangelo et al. (2009) showed a positive correlation. Since, evidence links hyperinsulinaemia with 
cancer development, it may be possible that an increase in CRP concentration levels may have an 
effect on the synthesis of IGF-1, thereby indirectly contributing to cancer development (Colangelo et 
al., 2009; Kaushal et al., 2004). 
In addition, during rapid adipose tissue expansion, hypoxia is induced (Figure 1.6) (Trayhurn, 2013). 
Adipose tissue in response to hypoxia synthesises hypoxia inducible factor-1α (HIF-1α) (Trayhurn, 
2013). Hypoxia inducible factor-1α binds to transcription factors on vascular endothelial growth 
factor (VEGF) and angiopoietin-2 genes and thereby inducing angiogenesis, thus contributing to 
cancer development (Trayhurn, 2013).   
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Lastly, human adipocytes express sex steroid hormone receptors, whereby oestrogens can stimulate 
the proliferation of pre-adipocytes, potentially contributing to obesity-associated inflammation (Suba, 
2012). Also, oestrogen-containing medications have an effect on CRP levels (Kushner et al., 2010).  
 
1.3.5 Role of sex hormones 
1.3.5.1 Introduction 
Epidemiological studies provide evidence implicating sex steroid hormones as a causal factor in the 
pathophysiology of the MetS and risk of cancer development (Iyengar et al., 2015; Zhu et al., 2010). 
Different components of the MetS have been associated with a deregulated sex steroid hormone 
profile, characterized by excessive androgen and oestrogen synthesis (Brand et al., 2011; Suba, 2012). 
A deregulated sex hormone profile has also been associated with the development and progression of 
various cancers types, including breast, ovarian and colon cancer (Floreani et al., 2002; Key et al., 
2011; Lin et al., 2013).  
1.3.5.2 Oestrogens and androgens 
Endogenous sex hormones can be classified into three steroid groups; oestrogens, androgens and 
progesterone’s (Kim & Halter, 2014). Oestrogen is known as the primary female sex steroid hormone 
having several endogenous forms, namely, oestrone (E1), oestradiol (E2), and oestriol, with E2 being 
the major physiological form (Pradhan, 2014). Oestrogen is responsible for the development and the 
maintenance of female gender characteristics (Folkerd & Dowset, 2010). In women, oestrogen is 
predominantly produced by the ovaries; however it can also be produced by peripheral tissues (Suba, 
2012). In post-menopausal women, the conversion of androgens to oestrogens can also occur in 
peripheral tissues, i.e. adipose, breast, brain, endometrium, bone, endothelium, muscle and aortic 
smooth muscle cells (Calle & Kaaks, 2004; Iyengar et al., 2013; Suba, 2012). Most of these tissues, 
specifically breast and endometrial tissue, have a high demand for oestrogen (Suba, 2012), and it is 
crucial that the production of sex hormones by peripheral tissues helps to preserve structural integrity, 
as well as its functional activity (Calle & Kaaks, 2004; Suba, 2012).  
Adipose tissue plays an endocrinological role in the synthesis of sex hormones as it contains enzymes 
involved in the biosynthesis of these sex hormones (Suba, 2012; Westley & May, 2013). Adipocytes 
express 17β-hydroxyl steroid dehydrogenase (17β-HSD), an enzyme responsible for the conversion of 
Δ4-androstenedione (ΔA4) to E2, while aromatase, a P450 cytochrome enzyme, catalyses the final 
step of oestrogen synthesis by aromatisation of androgens to oestrogens, i.e. testosterone (T) is 
converted to oestrone (E1) (Westley & May, 2013) (Figure 1.7).  
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Oestrogen has been associated with all the individual components of the MetS (Pradhan, 2014). 
Abdominal obesity is a primary component of the MetS and may be influenced by, the sex hormone 
profile. Oestrogen, for example, plays an important role in fat distribution (Momesso et al., 2011). A 
normal oestrogen profile in women is associated with gluteo-femoral fat deposition (gynoid body 
shape), while androgen excess and oestrogen deficiency is associated with visceral obesity and 
android body shape in both pre-and post-menopausal women, which in turn increases the risk for 
CVD and the MetS (Momesso et al., 2011; Orbetzova et al., 2012). In addition, oestrogen has a 
regulatory role in the differentiation and metabolism of adipocytes (Suba, 2012).  
Oestrogen may play a role in maintaining blood lipid levels, as shown in a study by Lin et al. (2013). 
Post-menopausal women have elevated levels of TC, LDL-c and TG and decreased HDL-c levels vs 
pre-menopausal women (Lin et al., 2013). Oestrogen has also been associated with hypertension, IR 
and, is also implicated in the regulation of insulin production capacity of pancreatic beta-cells (Suba, 
2012; Subramanian et al., 2011). Thus, changes in oestrogen levels in the body may influence the 
development of the MetS, or its components (Brand et al., 2011; Suba, 2012).  
Although testosterone is predominantly found in the testes of men (Al kindi et al., 2012), the adrenal 
glands are also capable of producing T in small quantities (Folkerd & Dowset, 2010). In women, T is 
produced by both the ovaries and the adrenal glands, however at a much lower concentration (Folkerd 
& Dowset, 2010). Over secretion of androgen (increased T, and SHBG Levels) has been observed in 
women with the MetS (Weinberg et al., 2006), and is also related to the individual components of the 
MetS itself (Suba, 2012). 
 
1.3.5.3 Sex hormone binding globulin (SHBG) 
Sex hormones circulate in the blood mainly in three forms; (i) bound to SHBG, (ii) bound to albumin 
or other plasma proteins or, (iii) in a free (unbound) state (Hammond et al., 2012).  
Sex hormone binding globulin’ functions include transport of sex steroids, regulating free (unbound) 
hormone concentration and their transport to target tissues (Avvakumov et al., 2010; Hammond et al., 
2012). Each SHBG consist of two steroid binding sites (Avvakumov et al., 2010), and research have 
shown that none, one or both binding sites may be occupied by the same or different sex steroid 
hormone simultaneously (Hammond et al., 2012). Testosterone has a much higher binding affinity for 
SHBG compared to E2 (Wallace et al., 2013). Sex hormone binding globulin levels also differ 
according to gender, due to occupancy of its binding sites (Wallace et al., 2013). This is evident in 
women, whereas, only a small fraction of SHBG binding sites are occupied by sex steroids, whereas 
in men it is mostly occupied by T (Hammond et al., 2012). According to the free sex hormone 
hypothesis, only sex hormones that are in the free (unbound) state are thought to be biologically 
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active, and since they have lipophilic properties, they have the ability to passively diffuse into target 
cells (Rosner, 2006).  
Measurement of SHBG, for example, is an indirect measurement of sex hormone excess, with its 
concentrations mainly related to the levels of free oestrogens and androgens (Kalyani et al., 2009). 
The free androgen index (FAI) is a ratio used to estimate the androgen status of both men and women 
(Al kindi et al., 2012), and it is calculated as the percentage ratio of total testosterone to SHBG 
concentration (Hammond et al., 2012). A high FAI has been associated with the MetS, and several 
individual components of the MetS in female participants (Folkerd & Dowset, 2010). 
1.3.5.4 Evidence of the MetS, sex hormone and SHBG alterations 
Components of the MetS have been shown to have an influence on the synthesis and the 
bioavailability of endogenous sex hormones, i.e. oestrogens and androgens (Brand et al., 2011). An 
increase in oestrogen and androgen production has been found in overweight and obese women due to 
excess adipose tissue after menopause (Kalyani et al., 2009; Weinberg et al., 2006). In addition, 
obesity has also been associated with an increase in tissue level of both E1 and E2 (Westley & May, 
2013). 
Kalyani et al. (2009) showed that high T and oestrogen levels in women are associated with a higher 
incidence of T2DM. Women who developed T2DM had much higher levels of T and total E2 
compared to those who didn’t develop T2DM after follow-up (Kalyani et al., 2009). Higher total E2, 
T and FAI, together with lower SHBG levels were found in women who had the MetS compared to 
controls (Weinberg et al., 2006). Higher total E2 levels were also associated with a higher BMI and 
abnormal glucose homeostasis, while low SHBG levels and high FAI was associated with all the 
components of the MetS (i.e. obesity, low HDL-c, high TC, high TG levels, hypertension and 
abnormal glucose metabolism) in post-menopausal women (Weinberg et al., 2006). One specific 
study also showed that post-menopausal women with the MetS had characteristics of 
hyperandrogenism (higher T and lower SHBG levels) when compared to post-menopausal women 
without the MetS (Ziaei & Mohseni, 2013). Results from these studies all concluded that the 
association between the MetS, or the MetS components, with the bioavailability of endogenous sex 
hormones may likely be due to adiposity and IR (Kalyani et al., 2009; Weinberg et al., 2006). This is 
plausible since IR, hyperinsulinaemia and high IGF-1 can lead to defective oestrogen production by 
inhibiting aromatase enzyme gene expression (Suba, 2012). 
Evidence suggests that SHBG may offer more biological significance in addition to its transport 
function (Folkerd & Dowset, 2010). Low serum SHBG levels have been found in patients with T2DM 
and have been associated with an increased risk for T2DM (Ding et al., 2009; Kalyani et al., 2009; 
Weinberg et al., 2006). Obesity, hyperinsulinaemia and high IGF-1 levels have also been associated 
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with a decrease in SHBG production, thus leading to an increase in oestrogen levels (Braun et al., 
2011; Westley & May, 2013). These associations have been found to be casual and likely to be 
mediated by effects of IR (Kalyani et al., 2009; Suba, 2012; Weinberg et al., 2006).  
The relationship between IR and low SHBG levels is stronger in women compared to men, and even 
stronger in post-menopausal women (Wallace et al., 2013). Two studies have shown that SHBG 
levels decrease in post-menopausal women (Folkerd & Dowset, 2010; Wallace et al., 2013), and that 
low levels of SHBG are associated with an androgen excess (Folkerd & Dowset, 2010). In addition, 
both hyperinsulinaemia and IR have been associated with hyperandrogenism in women (Suba, 2012). 
In pre-menopausal women on the other hand, low SHBG levels are usually linked to polycystic 
ovarian syndrome (Simó et al., 2015). More specifically, Korhonen et al. (2003) showed that pre-
menopausal women with the MetS had increased T, decreased SHBG levels and increased FAI, 
typical to that of polycystic ovarian syndrome (Korhonen et al., 2003) 
It may be possible that IR has an effect on hepatic synthesis of SHBG (Simó et al., 2015). However, 
the evidence supporting the association between IR and changes in sex hormone levels are largely 
circumstantial. Sex hormone binding globulin levels are low in most cases of hyperinsulinaemic 
patients; however most of these patients also have hyperglycaemia and present with other metabolic 
alterations that have the ability to alter transcription factors which regulates SHBG expression in the 
liver (Hammond et al., 2012).  
Multiple other factors may confound the association between IR and SHBG levels, such as 
menopausal status, age, gender, sex steroid concentration, obesity and body composition (Wallace et 
al., 2013). Body composition (in particular the percentage body fat) is a main determination factor for 
SHBG levels (Hammond et al., 2012). For example, high levels of SHBG have been found in 
anorexic women, being a reflection of a chronic fasted liver state, while obesity has been associated 
with a decrease in SHBG production (Koskova et al., 2009; Westley & May, 2013). This suggests that 
no single factor can explain this complex association.  
1.3.5.5 Proposed mechanisms behind sex hormone’s role in the pathophysiology of the 
MetS and cancer development 
Adipose tissue is known to produce endogenous sex hormone metabolising enzymes, namely 
aromatase, as well as hydroxysteroid dehydrogenase (17β-HSD) (Calle & Kaaks, 2004). These 
enzymes catalyse the synthesis of oestrogens from androgenic precursors produced by the gonads and 
adrenal glands (Calle & Kaaks, 2004).  
The MetS and its components are associated with increased oestrogen and T production (Brand et al., 
2011) (Figure 1.7). In overweight and obese individuals, there is an increase in aromatase and 17β-
HSD enzyme production. Which, can lead to an increase in the conversion of androgens, i.e. ΔA4 and 
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T into oestrogens (E1 and E2) (Brand et al., 2011; Braun et al, 2011; Mendonça et al., 2015), while, 
17β-HSD enzyme catalyses the conversion of ΔA4 into T and E1 into E2 respectively (Calle & 
Kaaks, 2004).  
Oestrogen is further increased by obesity-associated hyperinsulinaemia and IGF-1 overexpression, 
resulting in a decrease in SHBG produced by the liver (Braun et al, 2011). This increase in E2 and T 
production, in combination with a decrease in SHBG levels, leads to an increase in the bioavailability 
of E2 and T (Folkerd & Dowset, 2010), which then diffuses to target cells, where they can bind to 
their respective oestrogen and androgen receptors (Folkerd & Dowset, 2010).  
 
Figure 1.7: The proposed mechanisms by which sex hormones are linked to cancer development. 
(Adapted from: Donohoe et al., 2011; Folkerd & Dowsett, 2010) 
 
This excessive bioavailability of oestrogen is thought to act through ISR, IGF-1R and oestrogen-
receptor pathways, which results in the activation of MAPK pathways (Hursting et al., 2012). 
Mitogen activated protein kinase activation leads to mitogenic, anti-apoptotic and pro-angiogenic 
effects via oestrogen receptor-α antagonism, and ultimately leading to the promotion of cancer 
development in oestrogen-sensitive tissues (Braun et al., 2011; Hursting et al., 2012; Westley & May, 
2013). Oestrogen-sensitive tissues are overstimulated in obese vs lean women; this increases the risk 
for cancer by stimulating the growth and progression of cancer (Iyengar et al., 2013). Oestrogens are 
known to stimulate the proliferation of epithelial breast cells and exert a mutagenic effect (Iyengar et 
al., 2013). Furthermore, oestrogen can also be metabolised into deoxyribonucleic acid (DNA) reactive 
metabolites leading to the induction of mutagenesis, i.e. inducing free-radical DNA production, 
causing genetic instability and mutations in cells (Hursting et al., 2012; Roberts et al., 2010). In 
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addition, inflammatory mediators like IL-6, TNF-α and leptin has also been shown to induce 
aromatase production which leads to an increase in oestrogen production (Morris et al, 2011).  
Body composition compartments, especially abdominal obesity, seem to be an underlying factor in the 
pathophysiology of the MetS and the risk of cancer development. For example, adipose tissue plays a 
role in oestrogen production; it is a source of low-grade inflammation and plays an important role in 
the development of IR (Cefalu, 2009; Friedrich et al., 2012; Suba, 2012). Since adipose tissue is an 
important part of the puzzle, body composition will be discussed in the next section. 
 
1.4 Body composition 
1.4.1 Introduction 
Anthropometry is defined as the study of human body measurements in terms of adipose, muscle and 
bone tissue dimensions (Stewart & Sutton, 2012). The study of anthropometry includes a variety of 
different body measurement, i.e. weight, height, recumbent length, skinfold thickness, circumference, 
limb lengths and breaths using standardized equipment (Eston & Reilly, 2009; Stewart & Sutton, 
2012). Anthropometry is also a key contributor of knowledge in terms of nutrition assessment in both 
adults and children (Eston & Reilly, 2009), and can be used to estimate the different levels of body 
composition (Cornier et al., 2011).  
1.4.2 Body composition: measurements, indices and ratios in health assessment 
The main rationale of utilizing body composition in a clinical setting is to describe and evaluate 
changes in the body in relation to nutritional status and lifestyle-related diseases (Thibault et al., 
2012). The assessment of body composition has been applied in various disciplines including medical 
science, sport science, anthropology and child growth (Eston & Reilly, 2009; Norton & Olds, 1996; 
Stewart & Sutton, 2012). Interestingly, body composition does not only provide information regarding 
disease risk, but also morbidity, mortality, and contributes to improve general health care guidelines 
(Stewart & Sutton, 2012). Over the last few decades there has been an increase in the number of 
techniques to assess body composition, specifically adiposity (Stewart & Sutton, 2012), which include 
BIA and traditional anthropometric assessments (BMI, WC, hip circumference (HC) and WHR). 
1.4.2.1 Bio-electrical impedance analysis (BIA) 
To date there is no direct measure to assess adipose tissue (Stewart & Sutton, 2012).  However, an 
accurate estimate can be made by means of ultrasound, magnetic resonance imaging (MRI), computed 
tomography (CT) and dual-energy X-ray absorptiometry (DEXA) techniques (Eston & Reilly, 2009; 
Rothney et al., 2009; Stewart & Sutton, 2012).  
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Magnetic resonance imaging, CT and DEXA are considered the gold standards for measuring adipose 
compartments of the abdomen and gluteo-femoral region, however these methods are relatively 
expensive and complex, and not really practical in a field study setting as it is not portable, and 
requires high levels of training (Eston & Reilly, 2009; Norton & Olds, 1996; Rothney et al., 2009; 
Stewart & Sutton, 2012), which is not the case with bio-electrical impedance analysis (BIA). 
Bio-electrical impedance analysis can be used to quantitatively measure different body composition 
compartments, including TBF %, fat mass (FM), fat free mass (FFM) and total body water (TBW) in 
men and women (Figure 1.8) (Stewart & Sutton, 2012; Thibault et al., 2012). The use of BIA to 
estimate body composition in a clinical setting has several advantages; (i) it is easily available, (ii) 
quick, (iii) portable, (iv) non-expensive, (v) and easy to use with minimal training, (vi) and has also 
been shown to produce similar results to that seen when using the gold standard techniques (Eston & 
Reilly, 2009; Stewart & Sutton, 2012; Thibault et al., 2012).  
 
 
Figure 1.8: Body composition compartments in the human body and estimated reference ranges. 
(Adapted from: Eston & Reilly, 2009; Stewart & Sutton, 2012; Thibault et al., 2012) 
 
Bio-electrical impedance analysis is based on the principle of electrical impedance, i.e. electrical 
conductivity characteristics of hydrous (electrolytes) and non-hydrous (cell membrane) components 
of cells (Eston & Reilly, 2009). This is possible due to the fact that water has a high electrolyte 
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content and can easily conduct an electrical current in comparison to adipose tissue which is a poor 
conductor of electrical current (Eston & Reilly, 2009; Thibault et al., 2012).  
Although BIA is a useful alternative to use in a clinical setting, most methods come with 
disadvantages; and BIA is no exception. Various predictive equations based on gender, age, height, 
weight and ethnicity is applied to estimate FM, FFM and TBW (Dehghan & Merchant, 2008). Bio-
electrical impedance analysis equations are population-specific and can only be useful for populations 
with similar characteristics to those of the reference population (Dehghan & Merchant, 2008; Thibault 
et al., 2012). Thus, these equations cannot be generalized to diverse populations as it will yield 
inconsistent results (Dehghan & Merchant, 2008). 
In addition, despite BIA’s ease of use and high reproducibility, BIA measurements are also influenced 
by the placement of the electrode, dehydration, exercise, temperature and a conductive surface (Eston 
& Reilly, 2009). Thus, special care should be taken in preparation of study participants and equipment 
prior to the performance of the BIA test. Despite these limitations, BIA is still a quick, easy and 
reliable method to estimate different body compartments, and is feasible to use in a field study setting. 
Various indices and ratios can be determined using anthropometry, the most well-known predictor 
being the BMI (Cornier et al., 2011). 
1.4.2.2 Body mass index (BMI) 
Different adiposity measurements have been used to categorize individuals as being underweight, 
normal, overweight or obese (Table 1.5) (Stewart & Sutton, 2012). Apart from BMI, other 
measurements typically include; WC, HC, WHR and TBF % (Eston & Reilly, 2009; Norton & Olds, 
1996; Stewart & Sutton, 2012). 
Body mass index (kg/m
2) is an index portraying an individual’s weight per unit of height, and is 
defined as weight in kilograms (kg) divided by the square height in meters (m) (Phillips et al., 2013; 
Stewart & Sutton, 2012). 
Although BMI cut-off points are age-dependant, they are similar for men and women (WHO, 1995; 
WHO, 2000; WHO Expert Consultation, 2004), and may also not correspond to the same degree of 
body fat in different populations. This is in part due to differences in body composition, i.e. 
percentage body fat and fat distribution in different populations which, can result in health risks 
associated with increased BMI. Thus, additional cut-off points have been recommended by the WHO 
to overcome these difficulties (WHO Expert Consultation, 2004). 
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Principal cut-off points Additional cut-off points 
Underweight < 18.50 < 18.50 
Severe thinness < 16.00 < 16.00 
Moderate thinness 16.00 - 16.99 16.00 - 16.99 
Mild thinness 17.00 - 18.49 17.00 - 18.49 
Normal range 18.50 - 24.99 
18.50 - 22.99 
23.00 - 24.99 
Overweight ≥ 25.00 ≥ 25.00 
Pre-obese 25.00 - 29.99 
25.00 - 27.49 
27.50 - 29.99 
Obese ≥ 30.00 ≥ 30.00 
Obese class I 30.00 - 34.99 
30.00 - 32.49 
32.50 - 34.99 
Obese class II 35.00 - 39.99 
35.00 - 37.49 
37.50 - 39.99 
Obese class III ≥ 40.00 ≥ 40.00 
(Adopted from: WHO, 1995; WHO, 2000; WHO Expert Consultation, 2004) 
There is a well-established association between a high BMI and an increased risk for morbidity rates 
of specific diseases and conditions. Some examples include coronary heart disease (CHD), T2DM, 
atherosclerosis, stroke, the MetS, hypertension and dyslipidaemia (Campbell, 2014; Morris, 2011; 
Phillips et al., 2013). The prevalence of the MetS is high among all BMI categories, but much higher 
in the obese category (Phillips et al., 2013). In recent years, several cancer types have also been 
associated with a high BMI, with an increased risk of post-menopausal breast cancer, colorectal, 
renal, endometrial, ovarian, and cervical cancer (Campbell, 2014; Kabat et al., 2015).  
The use of BMI as an assessment of body composition does have its advantages. Weight and height 
are routine measurements in various fields of study. It is quick, easy to obtain and can be used in 
adults and children of both genders (Eston & Reilly, 2009; Phillips et al., 2013). However, BMI is a 
not the best and most accurate predictor of adiposity, as it is only an estimate of adiposity (Eston & 
Reilly, 2009). The use of BMI has also been heavily criticized by the fact that it does not describe or 
distinguish between lean and FM, as well as fat distribution (Phillips et al., 2013). In addition, BMI 
does not take into account the actual shape of the body itself (Eston & Reilly, 2009). Body shape 
(android and gynoid) has been shown to play a bigger role in disease states (Orbetzova et al., 2012; 
Ronco et al., 2008), and this will be described in a later section of this thesis. 
1.4.2.3 Waist circumference, hip circumference & waist-hip-ratio 
Waist circumference has been shown to be a good alternative measurement for assessing abdominal 
obesity as it accounts for BMI’s limitations and correlates well with the gold standard methods (CT 
and MRI) (Stewart & Sutton, 2012). Currently WC is the only adiposity measurement used in the 
NCEP-ATP III and IDF MetS definitions (Expert Panel on Detection, Evaluation, and Treatment of 
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High Blood Cholesterol in Adults, 2001; IDF, 2006; Phillips et al., 2013), while BMI is used in the 
WHO definition (Alberti & Zimmet, 1998; Phillips et al., 2013). 
Waist circumference has been used to complement BMI for estimating obesity risk (Cornier et al., 
2011), and studies have actually shown it to be a better predictor of mortality and disease risk than 
BMI (Brenner et al., 2010; Campbell, 2014; Kabat et al., 2015), as well as the incidence of various 
cancers (breast, endometrium and colorectal) (Kabat et al., 2015). Although WC is a simple, 
affordable and non-invasive measurement of body composition (Eston & Reilly, 2009), it has not 
been well-implemented in clinical settings as there are controversies regarding the specific area for 
accurate measurement of WC (Cornier et al., 2011). The use of WC as a measurement of abdominal 
obesity is also limited by the fact that it is sensitive to body size, as well as fat percentage and 
distribution (Krakauer & Krakauer, 2012). 
Waist- and HC are used in combination to calculate WHR (Norton & Olds, 1996), which is an 
alternative index reflecting the accumulation of abdominal fat (Stewart & Sutton, 2012). The rationale 
behind this index is that the greater the accumulation of abdominal fat, the greater WC is relative to 
HC (Olds et al., 2013). It has been criticised for its use in assessment of body composition, as there is 
still no consensus on cut-off points defining obesity and central obesity (Cornier et al., 2011).  
A WC of > 94 cm in men, and > 80 cm in women, and a WHR of 0.94 in men and 0.85 in women 
have been associated with an accumulation of visceral fat, which is associated with an increased risk 
for CVD and T2DM (Eston & Reilly, 2009; IDF, 2006; Stewart & Sutton, 2012). Waist 
circumference, HC and WHR have been shown to be more useful than BMI in predicting CVD, CHD 
and other metabolic-related disorders (Cornier et al., 2011; Kabat et al., 2015). In addition, HC and 
WHR have been suggested as an alternative index of body shape to predict mortality compared to 
BMI (Stewart & Sutton, 2012).  
It should be noted that it is still uncertain which adiposity index is more strongly associated with the 
risk of cancer development (Krakauer & Krakauer, 2012). This could be due to differences in study 
designs and a lack of proper studies evaluating different anthropometric indexes in relation to cancer 
risk (Kabat et al., 2015). In addition, there is very little evidence in the literature on the association 
between body shape and predisposition to diseases including the MetS and cancer (Baltadjiev & 
Vladeva, 2014). A detailed discussion on body shapes will be the topic of the next section. 
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1.4.3 Somatotyping: Body shape  
1.4.3.1 Introduction  
Somatotyping describes body shape and body composition (Eston & Reilly, 2009; Stewart & Sutton, 
2012), and can be divided into anthropometric somatotyping and photoscopic somatotyping (Norton 
& Olds, 1996). Anthropometric somatotyping can be calculated using a combination of different 
anthropometric measurements (weight, height, skinfolds, bi-epicondylar breadths, and 
circumferences) (Norton & Olds, 1996). The gold standard for somatotyping is the combination of 
anthropometric and photoscopic evaluation (Eston & Reilly, 2009; Norton & Olds, 1996). 
Somatotyping has its advantages above routine anthropometrical measurements such as BMI and WC, 
as it indicates the difference between individuals with the same level of adiposity and BMI (Eston & 
Reilly, 2009; Norton & Olds, 1996). However, somatotyping is based on careful observation of the 
different components, and a trained eye is needed to perform this observation objectively (Eston & 
Reilly, 2009; Norton & Olds, 1996).  
1.4.3.2 Components of photoscopic somatotyping 
Photoscopic somatotyping, also known as anthroposcopic somatotyping, works on a rating system 
that is based on visual inspection of an individual itself or a photograph of the individual (Norton & 
Olds, 1996).  
Somatotyping is a quantitative expression or description of an individual’s morphological 
conformation (Eston & Reilly, 2009; Norton & Olds, 1996), and gives an overall summary of an 
individual’s present physique as a whole entity (Ronco et al., 2008). Somatotyping gives a useful 
summary of a variety of measurements, as well as observations of the human body, which should only 
be interpreted as a whole entity (Eston & Reilly, 2009; Ronco et al., 2008).  
Each component of somatotyping defines a specific aspect or trait of how the human body is built  
(Norton & Olds, 1996). This is expressed as a numeral on a continuous scale, which starts at zero and 
has no upper limit (Eston & Reilly, 2009; Norton & Olds, 1996).  
The first component of somatotyping is known as endomorph describes the degree of adiposity of the 
body  (Figure 1.9A) (Eston & Reilly, 2009; Norton & Olds, 1996). Physical aspects include degree of 
roundness of the body, softness of contours, and relative volume of the abdominal area (Norton & 
Olds, 1996). 




Figure 1.9: The different components of somatotyping. 
(Adopted from: Olds et al., 2013) 
 
The second component of somatotyping is known as mesomorph which describes the degree of 
musculoskeletal development of the body  (Figure 1.9B) (Eston & Reilly, 2009; Norton & Olds, 
1996). These physical aspects include robustness of the body in terms of muscle or bone, relative 
volume of the thoracic trunk, as well as muscle bulk (Norton & Olds, 1996).  
The third component of somatotyping known as ectomorph, describes the degree of slenderness of the 
body (Figure 1.9C) (Eston & Reilly, 2009). Physical aspects include relative linearity of the body and 
the fragility of the limbs in the absence of any bulk muscle, fat or other tissue type (Eston & Reilly, 
2009; Norton & Olds, 1996). 
Other anthropometric methods have been proven to be more useful in describing body shape; however 
somatotyping requires minimal equipment and is a portable method (Norton & Olds, 1996). 
Somatotyping has been mostly used in fitness and athletic assessments (Eston & Reilly, 2009; Norton 
& Olds, 1996), however, its use within the medical field has been mainly related to obesity and CVD 
risk and not in cancer research (Ronco et al., 2008). This is attributed to the fact that more advanced 
techniques like three-dimensional whole body scanning are being used to determine the somatotype 
(Olds et al., 2013).   
1.4.3.3 Android and gynoid body shape linked to disease states 
There are three extreme somatotypes namely extreme endomorph, extreme mesomorph and extreme 
ectomorph (Norton & Olds, 1996). For the purposes of this thesis, only extreme endomorph which 
includes android and gynoid body shapes will be discussed, as it has been associated with CHD, 
CVD, Type 1 diabetes mellitus (T1DM), cardio-metabolic abnormalities, the MetS and cancer (Eston 
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& Reilly, 2009; Momesso et al., 2011; Orbetzova et al., 2012; Ronco et al., 2008; Samsell et al., 
2014).  
It has been well-established that men and women have distinct fat distribution patterns (Stewart & 
Sutton, 2012). Men store adipose tissue predominantly in the abdominal region and women in the 
femoral-gluteal region (Patidar, 2013). This sex-specific distribution is thought to appear during 
puberty (Stewart & Sutton, 2012). However, due to changes in dietary patterns and an increase in 
prevalence of sedentary behavior, this sex-specific distribution is being changed, as more women 
present with an android body shape (Sardinha et al., 2012). 
The android body shape is generally described to have the shape of an apple (Figure 1.10A). It is 
characterized by wide shoulders, arms, chest and a large abdomen, thus most of the fat being present 
in the abdominal region of the body (Patidar, 2013; Stewart & Sutton, 2012). With this shape, the 
gluteo-femoral region of the body, i.e. thighs, hips and legs are much leaner when compared to the 
abdominal region of the body (Patidar, 2013; Stewart & Sutton, 2012). The android body shape is 
predominately found in men and is a major risk factor for CVD, dyslipidaemia and IR (Eston & 
Reilly, 2009; Patidar, 2013). This is due to the fact that men store 20-30 % of their total body fat in 
the abdominal area, irrespective of obesity status (Donohoe et al., 2011). 
 In contrast, women only store a small quantity of total body fat in the abdominal area, and this 
quantity increases when a moderate level of obesity is reached (Donohoe et al., 2011). An increase in 
the prevalence of the android body shape is found in the MetS, overweight and/or obese females 
(Sardinha et al., 2012). In addition, the prevalence of an android body shape is also higher in post-
menopausal female’s vs pre-menopausal women (Noroozi et al., 2010).  
 
Figure 1.10: Android and gynoid body shapes. 
(Adapted from: Dorgan et al., 2012) 
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The gynoid body shape is generally described as pear-shaped (Figure 1.10B). It is characterized by 
broad thighs, hips and legs, with most of the storage fat being present in the gluteo-femoral region of 
the body (Patidar, 2013; Stewart & Sutton, 2012). The superior aspect (trunk) of the body is much 
leaner when compared to the gluteo-femoral region of the body (Patidar, 2013). This body shape is 
predominately found in women (Patidar, 2013; Ronco et al., 2008). 
Gynoid obesity is thought to have cardio-protective properties (Stewart & Sutton, 2012). However, 
there is a lack of research focussing on hip-girths, despite the fact that this hip area is a major storage 
site for adipose tissue in women (Mastaglia et al., 2012). This is attributed to the fact that the most 
health-risk research has been focusing on abdominal obesity (Stewart & Sutton, 2012). Although a 
higher HC and WHR was found to be significantly associated with an increases risk for various 
diseases (Noroozi et al., 2010), previous findings suggest that a larger HC, to some extent, are 
protective in women (Stewart & Sutton, 2012). This may be related to the fact that the hip area is an 
alternative storage site for excess fat, with gynoid adipocytes possibly having an increased lipoprotein 
lipase activity and therefore a more effectively storage capability compared to visceral adipocytes 
(Stewart & Sutton, 2012; Wiklund et al., 2008).  
Recent advances in software technologies have enabled the DEXA to assess regions of fat distribution 
(Figure 1.10C), therefore enabling the determination of an android-gynoid ratio (A/G ratio), which is 
related to disease risk, and has been found to be a good predictor of the MetS risk factors (Samsell et 
al., 2014). Since body shape is mostly gender-specific, it is thought that the gender-specific fat 
distribution pattern is sex hormone-regulated (Mastaglia et al., 2012). Oestrogen is a key regulator of 
adipose tissue distribution – after menopause oestrogen levels decline significantly and contributes to 
the distribution of adipose tissue to become more male-like and android shaped (Noroozi et al., 2010; 
Sardinha et al., 2012).  
A study by Mastaglia et al. (2012) indicated that older, apparently healthy Caucasian women (60-69 





, p<0.04). In addition, android fat mass (AFM) (1.5 ± 0.5 vs 1.3 ± 0.5 kg, p<0.04), and A/G 
ratio (0.7 vs 0.8, p<0.01) was significantly higher in post-menopausal women compared to pre-
menopausal women (Mastaglia et al., 2012).  
Wiklund et al. (2008) showed that AFM and gynoid fat mass (GFM) is associated with CVD risk in 
both men and women. In men, AFM was found to be the strongest predictor of most cardiovascular 
risk factors including TG, hypertension and impaired glucose tolerance (IGT), whereas in women, the 
A/G ratio was found to be the strongest predictor (Wiklund et al., 2008). 
A case control study by Orbetzova et al. (2012) found that obese women displaying both android and 
gynoid body shapes had significantly higher FM and FFM vs age-matched controls. Mean leptin 
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levels were found to be significantly higher in women with android obesity (21.28 ± 11.4 ng/ml units 
vs 10.02 ± 5.89 ng/ml, p<0.05) vs controls. In addition, android obesity had significantly higher mean 
insulin levels (20.13 ± 8.17 mIU/ml vs 10.47 ± 5.24 mIU/ml, p<0.05) compared to gynoid obesity 
(Orbetzova et al., 2012), suggesting, that an android fat distribution may play a role in the 
development of IR/hyperinsulinaemia.  
Momesso et al. (2011) aimed to assess the relationship between body composition, MetS and IR in 
female patients with T1DM. Dual-energy X-ray absorptiometry revealed that women with T1DM and 
the MetS had a higher android fat distribution (41.9 ± 2.0 % vs 33.7 ± 1.8, p=0.004) and A/G ratio 
(0.9 ± 0.005 % vs 0.7 ± 0.03 %, p=0.0002) when compared to women with only T1DM. Total body 
fat, as well as gynoid fat percentage was not found to be significantly different between groups with 
and without the MetS. In addition, the estimated glucose disposal rate as an estimate of insulin 
sensitivity, was negatively associated with android fat percentage (r =-0.33, p=0.03), A/G ratio (r=-
0.51, p=0.004), WC (r= -0.50, p< 0.001), as well as WHR (r=-0.63, p< 0.0001). Android fat 
percentage was also positively associated with LDL-c (r=0.38, p=0.01) and TG levels (r=0.35, 
p=0.019) and negatively correlated with HDL-c (r=-0.38, p=0.01). These results indicate that 
abdominal fat depositions are associated with the MetS and IR, which may lead to an increased risk 
for cardio-metabolic diseases (Momesso et al., 2011). 
 
Namwongprom et al. (2014) found that height, weight and WC were significantly higher in 
participants with the MetS than those without the MetS. Regional fat distribution parameters, AFM, 
android lean mass, GFM, gynoid lean mass and A/G ratio, was significantly higher in those with the 
MetS compared to those without the syndrome (p<0.001 for all parameters). Significant positive 
correlations were also observed between TG, SBP, diastolic blood pressure (DBP), fasting plasma 
glucose (FPG) and several body composition parameters (p<0.05). To adjust for BMI, gender, birth 
weight and BMI, linear regression analysis revealed significant positive correlations with the MetS 
risk components score and WC (p<0.001), AFM (p<0.001) and A/G ratio (p<0.001). These results 
support evidence that abdominal fat is a major predictor of the MetS and other metabolic 
abnormalities (Namwongprom et al., 2014). 
Body shape, increased weight, obesity and fat distribution patterns have been associated with an 
increased risk for cancer especially in women (Healy et al., 2010; Kim et al., 2007; Zhang et al., 
2010
B
). However, these studies were based on anthropometric methods utilising BMI, WC or skin 
fold measurements to represent obesity or abdominal obesity. A study by Ronco et al. (2008) 
investigating whether body shape was associated with an increased risk for breast cancer development 
in women, found that of all the somatotype variables, only endomorph was significantly higher in 
cases vs controls (6.91 ± 1.96 vs 6.54 ± 1.81, p=0.004). In addition, a high endomorph somatotype 
was associated with an increased risk for breast cancer. When endomorph was distinguished by 
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menopausal status, it was found that pre-menopausal women had an increased risk for breast cancer, 
whereas in post-menopausal women only the adjusted OR was significantly associated with breast 
cancer risk (OR 19.8, CI 95%, 1.00-3.90, p=0.03). Thus, endomorph was associated with an increased 
breast cancer risk irrespective of menopausal status (Ronco et al., 2008). On the other hand, Dorgan et 
al. (2012) showed that total adiposity and body fat distribution were significantly inversely associated 
(p<0.001) with increased breast tissue density. In addition, A/G ratio was negatively correlated with 
denser breast tissue, which has also been linked to an increased risk of breast cancer (Dorgan et al., 
2012).  
Scientific evidence reveals a direct relationship between obesity, especially central obesity and 
chronic diseases including the MetS (Haghighatdoost et al., 2014). Thus, it is pivotal to make use of 
validated and reliable anthropometric indexes such as BMI, WC, WHR, to estimate disease risk 
associated with obesity and the MetS (Samsell et al., 2014).  
 
1.4.4 A body shape index (ABSI) 
The use of the BMI as a metric of obesity classification is limited by the fact that it does not have the 
ability to distinguish between fat and muscle mass, and only provide information on the distribution 
of fat mass (Haghighatdoost et al., 2014). Waist circumference has been recommended as 
measurement of abdominal obesity to account for BMI’s limitations (Haghighatdoost et al., 2014). 
However, the use of WC as a measurement of abdominal obesity is limited by the fact that it is 
sensitive to body size, as well as TBF percentage and fat distribution (Kabat et al., 2015). 
These limitations should be recognized; as evidence clearly shows that an increase in abdominal fat 
leads to an increased risk for the incidence and mortality of non-communicable diseases, while an 
increase in muscle mass decreases mortality risk (Haghighatdoost et al., 2014; Krakauer & Krakauer, 
2012).  
Due to the limitations and discrepancies for the use of BMI and WC, a new metric has been proposed, 
known as a body shape index (ABSI) (Krakauer & Krakauer, 2012). This new metric takes weight, 
height and WC into account, and is independent from BMI (Krakauer & Krakauer, 2012).  
Equation 1 








The ABSI formula was derived from data obtained from the National Health and Nutrition 
Examination Survey (NHANES) (1999-2004), a survey based on mortality to better quantify the risk 
associated with abdominal obesity (Krakauer & Krakauer, 2012). Due to the fact that ABSI uses WC, 
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height and weight, it may improve methods of assessing risks related to obesity and body composition 
that is not captured by BMI (Krakauer & Krakauer, 2014).   
The ABSI is thought to be a more reliable method to measure body fat, because it takes height into 
account, as well as where fat is distributed (Krakauer & Krakauer, 2012). In addition, it is thought to 
give a better representation of overall body shape (Krakauer & Krakauer, 2012). A high ABSI value 
means that WC is higher than expected for a given height and weight, and this in turn corresponds to a 
larger abdominal area (Krakauer & Krakauer, 2012). A high ABSI value may also correspond to an 
increase in VAT compared to peripheral tissue (Krakauer & Krakauer, 2012). Furthermore, it may 
suggest that these individuals have decreased FFM and lean tissue, and it is for this reason that ABSI 
may be regarded as a better predictor for metabolic-related disease (Krakauer & Krakauer, 2014). 
Advantages of ABSI include the fact that it accounts for a sub-linear increase of WC and BMI, and a 
non-linear association of WC with height (Krakauer & Krakauer, 2012; Krakauer & Krakauer, 2014). 
In addition, ABSI is a convenient method to use in a clinical setting as it only requires standard 
weight, height and WC measurements, which are routinely done (Krakauer & Krakauer, 2012; 
Krakauer & Krakauer, 2014).   
To date, possible applications of ABSI include predicting all-cause mortality, CVD mortality, onset of 
T2DM, the MetS and high blood pressure to name but a few (Krakauer & Krakauer, 2014). However, 
data on ABSI and relative health risk are still controversial (Krakauer & Krakauer, 2012; Krakauer & 
Krakauer, 2014). Only one study has thus far shown that ABSI is a much stronger predictor of 
mortality than BMI and WC (Krakauer & Krakauer, 2012). This American-based study revealed that 
the risk factors for death increased by 1.13 % for each standard deviation increase in ABSI, and that 
the individuals in the highest ABSI quartile had death rates that were 61 % higher than those in the 
lowest quartile. In addition, the study showed that ABSI was significantly and positively correlated 
with abdominal adiposity (r=0.45, p<0.05) and negatively correlated with limb lean mass (r=-0.26, 
p<0.05). This study therefore concluded that a high ABSI value is a risk factor for pre-mature 
mortality in the general population. However, although ABSI predicted mortality risk across age, sex 
and weight, ethnic differences were evident, which limited the utility of ABSI. This further suggests 
that more studies are needed to strengthen the use of this metric (Krakauer & Krakauer, 2012). 
Haghighatdoost et al. (2014) investigated the predictive ability of ABSI for the MetS and CVD risk 
compared to BMI and WHR in an Iranian population. In this study, a weak correlation between ABSI 
and numerous CVD risk factors (TC, TG, HDL-c, LDL-c, FPG, CRP, Apo lipoprotein A & B, SBP 
and DBP), as well as the MetS were evident. ABSI was found to be a weak predictor of both CVD 
risk and the MetS (Haghighatdoost et al., 2014), whereas in the case of T2DM and hypertension 
onset, ABSI showed a stronger predictive ability than BMI (Duncan et al., 2013; He & Chen, 2013).  
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Biolo et al. (2015) assessed the efficiency of ABSI to predict variability of fat free mass index (FFMI) 
in men and women and reported that FFMI was negatively associated with ABSI and positively 
associated with BMI. Linear regression analysis showed that BMI and ABSI are both independent 
predictors of FFMI in men and women respectively. In addition, men and women with a lower ABSI 
showed a significantly greater FFMI, and the ABSI also positively correlated with log CRP (r= 0.30, 
p< 0.05) and negatively with a reciprocal of plasma insulin (r= -0.25, p< 0.05), which is an index of 
insulin sensitivity.  
Evidence from various studies postulates the possibility that ABSI may be a useful index to possibly 
assess the association of obesity to the potential risk of developing certain cancer types. A study by 
Kabat et al. (2015) in post-menopausal women, investigated ABSI and its association with the 
incidence of specific cancer types. Firstly, ABSI was weakly associated with height (r=0.047), weight 
(r=0.018, and BMI (r=-0.003), however it was strongly associated with WHR (r=0.75, p<0.0001). The 
study further revealed that ABSI was not associated with an increased risk for breast and endometrial 
cancer, while BMI and WC were strong predictors. In addition, WC and WHR showed a stronger 
association with colorectal and kidney cancer when compared to BMI. While ABSI was a significant 
predictor for colorectal cancer (Harding et al., 2015; Kabat et al., 2015), WC showed a stronger 
association when compared to ABSI (Kabat et al., 2015). This study showed that ABSI does not pose 
any improvement for assessing the association between abdominal obesity and the risk of obesity-
related cancers, since the association of WC and WHR with these cancers was much stronger 
compared to ABSI (Kabat et al., 2015)  
Overall, evidence for the use of ABSI as a predictive tool for disease risk still remains controversial. It 
is suggested that ABSI’s poor performance in estimating disease risk can be attributed to the fact that 
it has only been used to estimate total mortality and certain disease states. Further studies are therefore 
needed to investigate ABSI’s potential association with cancer incidence, mortality and risk.  In 
addition, ABSI has not been validated in other epidemiological studies which may differ in study 
population, outcomes, design, disease, and sample size.  
 
1.5 Problem statement & relevance of the study 
The MetS has been extensively studied in various populations with evidence pointing to a high 
prevalence of the MetS in all regions of the world (Awosan et al., 2013; Hu et al., 2004; Prasad et al., 
2012; Tachang et al., 2012). This is especially true for women as the prevalence of the MetS is higher 
in women vs men (Bhanushali et al., 2013). More specifically, there is an increase in the prevalence of 
abdominal obesity (android body shape) observed amongst women, which in turn, exacerbates the 
global prevalence of the MetS and its components amongst women (Momesso et al., 2011). Despite 
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this, there are still limited data on the prevalence of the MetS and its components in South Africa, 
especially the Western Cape (Peer et al., 2015
A
).  
In addition, evidence points to a link between the MetS, and its individual’s components, 
inflammatory markers as well as the sex hormone profile, and the risk of developing various lifestyle 
cancers (Alokail et al., 2013; Roberts et al., 2010). It is still unclear what the specific role of the MetS 
or its individual components is in the pathophysiology of cancer development, or if the risk is only 
associated with the MetS as a whole entity (Sinicrope & Dannenberg, 2011). It is thus important to 
establish whether the MetS and its components are precursors for various lifestyle cancers since the 
MetS is reversible and preventable by lifestyle interventions (Redig & Munshi, 2010). Despite the 
clinical significance of the MetS and the risk of cancer development, the pathophysiology is still 
understudied in the South African setting. 
South Africans need to recognize the burden and costliness of chronic lifestyle diseases. Early and 
accurate detection, diagnosis, treatment and prevention of the MetS and its components may decrease 
the disease burden of chronic diseases of lifestyle on private, as well as government healthcare 
providers in South Africa. In light of this, determining the prevalence of the MetS in the Western 
Cape will enable us to understand and resolve the effects of the MetS and its components to the risk of 
developing lifestyle cancers. This will provide significant insights into the extent of the MetS in the 
Western Cape, and in turn will contribute to the identification of underlying reasons. 
In addition, determining and understanding the prevalence and disease risk associated with the MetS 
will provide information that will benefit public health systems, by implementing earlier therapeutic 
and preventative targets (Beltrán-Sánchez et al., 2013). There is also the possibility that the risk of 
cancer can be reduced by lifestyle interventions such as dietary changes, i.e. calorie restriction and 
increased physical activity (Agnoli et al., 2010). In addition, identifying and understanding the 
pathophysiology behind the MetS and the association with cancer will enable researchers to develop 
new therapeutic targets, as well as develop new diagnostic tests based on biological markers playing a 
role in this MetS-linked cancer development. 
 
1.6 Aims and objectives 
1.6.1 Aims 
The primary aims were to describe the prevalence of the MetS and its association with cancer risk in a 
selected female population. Furthermore, we aimed to classify the female sample population based on 
their body shape, (android or gynoid), as well as body composition assessment measurements and 
describe biochemical associations that might increase their overall risk of cancer development. 




1. Determine the prevalence of the MetS in a female population.  
2. Determine if metabolic status and body-shape measurement/classification could predict 
changes in body composition, physiological and blood parameters and cancer risk. 
3. To investigate possible correlations/associations between selected anthropometric, BIA and 
blood markers (IGF-1, CRP, E2 and SHBG), the MetS and cancer risk. 
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CHAPTER 2:    MATERIALS AND METHODS
 
2.1 Introduction 
This chapter will focus on the materials and methods used for quantitative data collection. Other 
methods such as standard enzyme-linked immunosorbent assay’s (ELISA) will be presented as a 
summary and the full method listed as an addendum. 
2.2 Ethical considerations 
This study received ethical approval from Stellenbosch University’s Health Research Ethics 
Committee I (HREC I) (protocol number N13/04/052) (Appendix I). All principal investigators and 
researchers were familiarised with the ethical code of conduct, and were also certified in good clinical 
practice (GCP). 
Farm workers from three different locations, which included Villiera Wines at the Owethu Clinic 
(Stellenbosch), Neethlingshof (Stellenbosch), and Solms-Delta Wine Estate (Franschhoek), were 
invited to attend an information session regarding the specific research project. Farm workers could 
then volunteer to participate in the study, where after 20-30 minutes visitations were scheduled for 
each volunteer on different days during the week.  
At each scheduled visitation the researcher verbally explained to the participant what was expected of 
them during the data collection process, and that there would be a time investment of approximately 
20-30 minutes. Participants were given time to thoroughly read through the participant information 
leaflet and consent form (Appendix II), after which they were free to ask questions if they had any 
uncertainties. After reading through the informed consent form, the document was signed. It was 
made very clear that all participants volunteered to take part in the study and could withdraw their 
consent at any point in time during data collection. The participants were also assured of their 
anonymity as no names were used on any data collection forms - only the principle investigator had 
access to personal information. All information was number coded and stored in a lockable cupboard 
and office. These number codes were used in all data capturing procedures, as well as laboratory 
analyses. For privacy reasons, all participants were spaced apart (with dividers) so that they could not 
hear or see each other. Following laboratory analyses, individual feedback session were provided to 
all volunteers at the respective data collection sites.  
2.3  Study design and setting 
The initial study design was intended to be a cohort (>6 years), with the focus on the effect of 
urbanization on health change or disease risk, on different strata i.e. deep rural, rural, peri-urban 
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(includes farm workers) and urban. However, due to the collapsing of funds this current study’s 
design is cross-sectional, with the focus on farm workers.  
A cross-sectional, baseline descriptive study design was followed in the Stellenbosch Municipal 
region focussing on the surrounding wine estates in the Western Cape Province. Data collection 
commenced between March 2015 until July 2015, from three different locations; Owethu Clinic 
(Stellenbosch) on the Villiera Wine Estate, Neethlingshof Wine Estate (Stellenbosch), and Solms-
Delta Wine Estate (Franschhoek).  
 
2.4  Study population 
The study population included volunteering women between the ages of 20-60 years. 
 
2.5 Study inclusion and exclusion criteria 
For eligibility into the study, the participants had to meet the following inclusion criteria: (1) they 
must be between the ages of 20-60 years, (2) must be permanent residents of the Western Cape 
Province (Winelands region), and (3) must have the ability to provide informed consent. Those who 
were ineligible were either younger or older than 20-60 years, not usual residents from the Western 
Cape Province, or pregnant or lactating at the time of data collection.   
2.6  Selection of participants 
The total number of successfully recruited, volunteering participants (which included both men and 
women) was n=191 (Figure 2.1). From this initial sample, n=42 men were excluded for this particular 
study, and n=2 women withdrew consent due to time constraints. Following data collection, a further 
n=7 women were excluded due to the inability to classify their body shape. Due to technical errors, 
n=12 women also had to be excluded. Thus, a total of n=63 participants were excluded.  
 
The remaining n=128 women were then either classified as having the MetS or not, based on the 
IDF’s criteria. This definition includes WC as the first compulsory criteria, based on population and 
country-specific cut-off values, and also recognizes that inflammation plays a role in the 
pathophysiology of the MetS (IDF, 2006). 
 
 




Figure 2.1: Selection process of participants for this current study. 
The classification of participants was according to the IDF’s guidelines, the following criteria were 
used. Central obesity, WC ≥ 80 cm for women, had to be present, plus any two of the following 
components: blood pressure (SBP ≥ 130 mmHg, and DBP ≥ 85 mmHg), fasting blood glucose (FBG) 
(≥ 5.6 mmol/L), HDL-c (< 1.3 mmol/L for women) or TG (≥ 1.7 mmol/L) (IDF, 2006). Following this 
classification, n=62 participants were divided into the non-MetS group, whereas n=66 were classified 
as having the MetS. 
 
Female participants within the MetS or Non-MetS groups were also further classified according to 
body shape, to render the following groups (Figure 2.1):   
1. MetS with gynoid body shape (MetSG) (n=29). 
2. MetS with android body shape (MetSA) (n=37). 
3. Non-MetS with gynoid body shape (NMetSG) (n=50). 
4. Non-MetS with android body shape (NMetSA) (n=12). 
 
In order to obtain a final sample size of n=80 for all data and laboratory analyses, the n=128 
participants, belonging to the different groups, underwent random allocation to ensure an equal 
probability to be included in the final sample, with the exception of the NMetSA group, which only 
had n=12 participants (Figure 2.1). 
The n=80 women were randomly allocated to the specific subgroups as follows (Figure 2.1): 
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1. MetSG (n=23) 
2. MetSA (n=23) 
3. NMetSG (n=22) 
4. NMetSA (n=12) 
2.7 Data collection and handling 
Each participant spent approximately 30 minutes completing a series of questionnaires, tests and 
assessments. All data files and questionnaires were number coded, and these number codes were used 
during all data capturing procedures, as well as laboratory analyses to ensure confidentiality and 
anonymity. Data collected from each participant was captured on separate data sheets, where after all 
the collected data were entered into an excel spread sheet and thoroughly checked for any missing 
values, inconsistencies or any typing errors. To further ensure anonymity, excel sheets were password 
protected. 
2.8 Lifestyle questionnaires 
 
2.8.1 Global physical activity questionnaire (GPAQ) 
Physical activity was indirectly assessed using the global physical activity questionnaire (GPAQ) 
version 2 (WHO GPAQ, 2004) (Appendix III). This questionnaire is a standardized questionnaire 
developed by the WHO to assess physical activity in epidemiological field studies. It is a reliable 
physical activity assessment tool, and has been validated in several countries (Bull et al., 2009). The 
GPAQ consists of 16 questions, which were developed to assess various components of physical 
activity, i.e. intensity, duration and frequency. In addition, it assessed physical activity in three 
different settings i.e. occupational-related, transport-related and physical activity during leisure time 
(WHO GPAQ, 2004). 
2.8.2 Smoking and drinking questionnaire 
Smoking and drinking (alcohol) was indirectly assessed using a standardised questionnaire. Each 
questionnaire included questions regarding history of smoking/drinking, the quantity in relation to 
smoking/drinking, as well as how long participants have been smoking/drinking (Appendix IV).  
2.9 Anthropometrical assessments  
All anthropometrical measurements performed and included in this study were done according to 
guidelines set out by the International Society for the Advancement of Kinanthropometry (ISAK) 
(Olds et al., 2006; Stewart et al., 2011). Indices of body fat distribution included in this study were 
BMI, WC, HC, WHR, photoscopic somatotyping (Appendix V) and BIA (Appendix VI). 
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In order to obtain information on body shape and body composition, all participants were informed 
during the consent process that they would have to remove some (not all) clothing for body dimension 
assessment. Any metal objects were also removed prior to the BIA assessment, to adhere to the 
standard pre-test BIA protocol. All measurements were done in a private, separate section of the 
examination room with a divider. All anthropometric measurements were measured in duplicate to 
ensure accuracy. 
2.9.1 Base measurements: body mass and stretched stature 
For base measurements, all study participants were instructed to remove all heavy clothing, shoes and 
any other additional clothing accessories (i.e. hats, head bands) to ensure measurement accuracy. 
2.9.1.1 Body mass 
Participants were requested to void before any anthropometrical assessment commenced. Before body 
mass was taken, the electronic scale was set to zero. The participants were instructed to stand in the 
centre of the scale (Seca 634; Seca United Kingdom, Birmingham, England) without any support, and 
with the weight evenly distributed between both feet. The weight measurement was taken to the 
nearest 0.01 kg. 
2.9.1.2 Stretched stature  
Each participant’s height was measured using a portable, standard stadiometer (Leicester™; Leicester, 
England) without shoes. Participants were instructed to stand on the foot base of the stadiometer 
assuming the correct anatomical stance. Participants were then told to stand in an upright position 
(heels together) with the scapula and buttocks as close to the vertical sliding bar as possible, with 
arms relaxed. The participants’ head was placed in the Frankfort plane, and using the sliding head 
board (Broca plane) of the stadiometer, the height was measured to the nearest 0.1 cm. The BMI 
(kg/m
2
) was calculated using these base measurements.   
2.9.2 Waist and hip circumference measurements 
Waist circumference and HC measurements were assessed using a Lufkin tape measure (Lufkin, 
USA). The cross-hand technique was used for all circumference measurements. Participants were 
instructed to stand in an upright position with the abdomen relaxed, arms at sides and feet together. 
For the WC, the measuring tape was placed around the participant’s waist between the 10th lower 
costal rib and the superior iliac crest at the narrowest plane of the abdomen (Eston & Reilly, 2009; 
Olds et al., 2006). For the HC, the measuring tape was placed around the largest area of the buttocks 
(i.e. around the gluteal muscles), with the participants’ feet together. Both the WC and HC 
measurements were taken to the nearest 0.1 cm (Eston & Reilly, 2009; Olds et al., 2006). Waist-to-hip 
ratio was calculated by dividing WC by HC. 
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2.9.3 Photoscopic somatotyping 
Somatotyping was done using the photoscopic somatotyping technique (Norton & Olds, 1996). This 
technique involves the visual inspection of participants in order to evaluate the relative degree, 
presence or absence of each component of somatotype, in order to classify them as either android or 
gynoid body shape. The android body shape is generally described to have the shape of an apple, with 
most of the fat being present in the abdominal region (Patidar, 2013; Stewart & Sutton, 2012). The 
gynoid body shape is generally described to have the shape of a pear, with most of the fat being 
present in the gluteo-femoral region of the body, while the abdominal part of the body is much leaner 
(Patidar, 2013; Stewart & Sutton, 2012). 
2.9.4 Bio-electrical impedance analysis (BIA) 
Bio-electrical impedance analysis measurements were done using the multi-frequency Bioscan 920 II 
analyser (Maltron 920, UK), to assess FM (%), FFM (%) and muscle mass (kg). All participants were 
instructed to remove all forms of metal, which included jewellery, cell phones, money or any other 
electronic equipment that might interfere with the Bioscan 920 II multi frequency analyser during 
analysis A pre-test protocol was followed prior to measurements (Appendix VI). 
2.9.4.1 Full body analysis 
A full body analysis was conducted with the Maltron Bioscan 920 II analyser (Appendix VI). For the 
full body analysis, the participants were requested to lie on the examination bed in the supine position 
with their legs and arms slightly apart. The dominant (mostly right side) of the participants were 
always used for the BIA assessments. In some cases scar tissue, or prosthesis implants made accurate 
measurements difficult, in which the left side was used. The specific skin areas (hand and foot) used 
for testing were cleansed with 70 % v/v alcohol swabs (WebCol, USA, Illinois) before placement of 
the electrodes (Bodystat, United Kingdom). Prior to the measurement of a specific subject, their base 
measurements, i.e. weight, height, age, gender and ethnicity were entered in the Maltron Bioscan 920 
II analyser. 
The impedance of biological tissues was measured by placing the electrodes (with different channels 
and colours as seen in Figure 2.2) on the right hand and foot of the participant. Two current-
introducing electrodes were placed at the dorsal surfaces of the hand (near metacarpal phalangeal 
joint) (Channel 1) and foot (near metatarsophalangeal joint) (Channel 3), while two voltage-detection 
electrodes were placed proximal of the wrist (pisiform prominence) (Channel 2), and ankle (medial 
and lateral malleoli) (Channel 4) respectively (Walter-Kroker et al., 2011). The Maltron Bioscan 920 
II analyser applies various excitation currents i.e. 5, 50, 100 and 200 kHz via channel 1 and channel 3 
and detects the voltage drops via channel 2 and channel 4. 




Figure 2.2: The correct electrode placement for the BIA full test. 
(Adopted with permission from Maltron products Bioscan 920 II) 
 
Participant’ test results were initially stored on the Maltron Bioscan 920 II multi frequency analyser, 
and were later exported to Microsoft Office Excel 2010. All test results were number coded, and 
password protected to ensure anonymity.  
 
2.10 Blood pressure 
Blood pressure measurements were taken from each participant, and included in the IDF’s criteria for 
the MetS classification. Participants were allowed to sit in a relaxed position for approximately ten 
minutes before any blood pressure measurements were taken. Blood pressure was measured on the 
right arm, using a calibrated aneroid sphygmomanometer (Erka Perfect Aneroid 48, Germany), and 
stethoscope (Littmann 3M stethoscope, USA) with an appropriate sized cuff.  
Systolic blood pressure was recorded as the first Korotkoff sound, and DBP as the last Korotkoff 
sound (Frese et al., 2011). All blood pressure measurements were measured in duplicate to ensure 
accuracy. In cases where severe elevated blood pressure was detected participants were immediately 
referred to the clinic or health care providers. 
2.11 Blood sampling and analysis  
A Health Professions Council of South Africa (HPCSA) registered medical biological scientist (MW 
0010782) and phlebotomist performed blood collection from the cubital vein of the right arm by 
aseptic techniques into different blood collection tubes.  
One sodium fluoride (SF) tube (4 ml) was placed on ice and transported to the local PathCare 
laboratory in Stellenbosch for fasting blood glucose analysis. Two separate serum separator tubes 
(SST, 2x4 ml) were allowed to coagulate for 15 minutes at room temperature, after which it was 
centrifuged at 4000 revolutions per minute (rpm) for ten minutes at four °C. One of these tubes was 
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send to PathCare for a fasting serum lipogram profile and insulin analysis. The remaining SST’s 
serum was aliquotted into different Eppendorf tubes and frozen on dry ice, where after the samples 
were transported to the Department of Physiological Sciences’ Molecular Laboratory and stored at -80 
˚C, until subsequent biochemical analysis. Serum samples were used to analyse CRP, IGF-1, 
oestrogen and SHBG respectively. Serum oestrogen, as well as sex hormone binding globulin 
(SHBG) were assessed by the local PathCare (Stellenbosch), whereas, IGF-1 and CRP were assessed 
using ELISA kits. 
2.11.1 C-reactive protein (CRP) ELISA 
In comparison to other inflammatory markers, CRP has a large range of reliable high sensitivity 
assays available. C-reactive protein is stable in plasma and serum samples; and stable during long 
term storage at -20 °C and -80 °C. It is furthermore cost-effective, not influenced by diurnal variation 
and nutrition, available in various countries, and correlates well with other inflammatory biomarkers 
(Allin & Nordestgaard, 2011; Brenner et al., 2014; Guo et al., 2015; Ingle & Patel, 2011; Salazar et 
al., 2014; Shrivastava et al., 2015). Thus, CRP was considered a suitable biomarker to describe 
inflammation.  
A highly sensitive CRP ELISA (CRP human simple set ELISA kit®, Abcam, UK) kit was used to 
quantify CRP protein concentration in serum (appendix VII). The CRP concentration was assessed 
based on a solid phase sandwich-based ELISA assay, where the wells are pre-coated with an anti-tag 
antibody to immobilize the antibody-analyte complex (capture antibody\analyte\detector antibody). 
The CRP top standard (2000 pg/ml) was reconstituted with 0.2 ml water before making serial 
dilutions for the standard curve with the following concentrations: 1000 pg/ml, 500 pg/ml, 250 pg/ml, 
125 pg/ml, 62.5 pg/ml, 31.3 pg/ml and 15.6 pg/ml.  Fifty μl of each of the diluted standards, including 
a blank were added to the first 8 wells (in duplicate), whereas the rest of the wells were filled with 
different samples and the antibody cocktail (capture and detector antibodies to all wells) and allowed 
to incubate for one hour at room temperature. After incubation, the fluid was aspirated and wash 
buffer was added to each assay well (250 μl/well), and this step was repeated three times. This was 
followed by the addition of the 3, 3′, 5, 5′-tetramethylbenzidine (TMB) substrate solution, with the 
reaction brought to a stop after ten minutes with the addition of the stop solution. The assays’ 
sensitivity ranges from 15.63 pg/ml – 1000 pg/ml with a minimal detectable dose of 4 pg/ml 
(Appendix VII). 
The optical densities of all participant samples were measured at 450nm on an EL800 universal 
microplate reader (Bio-tek Instruments, Weltevreden Park, South Africa) within 15 minutes after the 
reaction was stopped. The optical density was directly (linearly) proportional to the CRP protein 
concentration of the participant sample. The concentration of all the participant samples was 
calculated by the formula produced by the standard curve. Serum samples were diluted 25 000x after 
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consideration of relevant literature (Alwachi et al., 2013; Barinas-Mitchell et al., 2001; den Engelsen 
et al., 2012; Lapice et al., 2009; Laugsand et al., 2011; Santos et al., 2005; Vidyasagar et al., 2013).  
2.11.2 Insulin-like growth factor-1 (IGF-1) ELISA 
A highly sensitive IGF-1 ELISA (IGF-1 human ELISA kit®, Abcam, UK) was used to quantify IGF-
1 concentration in serum (appendix VIII). This assay is based on a similar principle as the CRP 
ELISA, the only exception being the assays’ sensitivity range, from (0.1 ng/ml – 30 ng/ml), the 
minimal detectable dose of (< 0.2 ng/ml). 
The optical densities of all participant samples were also measured at 450nm on an EL800 universal 
microplate reader (Bio-tek Instruments, Weltevreden Park, South Africa) within 15 minutes after the 
reaction was stopped. Serum samples were diluted 20x after consideration of relevant literature 
(Friedrich et al., 2012; Friedrich et al., 2013; Gram et al., 2006; Kaushal et al., 2004; Oh et al., 2012; 
Schernhammer et al., 2007; Schmitz et al., 2011)  
  
5.12 Statistical analysis 
All collected data was captured in Microsoft Office Excel 2010. Statistica Software version 12 
(StatSoft, Inc., USA) was used to analyse data and the level of significance set as p<0.05.   
All results are reported as means ± standard error of the mean (SEM) or medians depending on 
normality of data. For normally distributed data, student t-tests were performed to determine the 
difference in variables between two groups, and factorial analysis of variance (ANOVA) with 
Bonferonni post hoc test was done to establish significance between the four respective groups.  
For data that was not normally distributed, non-parametric tests were performed. Mann-Whitney U 
tests were employed to determine the difference in variables between two groups and a one-way 
Kruskal-Wallis ANOVA was performed to determine the difference in variables between all the study 
groups. Pearson correlations were also used on selected parameters in each group and 2D scatter plots 
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CHAPTER 3:         RESULTS
 
3.1 Context of the chapter 
This chapter focussed on the results obtained in the current cross-sectional observational study. The 
results are presented in a logical flow, interpretable format, according to the aims and objectives as 
described in Chapter one. The chapter will further describe the study population, followed by a 
thorough portrayal of the population according to metabolic status and body shape. Finally, the 
chapter will make use of correlations to determine possible associations between selected parameters 
of physiological interest. 
3.2 Descriptive profile of the study population  
From the total sample (n=80) women, n=46 were identified by using IDF criteria with the MetS (57.5 
%), while n=34 did not present with the MetS (42.5 %) (Figure 3.1A). Considering body shape, n=23 
women in the MetS group exhibited a gynoid body shape, and n=23 women had an android body 
shape (Figure 3.1B). Sixty five percent, and 35 % of the women in the non-MetS group presented 
with a gynoid (n=22) and android (n=12) body shape respectively (Figure 3.1C).  
 
 
Figure 3.1: The distribution of women in (A) the total study population according to metabolic status, (B) the MetS, 
or (C) the Non-MetS groups according to body shape. 
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3.3 Descriptive profile of the MetS and non-MetS groups 
3.3.1 Anthropometric and BIA characteristics 
The first aim of this study was to describe and compare women with and without the MetS in relation 
to age and body compositional differences. The women in the MetS group were significantly older 
compared to the non-MetS group (40.07 ± 1.58 vs 32.21 ± 1.36 years, p<0.001) (Table 3.1). 
Participants in the MetS group also displayed a significantly higher body mass (BM), BMI, WC, HC, 
WHR, and FM (%) than their non-MetS counterparts (p<0.001 for all except WHR: p<0.05), while 
FFM (%) was significantly lower (p<0.001). No significant differences were observed for height, 
ABSI, and muscle mass between these groups. 
 
Table 3.1: Summary of anthropometric and BIA characteristics for the MetS and non-MetS 
groups. 
Variable  MetS (n=46) Non-MetS (n=34) p-value 
Age (years) 40.1 ± 1.6 32.2 ± 1.4 p<0.001 
BM (kg) 84.81 ± 2.54 69.10 ± 3.43 p<0.001 
Height (m) 1.57 ± 0.01 1.58 ± 0.01 ns 
BMI (kg/m
2
) 34.4 ± 0.9 27.4 ± 1.2 p<0.001 
WC (cm) 93.10 ± 1.55 79.48 ± 2.28 p<0.001 
HC (cm) 114.66 ± 1.96 102.64 ± 2.63 p<0.001 





) 0.07 ± 0.00 0.07 ± 0.00 ns 
FM (%) 42.42 ± 1.64 32.04 ± 2.74 p<0.001 
FFM (%) 57.58 ± 1.64 67.96 ± 2.74 p<0.001 
Muscle mass (kg) 22.75 ± 1.32 19.87 ± 0.75 ns 
All values are presented as mean ± SEM. Student t-tests were employed, and p<0.05 were considered as statistically 
significant. ns=not significant 
 
BMI categories between women in the MetS and non-MetS groups 
With particular reference to BMI, approximately two thirds of the MetS population were classified as 
being obese (67 %), 31 % as overweight, and two percent as having a normal weight (Figure 3.2A). In 
the non-MetS group, 47 % of the females were overweight, 29 % had a normal weight, 21 % were 
obese, and only three percent were underweight (Figure 3.2B). 




Figure 3.2: Distribution of women in (A) the MetS and (B) the non-MetS groups according to the respective BMI 
categories. 
3.3.2 Physiological and biochemical blood parameters 
Analysis of specific physiological and biochemical blood parameters revealed significantly higher 
SBP, DBP, FBG, fasting insulin, LDL-c, TG and FAI in the MetS women, while HDL-c and SHBG 
were significantly lower (Table 3.2). All other parameters measured were found to not be significantly 
different between the groups.  
 
Table 3.2: Summary of physiological and biochemical blood parameters for the MetS and non-
MetS groups 
All values are presented as mean ± SEM with the exception of E2 and FAI which are presented as median ± IQR. Student t-
tests were employed for all parameters except for the E2 and FAI, where Mann-Whitney U tests were employed. p<0.05 was 
considered as statistically significant.*: Only n=64 samples included for analysis. #: Only n=61 samples included for 




















Obese   
21 % Normal 
29 % 
Variable  MetS (n=46) Non-MetS (n=34) p-value 
SBP (mmHg) 148.8 ± 3.8 125.1 ± 3.0 p<0.001 
DBP (mmHg 92.2 ± 2.2 77.4 ± 1.5 p<0.001 
FBG (mmol/L) 6.22 ± 0.51 4.67 ± 0.12 p<0.05 
Fasting Insulin (mIU/L) 35.69 ± 6.37 17.36 ± 2.07 p<0.05 
TC (mmol/L) 4.85 ± 0.16 4.47 ± 0.20 ns 
HDL-c (mmol/L) 1.02 ± 0.02 1.35 ± 0.06 p<0.01 
LDL-c (mmol/L) 3.13 ± 0.14 2.64 ± 0.16 p<0.05 
TG (mmol/L) 1.85 ± 0.16 1.02 ± 0.07 p<0.01 
CRP (mg/L)* 10.86 ± 1.53 6.68 ± 1.29 ns 
IGF-1 (ng/ml)
#
 79.50 ± 11.00 61.85 ± 12.35 ns 
E2 (pmol/L) 160.50 ± 75-218 137.00 ± 75-307 ns 
Female T (nmol/L) 1.2 ± 0.05 0.55 ± 0.08 ns 
SHBG (nmol/L) 42.57 ± 3.65 73.84 ± 12.52 p<0.01 
FAI 1.20 ± 0.80-7.75 0.70 ± 0.30-1.70 p<0.05 
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3.3.3 Distribution and prevalence of the MetS risk factors  
Apart from the fact that approximately 57.5 % of the study population presented with the MetS, we 
further aimed to describe the distribution of the MetS risk factors, as well as to establish which of the 
individual risk factors were more prevalent.  
 
Figure 3.3A illustrated that 57 % of the women presenting with the MetS, had three of the MetS risk 
factors (n=26), 28 % had four risk factors (n=13), and 15 % presented with five risk factors (n=7). In 
the non-MetS group, 18 % of the women presented with no risk factors (n=6), 35 % had one risk 
factor (n=12), 44 % had two risk factors (n=15), and 3 % had three risk factors (n=1) with the 
exception of WC (Figure 3.3B). 
 
 
Figure 3.3: Distribution of women in (A) the MetS, and (B) non-MetS groups according to the number of MetS risk 
factors present.  
For all the women in this particular study (irrespective of their metabolic status), the most prevalent 
risk factor was an increased WC (73.8 %, n=59) (Figure 3.4). This was closely followed by elevated 
blood pressure (BP), and decreased HDL-c levels (68.8 % for both, n=55), with approximately 27.5 % 
presenting with elevated TG levels (n=22), and 24.0 % with elevated FBG (n=19). When the 
metabolic status was considered, the most prominent risk factors still remained WC, BP and HDL-c 




































Figure 3.4 Prevalence of the MetS risk factors in women, irrespective of metabolic status. 
 
Figure 3.5: Prevalence of the MetS risk factors in women according to their metabolic status.  
 
 
3.4 Descriptive profile of the gynoid and android body shape groups 
3.4.1 Anthropometric and BIA characteristics 
Our next aim was to determine whether body shape had an effect on body composition, irrespective of 
the metabolic status. The women in the android group were significantly older compared to the 
women from the gynoid group (40.09 ± 1.68 vs 34.11 ± 1.49 years, p<0.01) (Table 3.3). Women in 
the android group also displayed a significantly higher BM, BMI, WC, HC, WHR, ABSI and muscle 
mass (kg), compared to the gynoid body-shaped group. No significant differences were observed for 
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Table 3.3: Summary of and BIA characteristics for the gynoid and android groups. 
Variable  Gynoid (n=45) Android (n=35) p-value 
Age (years) 34.1 ± 1.5 40.1 ± 1.7 p<0.01 
BM (kg) 72.06 ± 2.60 85.94 ± 3.46 p<0.01 
Height (m) 1.58 ± 0.01 1.57 ± 0.01 ns 
BMI (kg/m
2 
) 28.8 ± 1.0 34.8 ± 1.2 p<0.001 
WC (cm) 81.32 ± 1.76 95.02 ± 1.96 p<0.001 
HC (cm) 106.23 ± 2.04 113.81 ± 2.78 p<0.05 





) 0.0696 ± 0.00 0.0718 ± 0.00 p<0.05 
FM (%) 35.63 ± 2.01 41.08 ± 2.51 ns 
FFM (%) 64.38 ± 2.01 58.93 ± 2.51 ns 
Muscle mass (kg) 19.90 ± 0.44 23.61 ± 1.78 p<0.05 
All values are presented as mean ± SEM. Student t-tests were employed, and p<0.05 were considered as statistically 
significant. ns=not significant 
 
 
3.4.2 Physiological and biochemical blood parameters 
No significant differences were observed in any of the physiological and biochemical blood 
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Table 3.4: Summary of physiological and biochemical blood parameters for the gynoid and 
android body shape groups. 
Variable  Gynoid (n=45) Android (n=35) p-value 
SBP (mmHg) 135.8 ± 3.5 142.5 ± 4.6 ns 
DBP (mmHg) 83.6 ± 2.0 88.9 ± 2.6 ns 
FBG (mmol/L) 5.42 ± 0.41 5.75 ± 0.47 ns 
Fasting Insulin (mIU/L) 26.94 ± 4.04 29.14 ± 7.27 ns 
TC (mmol/L) 4.58 ± 0.16 4.82 ± 0.20 ns 
HDL-c (mmol/L) 1.20 ± 0.05 1.11 ± 0.04 ns 
LDL-c (mmol/L) 2.83 ± 0.14 3.04 ± 0.17 ns 
TG (mmol/L) 1.35 ± 0.11 1.69 ± 0.19 ns 
CRP (mg/L)* 8.06 ± 1.08 10.83 ± 2.02 ns 
IGF-1 (ng/ml)
#
 83.54 ± 12.40 62.37 ± 10.95 ns 
E2 (pmol/L) 137 ± 75-219 167 ± 91-280 ns 
Female T (nmol/L) 0.58 ± 0.05 0.59 ± 0.08 ns 
SHBG (nmol/L) 63.89 ± 9.82 45.53 ± 4.58 ns 
FAI 1.2 ± 0.45-1.95 1.1 ± 0.40-2.10 ns 
All values are presented as mean ± SEM with the exception of E2 and FAI which are presented as median ± IQR. Student t-
tests were employed for all parameters except for the E2 and FAI, where Mann-Whitney U tests were employed. p<0.05 was 
considered as statistically significant. *: Only n=64 samples included for analysis.  #: Only n=61 samples included for 
analysis. ns=not significant 
 
3.5 Differences between respective groups according to both metabolic 
status and body shape 
For a more thorough investigation into the effect of metabolic status and body shape, various 
anthropometric, BIA and blood-specific parameters were compared between the following four 
respective groups: (a) the MetS with gynoid body shape (MetSG) group, (b) the non-MetS with 
gynoid body shape (NMetSG) group, (c) the MetS with android body shape (MetSA) group, and (d) 
the non-MetS with android body shape (NMetSA) group. 
 
 
3.5.1 Anthropometric measurements 
3.5.1.1 Base measurements: body mass (BM) and height  
The participants in the MetSG group (Figure 3.6A) showed significantly larger BM compared to the 
NMetSG group (p<0.001). Similar results were also observed between the MetSA and NMetSA group 
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(p<0.01) (Figure 3.6A). No significant differences were observed for height between any of the 
respective groups (Figure 3.6B).  
  
Figure 3.6: Base measurements, which include (A) BM and (B) height, between the respective groups. 
 
3.5.1.2 Hip circumference (HC) and waist-hip-ratio (WHR) 
The MetSG group’s participants showed a significantly larger HC compared to the NMetSG group 
(p<0.01), however, this difference was not evident in the android group (Figure 3.7A). Although the 
WHR did not show any significant differences between the MetS and non-MetS groups for either 
body shape, the women in the NMetSA group showed a significantly higher WHR compared to those 


















































Figure 3.7: Hip circumference (A), and WHR (B) per body shape and metabolic syndrome status. The dotted lines 
represent normal levels for the respective parameters (WHO, 2008). 
 
3.5.1.3 Body mass index (BMI) and a body shape index (ABSI) 
Similar to the results observed for BM, significant differences in BMI were apparent between the 
MetSG, MetSA and their respective non-MetS body shape groups (p<0.001 for gynoid, and p<0.01 
for android) (Figure 3.8A). No significant differences were observed for ABSI (Figure 3.8B).  
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3.5.2 Bio-electrical impedance assessments 
The participants in the MetSG group had a significantly higher FM (%) (Figure 3.9A) and 
significantly lower FFM (%) (Figure 3.9B) compared to the NMetSG group (p<0.01 for both). No 
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3.5.3 The MetS risk factor measurements 
Women in the MetSG group displayed a significantly larger WC compared to their NMetSG 
counterparts (p<0.001), however these results were not evident in the android groups. Overall, the 
WC for the NMetSA group was significantly larger than that of the NMetSG group (p<0.001) (Figure 
3.10A). No significant differences were observed for FBG between any of the groups (Figure 3.10B). 
The women in the MetSG group furthermore showed both a significantly lower HDL-c and elevated 
TG levels compared to the women in the NMetSG group (p<0.001 for HDL-c and p<0.05 for TG) 
(Figure 3.10C&D). No other significant differences were observed for HDL-c, but TG levels were 
also significantly lower in the NMetSA group vs the MetSA group (p<0.05).  
Similar to that observed for HDL-c and TG, the non-MetS groups displayed significant lower SBP 












































































































Figure 3.10: MetS risk factors according to IDF criteria for (A) WC, (B) FBG, (C) HDL-c, (D) TG, (E) SBP, and (F) 
DBP. The dotted lines represent IDF cut-off criteria (IDF, 2006). 
 
3.5.4 Total cholesterol (TC) and low density lipoprotein-cholesterol (LDL-c) 
No significant differences were observed for both TC and LDL-c (Figure 3.11).  
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3.5.5 Fasting insulin and insulin-like growth factor-1 (IGF-1) 
No significant differences were observed for fasting insulin or IGF-1 between any of the groups 
(Figure 3.12).  
  
Figure 3.12: Fasting insulin (A), and IGF-1 (B) concentrations for the groups according to body shape and metabolic 
status. The dotted line represents normal cut-off criteria (reference range supplied by local pathcare laboratory, 
Stellenbosch). 
 
3.5.6 C-reactive protein (CRP) 
Similar to the data obtained for fasting insulin, IGF-1, TC and LDL-c, no significant differences were 
observed for CRP (Figure 3.13). 
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3.5.7 Oestrogen (E2) 




Figure 3.14: Median E2 concentrations with inter quartile ranges measured in the women belonging to the different 
groups. 
 
3.5.8 Female testosterone (T), and sex hormone binding globulin (SHBG)  
No significant differences were observed for female T, or SHBG in any of the different groups 
(Figure 3.15). From the normal level (Kozakowski & Zgliczyński, 2013), as indicated by the dotted 
line in Figure 3.15A for female T, females in all four groups displayed levels well within normal 






























Figure 3.15: Female-specific hormone analyses for (A) female T and (B) SHBG for the different body shape and 
metabolic status groups. The dotted lines represent normal cut-off criteria (Kozakowski & Zgliczyński, 2013). 
 
3.5.9 Free androgen index (FAI) 
Comparable to E2, no significant differences for FAI were observed between any of the groups 
(Figure 3.16).  
 
  











































































Stellenbosch University  https://scholar.sun.ac.za
71 
 
3.6 Correlation analysis 
Pearson correlation analysis were performed on selected anthropometric and biochemical parameters 
to establish any significant physiological relationships. For all correlation purposes, the MetSG and 
NMetSG groups will first be graphically presented, followed by the MetSA and NMetSA groups. For 
correlation analyses, r-values greater than 0.70 will be regarded as very strong, r-values between 0.40 
and 0.69 as strong, r-values between 0.30 and 0.39 as moderate and r-values between 0.20 and 0.29 as 
weak relationships. Any r-value less than 0.19 are indicative of no relationship (Scally, 2014). 
3.6.1 Insulin-like growth factor-1 (IGF-1) and anthropometric parameters 
Insulin-like growth factor-1 concentration positively correlated with the WHR for the women in all 
four study groups (Figure 3.17A&B). However, the correlations for both the MetS group’s gynoid and 
android were insignificant. Strong correlations were evident in both non-MetS groups, but only the 
NMetSG group showed significance (r=0.67, p=0.02). When FM (%) was correlated with IGF-1 
(Figure 3.17C&D), only the android groups showed a significant difference. The MetSA group 
displayed a strong positive correlation (r=0.45, p=0.05), whereas a very strong, negative correlation 
was found in the NMetSA group (r=-0.81, p=0.01).   
Insulin-like growth factor-1 concentration was negatively correlated to FFM (%) (Figure 3.17E&F) for 
the MetSG, NMetSG and MetSA groups, but a very strong positive correlation was evident for the 
NMetSA group. No significance was noted in any of the gynoid groups; however both the android 
groups showed significance (r=-0.45, p=0.05 for the MetSA and r=0.81, p=0.01 for the NMetSA 
groups respectively). Another correlation that was associated with IGF-1 included fasting insulin. A 
significant strong negative correlation was shown between fasting insulin and FM (%) in the women 
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Figure 3.17: Correlations between IGF-1 and WHR, FM% and FFM% for the gynoid and android groups according 
to the metabolic status. Correlations for IGF-1 and WHR are displayed in (A&B), IGF-1 and FM % in (C&D), and 
IGF-1 and FFM % in (E&F). 
3.6.2 C-reactive protein and anthropometric parameters 
Positive correlations were evident in all the study groups when CRP was correlated with BMI (Figure 
3.18A&B), with the exception of the NMetSG group which, showed a strong negative correlation. 
Only the MetSA groups’ correlation was shown to be significant (r=0.60, p=0.00). When CRP was 
correlated with WC (Figure 3.18C&D), significance was obtained in three of the four groups. The 
NMetSG group revealed a significant, strong negative correlation (r=-0.58, p=0.02), whereas both the 
MetSG and MetSA groups showed significant strong positive correlations (r=0.47, p=0.04 for MetSG 
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Figure 3.18: Correlations between MetS and non-MetS for the gynoid and android groups against CRP and BMI 
(A&B), and CRP and WC (C&D). 
 
3.6.3 Sex hormone binding globulin, and selected parameters 
Pearson correlation analysis further revealed a strong positive and significant correlation between E2 
and BMI (r=0.52, p=0.01) (Figure 3.19A), E2 and fasting insulin (r=0.43, p=0.05) (Figure 3.19C), and 
a strong negative correlation between SHBG and fasting insulin (r=-0.52, p=0.04) (Figure 3.19E) in 
women from the MetSG group. Negative correlations were observed for all other groups (Figure 
3.19A-F), except for the correlation between BMI and E2, which showed a weak positive correlation 

























































































   
Figure 3.19: Correlations between the MetS and non-MetS groups for the gynoid and android body shape against E2 
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3.5.4 ABSI and selected parameters 
Near similar results were obtained when correlations were drawn between ABSI and BMI for both the 
MetSG and MetSA, NMetSG and NMetSA groups respectively. Both the MetSG and MetSA groups 
displayed significant strong negative correlations (r=-0.48 for MetSG and r=-0.45 for MetSA, p=0.04 
for both) (Figure 3.20A&B), whereas the non-MetS groups showed a near similar correlation 
coefficient, however, only the NMetSG group showing a statistical trend towards significance (r=-
0.49, p=0.07). No significant correlations were evident for ABSI and IGF-1 in women of all the 
respective groups (Figure 34C&D). 
Significant, strong positive correlations were also found between ABSI and TG in the women from 
the MetSA group (r=0.55, p=0.02), and between ABSI and LDL-c in women of the NMetSG group 
(r=0.78, p=0.02; very strong) (appendix IX). 
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CHAPTER 4:        DISCUSSION
 
4.1 Context of this chapter 
This chapter argues the major findings of this current cross-sectional observational study. These 
findings include anthropometrical, BIA, physiological and biochemical blood parameters, and how it 
relates to the metabolic status, body shape and/or both, as well as possible cancer risk. Results within 
each sub-section will be discussed in a logical and integrated manner as described in Chapter 3. 
4.2 Major descriptive findings of the study population 
4.2.1 Overall high prevalence of obesity, the MetS and its individual components in 
women  
The prevalence of the MetS is on the rise in most populations around the world (Tachang et al., 2012) 
and South Africa is no exception. Approximately 57.5 % of the women in the current study were 
characterized as having the MetS classified according to the IDF criteria (Figure 3.1), a prevalence 
which is considerably higher than what was previously reported in American (Bhanushali et al., 
2013), Korean (Lim et al., 2011), European (Hu et al., 2004), Indian (Prasad et al., 2012), Australian 
(Cameron et al., 2007), and even in other South African (Motala et al., 2011; Peer et al., 2015
A
), as 
well as sub-Saharan African (Awosan et al., 2013; Tachang et al., 2012; Tran et al., 2011) 
populations. Although the prevalence of the MetS was significantly higher than that found in other 
parts of the world, our results confirmed the data obtained from another South African-based study 
which also made use of the IDF definition (Erasmus et al., 2012). Erasmus et al. (2012) found the 
prevalence of the MetS in Capetonian urban black women to be even higher (67.8 %) compared to our 
study. These discrepancies in the prevalence reported could be attributed to a number of factors. 
Firstly, the use of different definitions to characterize the MetS makes comparison between studies 
difficult. Our study population is somewhat similar to the population used by Erasmus et al. (2012), 
and the use of the IDF definition in our, as well as in Erasmus’ study could have accounted for the 
high prevalence reported. This is in contrast to the relatively low prevalence (26.5 %) found in the 
study by Peer et al. (2015
A
) in which the JIS definition was used to categorize the sample.  
Secondly, there are many confounding factors, including the region of interest, the population being 
studied (i.e. gender, age, ethnicity), the type of environment (i.e. urban or rural), as well as statistical 
adjustments (Prasad et al., 2012). Socio-economic status, sedentary lifestyles, level of physical 
activity, as well as genetic factors (Popkin et al., 2012) could also potentially have influenced the 
difference in prevalence. Although sample size might also impact the results (Prasad et al., 2012), this 
is not necessarily true for our population, since even with a small sample size (n=80), the prevalence 
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of the MetS was significantly higher than that reported by other studies. For example, Peer et al. 
(2015
A
) had a relatively large sample size (n=1099 men and women), but still reported a relatively 
low prevalence of the MetS. 
The clustering of none, one, two, three, four and five MetS risk factors were clearly dispersed 
between the MetS and non-MetS groups, with the majority of the MetS participants displaying three 
risk factors (57 %) compared to the three percent reported in the non-MetS counterparts (Figure 3.3). 
What is somewhat worrisome is that 15 % of the MetS group presented with all five risk factors. 
Another concern was that only 18 % of participants without the MetS presented with no risk factors. 
This number was alarming low, since studies have shown that the MetS and its risk factors have all 
been independently associated with CVD and T2DM (Alberti et al., 2009; Beltrań-Sánchez et al., 
2013; Kaur, 2014). This therefore suggests that even the women in our group with one risk factor 
could be at risk for CVD, however, it is still not entirely clear whether the MetS, or the sum of its 
individual risk factors are necessarily superior in determining cardiovascular risk.  
The current study found that abdominal obesity (measured by WC) (73.8 %), elevated blood pressure 
and decreased HDL-c (both 68.8 %) were the more prevalent MetS risk factors (Figure 3.4 & 3.5), 
which are in agreement with other South African studies. Peer et al. (2015
A
) showed that abdominal 
obesity (86 %) and decreased HDL-c levels were the most prevalent MetS risk factors in a black 
female population from Cape Town, while Motala et al. (2011) confirmed a high prevalence of 
decreased HDL-c levels in women. The high prevalence of elevated blood pressure in the current 
study contradicts previous studies that have found the prevalence of elevated blood pressure to be 
significantly higher in men (Erasmus et al., 2012; Motala et al., 2011; Peer et al., 2015
A
). Although 
this might be true, various studies have proposed that central obesity might be responsible; either 
independently, or through the induction of insulin resistance (via inflammatory mediators released 
from adipose tissue); for the development of systemic hypertension and dyslipidaemia (Alberti et al., 
2009; Fuentes et al., 2013; Zhao & Liu, 2013; Mendonça et al., 2015). Since the women in our study 
had an increased WC, this explanation might also hold true for our population. 
 
Other possible risk factors that might explain elevated blood pressure includes an unhealthy diet 
(calorie dense food, high salt intake, and low fruit and vegetable intake), lack of physical activity, as 
well as excessive alcohol consumption, and tobacco use (Peltzer & Phaswana-Mafuya, 2013; Ulasi et 
al., 2011). Smoking, alcohol consumption and physical activity levels of women in this current study 
could possibly explain the high prevalence of high blood pressure (Appendix X). Although we did not 
classify participants as heavy smokers or alcohol drinkers, approximately 56 % of our total study 
population were smokers, either previous smokers (20 %) or current smokers (36 %). In addition, 80 
% of the population were also classified as alcohol drinkers, either previously (25 %), or currently (55 
%) (Appendix X). Lastly, only a small proportion of the participants performed vigorous intensity 
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work (17.5 %) and recreational activity (7.5 %), whereas more participants partook in moderate 
intensity work (51.25 %), and recreational activity (71.25 %) (Appendix X). This therefor showed that 
more participants participated in a moderate level of physical activity. 
 
Although BMI is not normally used to indicate abdominal obesity (according to the IDF definition), 
various studies have linked the high prevalence of the MetS with a higher prevalence of 
overweight/obesity in South African women (Erasmus et al., 2012; Motala et al., 2011; Peer et al., 
2015
B
). The current study found an overall higher prevalence of overweight (31 %, n=14 vs 47 %, 
n=16), and obesity (67 %, n=31 vs 21 %, n=7) in both the MetS and non-MetS groups (Figure 3.2), 
which collectively accounts for a prevalence of 85 % (n=68). These results corroborated the findings 
by Peer et al. (2015
B), in which the prevalence of overweight/obesity (BMI ≥ 25 kg/m2) was shown to 
be 82.8 %, the highest reported prevalence of overweight/obesity in sub-Saharan Africa at the time. 
van Zyl et al. (2012) also showed that the prevalence of overweight/obesity in females is high (43.1 
%), although not as high as in our population. Taken together, obesity is a major problem in South 
African females and may predispose individuals to develop the MetS if it coincides with other MetS 
risk factors. 
In order to determine the effect of adipose tissue distribution on the metabolic status, females were 
grouped according to body shape. Males normally store adipose tissue in the abdominal region of 
their body, displaying an android body shape, while females store adipose tissue in the gluteo-femoral 
region, displaying a gynoid body shape (Patidar, 2013; Stewart & Sutton, 2012). Women only store a 
small percentage of their TBF in their abdominal area; however this percentage is significantly 
increased when a moderate level of obesity is reached (Peppa et al., 2012). This finding of an 
increased prevalence of android body shape in overweight and obese women, as well as women with 
the MetS, was also supported by Sardinha et al. (2012). Our data is in accordance with previous 
studies of an increased prevalence of an android body shape in women with the MetS compares to 
those without the MetS (MetSA, 50 % vs NMetSA, 35 %) (Figure 3.1B&C). Several studies relate 
these findings to changes in urbanization, nutrition transition, economy and lifestyle, i.e. unhealthy 
diets, sedentary behaviour and lack of physical activity (Bourne et al., 2002; Dias et al., 2014; 
Erasmus et al., 2012; Steyn et al., 2012; Vorster et al., 2005; Vorster et al., 2011), all of which have 
been shown to significantly impact lifestyle diseases, such as obesity and hypertension, ultimately 
resulting in a high prevalence of the MetS. We speculate that our findings may also in part be due to 
cultural beliefs, since unhealthy eating habits in some African cultures, and therefore a large BM is 
accepted and associated with a higher social status (Mciza et al., 2005). 
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4.3 Descriptive findings according to metabolic status 
4.3.1 Anthropometric and BIA findings: women with the MetS displayed an 
exacerbated body composition profile  
Anthropometric and BIA results revealed significantly higher BM, BMI, WC, HC, WHR and FM (%) 
in the MetS groups compared to their non-MetS counterparts, while FFM (%) was significantly lower 
(Table 3.1). Sigdel et al. (2014) was also able to show that BMI and WHR was significantly higher, 
whereas, Liu et al. (2013) found not only BMI, but also WC, WHR and FM (%) to be significantly 
elevated. Our findings of an increase in FM (%) and decrease in FFM (%) have also been supported 
by Park & Yoon (2013). Namwongprong and colleagues (2014) also concurred, but additionally also 
reported a higher BM.  
Peer et al. (2015
B
) showed that BMI, WC and WHR can predict the presence of the MetS, as well as 
its individual components in a South African population. Our findings adds value since the women in 
our study were predominantly obese (increased BM, FM and BMI), and displayed both android (WC 
and WHR), and gynoid body shapes (HC), which may play a role in the pathophysiology of the MetS, 
and may therefore be predictors of the MetS. On the other hand, Wang et al. (2009) showed that an 
increase in FM and decrease in FFM was also associated with a significantly higher risk for the MetS.  
During a positive energy state for example, adipose tissue stores excess energy in the form of TG in 
adipocytes, which in turn leads to hyperplasia, as well as hypertrophy, and ultimately to an increase in 
fat mass (Bjørndal et al., 2011; Jung & Choi, 2014). Alternatively, a change in FFM may lead to a 
change in insulin sensitivity and glucose disposal, and in that way contribute towards the development 
of the MetS and its components (Peppa et al., 2012; Zhang et al., 2015). Since high insulin exert 
catabolic effects on muscle mass (Peppa et al., 2012; Zhang et al., 2015), a decrease in muscle mass 
may also be considered a risk factor for the development of metabolic diseases and cardio-metabolic 
risk (Park & Yoon, 2013; Tanaka et al., 2012). However, muscle mass did not differ between the 
MetS and non-MetS groups in our study, which suggests that other factors might have accounted for 
these discrepancies. The main criticism of the study by Park & Yoon (2013) was that the unequal 
distribution of participants within the MetS and non-MetS groups– the non-MetS group had 
approximately ten times the number of participants compared to the MetS group. They also included 
male participants and participants were from a different ethnicity, and a different definition of the 
MetS. 
The body shape index, ABSI, did not show any differences, a finding that is supported by 
Haghighatdoost and colleagues (2014). They showed that ABSI was a weak predictor of both CVD 
risk, as well as the MetS itself (Haghighatdoost et al., 2014). Although ABSI was proposed to be a 
more reliable measure of body fat distribution vs traditional anthropometric indices, such as BMI and 
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WC (Krakauer & Krakauer, 2012), this is not the case for the current population. To our knowledge 
this was also the first South African study to report findings on ABSI in women with or without the 
MetS.  
4.3.2 Physiological and blood parameters: women with the MetS displayed a 
deregulated metabolic and sex hormone profile 
The MetS consists of, and is characterized by, several risk factors including obesity (abdominal 
obesity), dyslipidaemia, elevated arterial blood pressure, IR/hyperinsulinaemia and impaired glucose 
homeostasis (Alberti et al., 2009; Deprès et al., 2008; Kassi et al., 2011; Kaur, 2014; Okafor, 2012). 
Although the exact pathophysiology behind the MetS is still unclear, and several mechanisms have 
been proposed (Kassi et al., 2011), all studies are in agreement of the core factors involved in the 
development of the MetS (Kassi et al., 2011). 
In this current study, the women in the MetS group showed significantly higher SBP, DBP, FBG, 
fasting insulin, LDL-c and TG levels, whereas HDL-c levels was significantly lower, as well as TC 
was shown not to be significantly different compared to the non-MetS group (Table 3.2). These 
findings were corroborated by Liu et al. (2013) for all the mentioned parameters with the exception of 
insulin and LDL-c. Various other studies showed different combinations of the physiological and 
blood parameters found in the current study. Momesso et al. (2011) showed a significantly higher 
blood pressure, TG and decreased HDL-c in the MetS vs non-MetS groups. Total cholesterol was also 
unchanged in the study by Motala et al. (2011), which supports our findings, and it was suggested that 
this might be so due to it being a weak predictor of CVD and the MetS in both men and women 
(Karalis, 2014). Although TC was shown to be unchanged in all the studies mentioned thus far, Sigdel 
et al. (2014) showed TC, TG, LDL-c and insulin levels to be significantly higher in the MetS group.  
The MetS is also associated with a deregulated sex hormone profile (Sinicrope & Dannenberg, 2011). 
The women in the MetS group showed significantly higher FAI while, SHBG levels were 
significantly lower (Table 3.2). These results are supported by a relatively old study from Weinberg et 
al. (2006), in which increased T and FAI and decreased SHBG levels were observed. However, a 
more recent study by Ziaei & Mohseni (2013) reported similar results. Both these studies suggested 
that the altered sex hormone profile may be ascribed to obesity and IR/hyperinsulinaemia, which in 
turn can decrease E2 production (by inhibiting aromatase enzyme gene expression) and increase FAI 
by directly decreasing SHBG levels (Suba, 2012). This is a quite likely mechanism, since the fasting 
insulin levels were also significantly higher in the MetS group in the current study.  
Although no significant differences were observed for E2 and female testosterone, it might not 
necessarily indicate that the above mentioned mechanism may not be partly involved in the 
differences observed in the sex hormone profile. No statistically significant differences were observed 
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for CRP and IGF-1 in our study. Reasons for this finding might be explained by the specificity of the 
IGF-1 and CRP kits that were used, as well as the large variation in IGF-1 and CRP levels found in 
these women. Other reasons could include the small sample size which would have affected the 
statistical power of this study. 
4.4 Descriptive findings according to body shape 
4.4.1 Anthropometric and BIA findings: women with an android body shape displayed 
an exacerbated body composition profile 
Evidence shows that body shape classification, also known as fat pattering, rather than TBF % has a 
stronger clinical significance on the development of CVD; T2DM, MetS as well as the risk of cancer 
development (Eston & Reilly, 2009; Momesso et al., 2011; Kabat et al., 2015; Kim et al., 2007). The 
women with an android body shape in the current study were significantly older (Table 3.3), which is 
supported by a higher prevalence of android body shape found in post-menopausal vs pre-menopausal 
women, since post-menopausal women are in general older (Mastaglia et al., 2012; Noroozi et al., 
2010). Also, women with android body shape displayed a significantly exacerbated body composition 
profile (increased BM, BMI, WC, HC, WHR and ABSI) compared to the women with a gynoid body 
shape. Muscle mass was also found to be significantly higher in the android body-shaped women. In 
contrast, no difference was observed for FM (%) and FFM (%). These results confirmed the findings 
by Alwachi et al. (2013) who showed that android body shape is associated with an increase in age, 
BM, BMI, WC, HC and WHR. Orbetzova et al. (2012) showed that body shape did not alter BM, 
BMI, WHR, FM (%) and FFM (%); however, compared to an age-matched control group, significant 
differences in FM (%) and FFM (%) were evident. These observed differences could be due to the 
fact that Orbetzova et al. (2012) included an age-matched control group, and only included obese 
women in their study.  
Because the android body shape is mainly characterized by the presence of a large amount of storage 
fat in the abdominal area (Patidar, 2013), it is not uncommon to find an increase in BM, BMI, and 
WC. These anthropometric indices increase as a result of the increase in VAT (WC and WHR), as 
well as subcutaneous adipose tissue (SAT) (HC) (Peppa et al., 2012). These body composition 
changes, especially those associated with VAT can therefore also increase the risk for CVD, T2DM, 
the MetS and the risk of cancer development (Cornier et al., 2011; Namwongprom et al., 2014).  
A surprising finding from the current study was the higher muscle mass, evident in the android body 
shape group. This higher muscle mass in women with android body shape may be a compensatory 
mechanism in order to sustain a greater body weight. However, obesity, and fat deposition has been 
suggested to negatively impact muscle tissue (Koo et al., 2015), and was also negatively associated 
with BMI, WC, SAT and FM after adjustment for age (Hamasaki et al., 2015; Koo et al., 2015; Zhang 
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et al., 2015), possibly through the catabolic effects of insulin on muscle mass. It is also still unknown 
whether general adiposity or regional adiposity has an effect on muscle health, and this may be in part 
due to the fact that research in this field has extensively focused on the elderly population (Koo et al., 
2015).  
We observed that body shape might have the ability to predict ABSI, i.e. women in the android body 
shape group showed significantly higher ABSI compared to their gynoid counterparts. This 
observation is supported by the significant positive association between ABSI and abdominal obesity 
found by Krakauer & Krakauer. (2012). High ABSI values therefore correlated with high WC, and 
this in turn, corresponds to a larger abdominal area and increased VAT (Krakauer & Krakauer, 2012).  
4.4.2 Body shape alone does not predict changes in physiological or biochemical blood 
parameters in women 
Android obesity, characterized by an increase in VAT, is normally associated with a worsened 
metabolic risk factor profile (IR, hypertension, dyslipidaemia and inflammation) and seemed to be an 
underlying factor in the pathophysiology of various diseases including the MetS and cancer, while 
gynoid obesity, characterized by an increase in SAT, is thought to be cardio-protective, however its 
relationship with disease risk is still controversial (Orbetzova et al., 2012; Suba, 2012; Westley & 
May, 2013).  
No significant differences were found for any physiological or biochemical blood parameters between 
android and gynoid groups (Table 3.4). These findings contradict the results from previous studies 
investigating the effect of android and gynoid body shape on various metabolic-associated and other 
biochemical blood parameters. These studies showed that an android body shape is associated with a 
worsened physiological and biochemical profile (Momesso et al., 2011; Namwongprom et al., 2014; 
Simó et al., 2015; Wiklund et al., 2008). We speculate that these discrepancies may be due to the 
following: Firstly, our study had a relatively small sample size, which could have affected the 
statistical power, and therefore did not reveal differences. Secondly, somatotyping was used as 
classification method in contrast to the use of gold standard methods, i.e. DEXA, CT, MRI and other 
anthropometric indices (WC and WHR) (Eston & Reilly, 2009; Norton & Olds, 1996; Rothney et al., 
2009; Stewart & Sutton, 2012). Thirdly, since the women in both the android and gynoid groups had 
relatively high BMI, this could have accounted for the lack of differences in blood parameters as seen 
in this study. Lastly, body shape in relation to body composition and metabolic health has mostly been 
studied in menopausal women (Mastaglia et al., 2012; Noroozi et al., 2010), and women with 
hyperandrogenism (Simó et al., 2015), and not in apparently healthy female farm workers, such as 
this population.  
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4.5 Major findings of study population according to both metabolic status 
and body shape 
Various significant and interesting findings were observed when both body shape and metabolic status 
of the study population were taken into consideration. 
4.5.1 Metabolic status showed effects on certain anthropometric and BIA measurements 
in women with either gynoid or android body shape’s  
Irrespective of body shape, BM and BMI were significantly higher in both the MetS groups’ vs the 
non-MetS groups (Figure 3.6A & 3.8A). This finding is well supported by previous studies, and is 
considered as a causal factor in the pathophysiology of the MetS (Liu et al., 2013; Namwongprong et 
al., 2014; Peer et al., 2015
A
; Sigdel et al., 2014). Hip circumference was also shown to be 
significantly higher in the MetSG group vs the NMetSG group (Figure 3.7A). Although no differences 
were observed between the MetS and non-MetS groups in relation to body shape, a significant 
difference was evident in the NMetSG vs NMetSA groups for WHR (Figure 3.7B). This finding is 
well supported by studies showing a higher VAT content in the android body’s shape vs the gynoid 
body shape group (Bjørndal et al., 2011). Females normally store adipose tissue in the gynoid region 
and only store a small percentage of their TBF in their abdominal area; however this percentage is 
significantly increased when a moderate level of obesity is reached (Patidar, 2013; Peppa et al., 2012; 
Stewart & Sutton, 2012). 
No significant differences were observed for ABSI between women of all respective groups, similar 
to that observed when only metabolic status was taken into consideration (Figure 3.8B). Similar 
reasons could therefore account for the observation here as seen in section 4.3.1. Since ABSI has been 
proposed to be a more reliable measure of body fat distribution (Krakauer & Krakauer, 2012), and we 
observed equal participant distribution within the MetS and non-MetS groups with regards to body 
shape, it could explain the “no difference” observed. The participants in the MetSG group had a 
significantly higher FM (%) and significantly lower FFM (%) compared to the NMetSG group, thus 
indicating an effect of metabolic status (Figure 3.9A&B). Our findings are supported by evidence 
showing an increase in FM (%) in women with gynoid obesity vs age-matched controls (Orbetzova et 
al., 2012), and increase in FM (%) and decrease FFM (%) in the MetS (Park & Yoon, 2013). No 
significant differences were evident for muscle mass (Figure 3.9C), but this is not surprising since an 
increase in FM does not necessarily correlate with a difference in muscle mass. 
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4.5.2 Metabolic status showed effects on MetS risk factor measurements in women with 
either gynoid or android body shapes  
The literature indicates strong relationships between all the components of the MetS and fat storage 
distribution. This association is proposed to be a result of an increased VAT, and its associated 
dysfunction in the abdominal area (Bjørndal et al., 2011). However, the role of gynoid obesity 
(increased SAT) has also been implicated in the development of individual MetS risk factors (Patel & 
Abate, 2013).  
Waist circumference (reflective of an increased VAT) was significantly higher in the NMetSA group 
vs the NMetSG group (Figure 3.10A), which is supported by evidence from Bjørndal et al. (2011). A 
higher WC was also evident in the MetSG vs NMetSG women, which can be explained by an increase 
in SAT in the abdominal area in the MetSG group (Patel & Abate, 2013).  
No significant differences were observed for FBG between women of all respective groups (Figure 
3.10B). A possible explanation for this might be related to general obesity, irrespective of its 
anatomical distribution and metabolic status. However, BM and BMI were significantly different 
between the respective MetS groups and their non-MetS counterparts (Figure 3.6A & 3.8A). Waist 
circumference was also shown to be significantly different, not only between the MetSG and NMetSG 
group, but also between the gynoid and android groups of the non-MetS group. Thus, although 
obesity cannot elucidate this occurrence, adipokine deregulation (i.e. CRP), could possibly explain 
this occurrence, since a dysregulation in the synthesis of these adipokines and their actions in relation 
to obesity may lead to hyperglycaemia (Lasselin et al., 2014). No significant difference was evident 
for CRP therefor, no definitive conclusion could be drawn and the relationship between the MetS, 
body shape and FBG remains elusive. 
We found a significant difference of metabolic status in both the gynoid and android body shape 
groups for blood pressure (Figure 3.10E&F). Significantly higher results were obtained for both SBP 
and DBP in the MetS group’s vs the non-MetS groups. This is supported by evidence showing that the 
MetS is associated with an increased arterial blood pressure (Okosun et al., 2015; Yanai et al., 2008), 
which is also proposed to be directly due to IR and abdominal obesity (increased VAT) (Yanai et al., 
2008). This is likely since BM and BMI (Figure 3.6A & 3.8A) were significantly different between 
the MetS and its respective non-MetS groups.  
Obesity has been shown to have an effect on several factors that influence blood pressure, i.e. volume 
expansion and peripheral resistance (Daniels, 2012). Obesity-related insulin 
resistance/hyperinsulinaemia increases blood pressure by activating the sympathetic nervous and the 
renin angiotensin aldosterone system (RAAS), leading to an increase in sodium reabsorption by the 
kidneys, resulting in renal vasodilation and volume expansion, and ultimately leads to the 
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development of hypertension (Yanai et al., 2008). In addition, it has been shown that obesity-
associated hypertension, may also be due to increased peripheral resistance which ultimately leads to 
elevated blood pressure (Daniels, 2012). Similar reasons could also account for the observation here 
as seen in section 4.2.1. 
Dyslipidaemia is a characteristic of the MetS and also a risk factor for CVD and atherosclerosis 
(Okafor, 2012). The pathophysiology of the MetS directs to obesity (abdominal obesity (adipose 
tissue dysfunction)) and IR as the underlying factors in its pathophysiology (Kassi et al., 2011; Kaur, 
2014). Women with the MetS, especially those with abdominal obesity, show a more anthrogenic 
lipid profile and this may explain their greater CVD risk (Liu et al., 2013; Momesso et al., 2011; 
Sigdel et al., 2014). Android obesity and IR have been shown to be associated with a combination of 
dyslipidaemia characteristics (TG, HDL-c and LDL), and it is more likely to occur in this combination 
(Karalis, 2014). No differences were observed for HDL-c in the android groups, but a significant 
difference was observed for TG (Figure 3.10C&D). Although our results contradicts what has 
previously been reported for android obesity and its association with dyslipidaemia, the small sample 
size in the NMetSA group (n=12) could possibly explain these findings. Lower HDL-c and elevated 
TG levels were also evident in the MetSG vs NMetSG group. This is supported by evidence showing 
that the MetS is characterized by dyslipidaemia (Liu et al., 2013) and that GFM shows a positive 
association with TG and negative with HDL-c (Okosun et al., 2015).  
In summary, most previous studies investigating metabolic disease risk, android and gynoid body 
shapes, considered a normal BMI or either adjusted for BMI. In addition, the previous studies also 
only compared android to gynoid body shapes, and in most cases did not include a control group. In 
our study the metabolic status and body shape were both shown to have a high prevalence of 
overweight and obesity. We thus speculate that when a certain BMI is reached, body shapes might not 
necessarily have an effect on certain anthropometric, blood and BIA parameters. Recent evidence 
shows that both android and gynoid fat mass increases with the prevalence of cardio-metabolic risk 
factors and that the combination of increased android and gynoid fat mass is associated with increased 
odds of developing MetS risk factors compared to AFM and GFM alone (Okosun et al., 2015).  Thus, 
the A/G ratio has been suggested to be a better predictor of the MetS.  
Although TC and LDL-c are not considered as diagnostic criteria for the MetS, participants with the 
MetS have been found to display increased TC and LDL-c levels (Sigdel et al., 2014). Low density 
lipoprotein-cholesterol and TC did not differ in our study (Figure 3.11A&B). One specific study also 
showed that even though the other lipid levels may have been altered as a result of the MetS and body 
shape, TC can stay within its normal range (Karalis, 2014), which has also been shown in our study.  
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4.5.3 Insulin-IGF-1 axis: metabolic status and body shape combined does not predict 
changes of fasting insulin and IGF-1 in women 
High IGF-1 levels have been associated with an increased risk for cancer development (Arcidiacono 
et al., 2012); however, current evidence on IGF-1 in relation to metabolic disease states is still very 
controversial. For example, low levels of IGF-1 have been suggested to have beneficial effects on 
glucose homeostasis and may also sensitise insulin actions, thereby decreasing metabolic disease risk, 
while high levels have been associated with an increased risk for cancer development (Kabir et al., 
2010).  
Low levels of IGF-1 have been suggested to be associated with an increased risk for the MetS. In a 
study by Oh et al. (2012), IGF-1 levels were significantly lower in the MetS vs non-MetS participants, 
with IGF-1 being lowest in participants with the most MetS risk factors. The authors proposed that IR 
and hyperinsulinaemia may induce GH receptor resistance and thus decrease IGF-1 levels (Oh et al., 
2012). On the other hand, Friedrich et al. (2013) showed that participants with the MetS had 
significantly higher IGF-1 levels vs healthy age-matched controls.  
Two mechanisms are proposed to help explain the elevation in IGF-1 as a result of 
hyperinsulinaemia/IR. Directly, IGF-1 can increase by increasing hepatic GH receptor expression and 
thus the production of IGF-1 in the liver (Hursting et al., 2012). Indirectly, through the down 
regulation of IGF-BP production by reducing hepatic gene expression and protein synthesis of IGF-
BP, this in turn can increase the bioavailability of IGF-1 (Arcidiacono et al., 2012). Additionally, 
adipocytes itself can secrete IGF-1, which may explain the increase in IGF-1 (Hursting et al., 2012). 
Studies on IGF-1 and the MetS are however limited and various reasons could explain these 
discrepancies. The sample sizes, ethnic differences, selection bias, the study design and studies 
measuring either free IGF-1 or total IGF-1 can all be confounding factors. Studies on body 
composition, and body shape in relation to IGF-1 levels are however also limited. 
In the current study, no significant differences were observed for fasting insulin or IGF-1 between any 
of the women in their respective groups (Figure 3.12A&B). Our findings are in agreement with 
findings of Kabir et al. (2010), who found no difference in IGF-1 levels in participants with metabolic 
disturbances vs matched controls. This suggests that although free IGF-1 may change due to 
adiposity, total IGF-1 remains within its reference range (Renehan et al., 2006), and therefore remain 
unchanged. Another reason for the observation of “no difference” could include the specificity of the 
human IGF-1 ELISA kit. Seventeen participants were excluded because their IGF-1 levels were 
below detection limit (< 0.1 ng/ml), whereas two participants were excluded because their IGF-1 was 
extremely high. Age, gender, ethnicity and obesity have also been shown to influence IGF-1 levels 
(Gram et al., 2006). It should however be stressed that no accurate conclusion could be drawn linking 
the MetS, body shape and cancer risk with the data obtained from this study. 
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4.5.4 Inflammation: both metabolic status and body shape does not predict changes in 
CRP  
The role of inflammation as an underlying factor in the pathophysiology of metabolic conditions 
(obesity and the MetS) has been extensively studied, but has recently also been implicated in risk of 
cancer development (Cefalu, 2009; Shrivastava et al., 2015). An increase in inflammatory biomarkers 
in obesity (Kao et al., 2009), android body shape (Alwachi et al., 2013) and the MetS (den Engelsen 
et al., 2012) have been well documented. Evidence for an increased BMI and WC in relation to 
increased CRP levels has also been shown (Aronson et al., 2004; Kao et al., 2009). However, the 
specific mechanism responsible for the pathophysiology linking the MetS and inflammation still 
needs to be elucidated. One proposed mechanism states that an increase in adipose tissue (in obesity 
and the MetS) as a result of adipose tissue dysfunction (hypertrophy, hyperplasia and adipokine 
deregulation) can lead to an increase in IL-6 synthesis. This in turn regulates hepatic CRP-synthesis 
and thereby increases CRP levels (Braun et al, 2011; Choi et al., 2013). Also, adipose tissue itself 
may be a source of CRP (Braun et al, 2011). 
The current study contradicts the above evidence as we found neither metabolic status, nor body 
shape to have an effect on CRP levels (Figure 3.13), even though clear differences were observed for 
almost all anthropometric and BIA measures of obesity. Reasons for this finding may include the 
relatively small sample size, which combined with the large variation in CRP levels could have 
accounted for no difference found. Literature has highlighted differences in CRP levels in relation to 
the MetS and body shape. For example, mean CRP levels in participants with the MetS with android 
body shape were reported to be 1.4 mg/L (Vidyasagar et al., 2013), mean CRP levels of 5.39 mg/L in 
post-menopausal females with android body shape (Alwachi et al., 2013), and mean CRP levels of 
1.96 mg/L in healthy participants with android body shape (Lapice et al., 2009). These studies 
therefore highlight the differences in CRP levels even when measured in women with the same body 
shape. In addition, the human CRP ELISA kit that was used could not detect any CRP levels below 15 
pg/ml, therefore excluding n=14 individuals. Two women were also excluded as their levels were 
extremely high and deemed as outliers and were subsequently removed prior to analysis.  
Although no significant differences were evident between any of the groups, we did however observe 
the mean CRP levels in the MetS groups to be greater than 10 mg/L, similar to what has already been 
reported in the literature (Aronson et al., 2004; Ishii et al., 2012). This level is suggestive of an 
underlying infection or low-grade inflammation. Evidence shows that CRP levels greater than 10 
mg/L in obesity are not uncommon and have been documented (Aronson et al., 2004; Ishii et al., 
2012). Furthermore, both studies have also shown that people with a more severe class of obesity, 
have higher CRP levels beyond this reference range, which suggests that CRP levels greater than 10 
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mg/L is associated with overweight and obesity. It should however be noted that inflammation could 
also have contributed considerably.  
Since the metabolic status and body shape did not alter CRP levels, its effect still warrants further 
investigation, especially with regards to the link between the MetS, inflammation and risk of cancer 
development. 
4.5.5 Sex hormone profile: metabolic status and body shape in combination does not 
predict changes in E2, female T, SHBG and FAI  
Evidence on the role of sex hormones in the pathophysiology of certain disease states (obesity, IR, 
CVD, the MetS and the risk of cancer development), and its associated risks are still lacking, despite 
the fact that there is convincing evidence of a casual role of sex hormones in the development of these 
diseases of lifestyle (Torréns et al., 2009). Furthermore, it seems that oestrogen might also play a 
pivotal role in these disease states (Suba, 2012).  
The MetS is characterized by an altered sex hormone profile, i.e. increased oestrogen and an increase 
in androgen excess (increased female T, FAI and decrease in SHBG) (Calle & Kaaks, 2004; 
Korhonen et al., 2003; Weinberg et al., 2006; Ziaei & Mohseni, 2013). An increase in E2 levels and 
androgen excess is also associated with an increased cancer risk in women (Westley & May, 2013). In 
contrast, androgen excess (female T, FAI and decrease in SHBG) and E2 deficiency have been 
associated with an increase in VAT and an android body shape, both in pre-and post-menopausal 
women, which increases the risk to develop CVD and the MetS (Gravena  et al., 2013; Kim & Halter, 
2014; Momsesso et al., 2011; Weinberg et al., 2006). These findings highlight the controversies 
around the role of sex hormones in the development of certain diseases such as lifestyle associated 
cancer and other diseases of lifestyle. 
Changes in E2 levels in the body also influence the risk and development of the MetS by influencing 
its individual components. For example, E2 has regulatory effects on lipid and glucose metabolism, it 
also has been associated with hypertension, as well as IR (Brand et al., 2011; Suba, 2012), and have 
been shown to increase during obesity (Kalyani et al., 2009). In addition, both E2 and female T levels 
can be increased due to a decrease in SHBG levels due to obesity-associated hyperinsulinaemia 
(Folkerd & Dowset, 2010; Mendonça et al., 2015; Westley & May, 2013).  
We found no significant differences for E2 in all the women of the respective groups (Figure 3.14), 
and therefore the effect of metabolic status and body shape on E2 levels remains inconclusive. We 
conclude that the variation in E2 levels reported between the different groups might be related to the 
changes in E2 concentrations during the different phases of the menstrual cycle. We could not 
establish in what menstrual phase each of the women were, and thus could not establish if E2 levels 
were lower, within range, or higher than the normal physiological levels for each individual. 
Stellenbosch University  https://scholar.sun.ac.za
89 
 
Approximately 18.75 % (n=15) of the total population of women were found to have primary or 
secondary hypogonadism, which might suggest menopause, ovarian failure, birth control usage, 
pituitary or hypothalamic dysfunction (Fraietta et al., 2013). However, further investigation with 
appropriate study design is needed to warrant this finding. Although E2 is known to increase during 
obesity, and clear differences were observed in anthropometric and BIA parameters in our study; 
glucose, as well as insulin levels were not different, which could have resulted in “no difference” 
observed in E2 levels. 
As a result of obesity, and its association with hyperinsulinaemia, both E2 and female T can increase 
with a concomitant decrease in SHBG. However, no differences were observed for T, SHBG, as well 
as FAI (Figure 3.15 & 3.16). Furthermore, women in all four groups displayed mean female T levels 
within normal physiological range (Figure 3.15A). This could be explained by the fact that female T 
is produced in very small quantities in women, by the ovaries and adrenal glands (Al Kindi et al., 
2010). In addition, the deregulated adipokine profile, as a result of obesity, may also be responsible 
for the low female T levels. For example, obesity is associated with an increase in leptin levels, and 
this in turn can interfere with luteal hormone stimulation of androgen synthesis, resulting in a 
decrease in female T production, which may explain why female T levels were below normal 
physiological cut-off value (Salam et al., 2012). Previous studies have however shown that female T 
is increased in the MetS, but didn’t show that it was above the normal physiological levels (Momsesso 
et al., 2011; Weinberg et al., 2006). Since no differences were observed for insulin and glucose, and 
both are known to affect the sex hormone profile, it might help explain that “no differences” were 
observed in any of the sex hormones measured. The results for FAI are conflicting and limited since 
FAI has not been studied in apparently healthy women in this specific setting. Other confounding 
factors could include age, menopausal status, obesity, thyroid dysfunction, ovarian failure, polycystic 
ovarian syndrome, as well as sample size (Wallance et al., 2013). 
The effect of both metabolic status and body shape on sex hormone levels remains inconclusive since 
no differences were observed. Furthermore, no immediate conclusions could be drawn to describe the 
link between the MetS, sex hormones and cancer risk. 
 
4.6 Correlation analysis findings 
4.6.1 Obesity, body shape and adipose tissue’s relationship with growth factor (IGF-1), 
metabolic status and cancer risk  
Adipose tissue distribution seems to play a role in the pathophysiology of the MetS and cancer risk by 
having an effect on growth factors (Arcidiacono et al., 2012). Literature suggests that 
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hyperinsulinaemia/IR and increased IGF-1 levels increases cancer risk by affecting downstream 
signalling pathways regulating mitogenesis, apoptosis and angiogenesis (Hurstings et al., 2012; 
Ramos-Nino, 2013). Correlation analysis revealed significant associations between IGF-1 and 
selected anthropometric and BIA parameters (Figure 3.17).  
Correlation analysis for IGF-1 and WHR revealed a positive relationship in all four study groups 
(Figure 3.17A&B), however, only the NMetSG group’ correlation coefficient showed significance. 
This finding was somewhat unexpected, since theoretically, android body shape, characterized by a 
higher WHR, should result in an increase in IGF-1 levels. These discrepant findings may be explained 
by the controversial role of IGF-1 in disease states. Alderete et al. (2010) reported a negative 
association between IGF-1 and VAT (android body shape), while Schmitz et al. (20110) showed IGF-
1 to be negatively correlated with BMI and WHR. These differing outcomes suggest that in a normal 
overweight person with android body shape (NMetSA in our scenario), as WHR increases, IGF-1 
should decrease. However, this was not evident in our study population which revealed positive 
relationships.  
Literature also states that increased insulin levels, which cause a decrease in IGF-BP, can thereby 
indirectly increase IGF-1 levels (Arcidiaconco et al., 2012). Insulin-like growth factor-1 levels will 
increase in relation to a certain level of obesity, but with greater adiposity, this increase will induce a 
negative feedback mechanism on GH secretion, and this will result in a decrease in IGF-1 (Gram et 
al., 2006). This could therefore suggest that the level of adiposity necessary to decrease IGF-1 has not 
been reached in our different study groups. Body mass index, could explain these findings, since a 
higher BMI was observed in both the MetSA and MetSG groups (Figure 3.8A), which relates to the 
almost negligible correlations found between IGF-1 and WHR. The BMI for both NMetSG and 
NMetSA were significantly lower than that of their respective MetS groups, with the gynoid group 
here displaying a higher BMI and therefore a stronger positive correlation.  
However, BMI and WHR only confirms body shape and obesity, but it does not inform about the 
adipose tissue per se. Correlations between FM (%), FFM (%) and IGF-1 or insulin might be more 
informative. Correlation analysis between IGF-1 and FM (%), and, IGF-1, and FFM (%) revealed 
opposite findings (Figure 3.17C-F), with only the android body shape groups indicating significant 
correlations. For IGF-1 and FM (%), all group correlations were positive, except for the NMetSA 
group. The opposite was true for the correlation between IGF-1 and FFM (%). This is not unexpected 
since a person with a high FM (%), normally has a lower FFM (%), possibly explaining these 
contrasting associations (Park & Yoon, 2013). Interestingly, even though insulin or IGF-1 did not 
differ between the different study groups, both the MetSA and NMetSA groups’ correlations were 
significant.   
Stellenbosch University  https://scholar.sun.ac.za
91 
 
The positive associations between IGF-1 and FM (%), and the negative associations between IGF-1 
and FFM (%) may be explained by obesity since adipocytes secrete IGF-1 (Hursting et al., 2012. 
Furthermore, since more storage fat is normally disturbed around the abdomen (Patidar, 2013), it 
could account for the significant positive correlation observed in the MetSA group. The negative 
association between IGF-1 and FM (%) in the NMetSA group, and therefore the positive association 
between IGF-1 and FFM (%), is more complicated to explain since this indicates that the higher the 
FM, the lower the IGF-1. However, it is worth mentioning that even though neither FM (%), nor IGF-
1 differed between the groups, overall, the NMetSA group displayed a lower mean IGF-1 level 
compared to the other groups which could have contributed to this negative association. Furthermore, 
this groups’ small sample size (n=12) could have also played a role here by affecting the statistical 
power of this study. 
 
4.6.2 Inflammation and anthropometric measurements: obesity and abdominal 
obesity’s relationship with metabolic status and cancer risk  
Adipose tissue distribution is also proposed to have a primary role in the pathophysiology of the MetS 
and cancer risk by affecting inflammatory mediators (Jung & Choi, 2014; Shrivastava et al., 2015). 
The MetS is characterized by a deregulated inflammatory profile, which leads to a chronic low-grade 
inflammatory state (den Engelsen et al., 2012). Supporting evidence shows that various inflammatory 
mediators can contribute to the overall risk of cancer development by promoting cell-growth and 
angiogenesis, and decreasing apoptosis (Pèrez-Hernández et al., 2014; Rodríguez et al., 2013). 
However, the role of CRP specifically remains unclear. 
Correlation analysis between BMI, WC and CRP revealed moderate positive correlations for all 
respective groups (Figure 3.18), expect the NMetSG group. For BMI and CRP, only the correlation 
for the MetSA group was shown to be significant, whereas the correlation between WC and CRP 
reported significance in both the NMetSG and MetSG groups, as well as the MetSA group. These 
findings are supported by evidence showing that CRP levels increase with increasing BMI and WC 
are even higher when measured in individuals with an android body shape (Kao et al., 2009; Tolmay 
et al., 2012). Since the occurrence of both obesity and the MetS are characterized by adipose tissue 
dysfunction, the resultant chronic low-grade inflammation (measured by CRP) is not an uncommon 
occurrence through its IL-6 action (Braun et al., 2011; Choi et al., 2013). Adipose tissue itself are also 
responsible for the production of CRP (Braun et al., 2011), which increase with an increase in central 
obesity.  In addition, evidence also reveal a positive association between BMI, TBF %, WC, VAT, 
SAT and CRP levels (da Cruz et al., 2013; Tolmay et al., 2012; Tsuriya et al., 2011).  
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Although the correlation between CRP and BMI in the MetSG and NMetSG groups did not show any 
significance, the correlation between CRP and WC were however highly significant in these groups. 
The positive association in the MetSG groups might be explained by the fact that WC is a better 
predictor of abdominal obesity, and therefore the MetS according to the IDF definition (IDF, 2006). A 
possible explanation for the negative association in the NMetSG group could be related to the 
hypothesis that individuals with a gynoid body shape presents with a less metabolically active SAT 
depot, compared to VAT, which is more lipolytically active (Bjørndal et al., 2011).  
4.6.3 Sex hormone parameters’ relationship with obesity-related insulin dysfunction, 
metabolic status and cancer risk  
Different components of the MetS have been shown to influence the synthesis and bioavailability of 
both oestrogen and androgens (Brand et al., 2011), of which adipose tissue distribution have been 
shown to be the main contributor, not only in the pathophysiology of the MetS and cancer risk, but 
also on sex hormonal profiles (Iyengar et al., 2013; Preis et al., 2010; Orbetzova et al., 2012). An 
increase in E2 has been found in overweight and obese post-menopausal women, as well as in 
individuals with the MetS, and it is proposed to be as a result of the excess adipose tissue (Momsesso 
et al., 2011; Weinberg et al., 2006). Braun et al. (2011) also suggested that E2 can be increased in 
obesity-associated hyperinsulinaemic individuals through a decrease in SHBG. Furthermore, 
hyperinsulinaemia can also cause defective and decreased oestrogen synthesis by inhibiting aromatase 
gene expression (Suba, 2012), which might explain the negative associations between BMI and E2, 
insulin and E2, as well as SHBG and insulin, in almost all groups (Figure 3.19). However, most of 
these associations were found to be negligible to weak. The MetSG group was the only group that 
showed significant correlations, a positive association between BMI and E2, and negative associations 
between insulin and E2, as well as between SHBG and insulin. These findings confirm the suggested 
explanations by Momesso et al. (2011), Weinberg et al. (2006) and Braun et al. (2011), which 
suggests that obesity (BMI) interferes with insulin production (increased production), thereby 
decreasing SHBG and increasing E2. 
4.6.4 Relationship between ABSI and obesity, IGF-1 and certain MetS risk factors  
Krakauer & Krakauer (2012) postulated that a high ABSI value represents a higher WC than expected 
for a given height and weight, which in turn correlates to a larger abdominal area. In other words, 
ABSI can adjust WC for a certain BMI and height (Cheung, 2014). Data on ABSI are still limited and 
controversial and requires further investigation to strengthen its use in disease conditions (Cheung, 
2014).  
A negative correlation between ABSI and BMI was evident in all four groups (Figure 3.20A&B). The 
MetSA and MetSG showed significant correlations, whereas a trend towards significance was evident 
in the NMetSG group. This finding is supported by Cheung (2014) who also showed a negative 
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association between ABSI and BMI in women. Therefore, theoretically as BMI increases, WC also 
increases, and thus in turn ABSI will decrease. We further speculate that the NMetSG and NMetSA 
group’ correlation might also have been significant if the sample size for each group was larger.  
No significant differences were evident for ABSI and IGF-1 (Figure 3.20C&D). Although this 
relationship did not show any significance in any of the groups, this was the first study to report on 
this specific relationship using the current study population. We do however admit that the small 
sample sizes, as well as the large variability in IGF-1 levels are possible factors that could have 
attributed to this negligible relationship.  
Although the use ABSI is thought to be a more reliable method to measure disease risk than 
traditional indices, ABSI has been found to weakly correlate with components of the MetS 
(Haghighatdoost et al., 2014; Malara et al., 2014). We have also observed this association between 
ABSI and TG in the MetSA group of the current study (Appendix IX), however our study showed 
significance. We also found a significant positive association between ABSI and LDL-c, which might 
be explained by gynoid body shapes’ cardio-protective properties. 
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CHAPTER 5:        CONCLUSION 
 
5.1 Introduction 
The previous chapter included the interpretation of results found in the current study. In this chapter, 
the main findings of the study will be presented, together with conclusions, followed by study 
limitations, as well as future recommendations. 
5.2 Summary and conclusions of the main findings 
5.2.1 Prevalence of the MetS and MetS risk factors 
The prevalence of the MetS was found to be considerably high in this female population, with the 
predominant risk factors being abdominal obesity, elevated blood pressure and decreased HDL-c 
levels. In addition, an alarming low number of the women without the MetS presented with no risk 
factors. Furthermore, the high prevalence of obesity (especially abdominal obesity) observed in this 
population of women may have exacerbated the prevalence of the MetS as well as the individual 
components. This high prevalence of the MetS and its individual components in these women are 
worrisome, since the MetS has been associated with an increased risk of developing various lifestyle 
diseases.  
Women need to recognize this burden of obesity and its associated metabolic dysfunction, and should 
be motivated to make changes regarding their metabolic health, i.e. the MetS can be prevented, as 
well as reversed by cultural sensitive lifestyle interventions. The early detection, treatment and 
prevention of the MetS and its components may decrease disease burden of chronic lifestyle diseases. 
5.2.2 The effects of metabolic status and body shape on: anthropometry, BIA, 
physiological and biochemical blood parameters 
Firstly, women with the MetS and android body shape respectively, displayed a significantly 
exacerbated body composition profile. Thus, metabolic status and body shape alone were found to be 
predictors of anthropometric and BIA parameters. Our findings added value since the women in our 
study were predominantly obese and displayed android and gynoid body shapes, which may play a 
role in the pathophysiology of the MetS, and may thus be predictors of the MetS.  
Secondly, women with the MetS displayed a deregulation in physiological, metabolic and sex 
hormone parameters. However, body shape alone was not found to be a predictor of any physiological 
and biochemical blood parameters. Lastly, both metabolic status and body shape could not predict any 
changes in the parameters linking the MetS to cancer risk. Thus, no accurate conclusion could be 
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drawn linking the MetS or body shape and cancer risk with the data obtained from this study and 
future investigations are needed to elucidate these links. 
5.2.3 The effects of metabolic status and body shape combined on: anthropometry, BIA, 
physiological and biochemical blood parameters  
Metabolic status was found to have an effect on BM, BMI, HC, FM (%) and FFM (%) in women with 
gynoid body shape, and only on BMI in women with android body shape. The only effect of body 
shape (android) was evident in women without the MetS for WHR.  
Metabolic status was found to have an effect on several MetS risk factors in the gynoid body shape 
groups i.e. WC, HDL-c, TG, SBP and DBP, while; metabolic status showed an effect on TG, SBP and 
DBP in the android body shape groups. The only effect of body shape (android) was evident in 
women without the MetS for WC. Both metabolic status and body shape did not show any effect on 
ABSI, TC, LDL-c, fasting insulin, CRP and all sex hormone parameters. 
Thus, metabolic status and body shape combined showed an effect on various body composition, 
physiological and biochemical blood parameters, but did not show any effect on the parameters 
linking the MetS to the risk of cancer development. 
We showed that body shape alone has the ability to predict ABSI, whereas metabolic status, and body 
shape and metabolic status combined did not. We also showed weak correlations for ABSI and MetS 
components. However, the findings on ABSI are still controversial and understudied, and more 
research is required to substantiate the use of this metric in relation to the MetS, body shape and 
cancer risk. 
5.2.4 Correlations  
Correlation analysis revealed that adipose tissue distribution in relation to the MetS and risk of cancer 
development may play a role in this complex pathophysiology, by showing significant relationships 
between body composition parameters and IGF-1, CRP and sex hormone parameters. However, our 
study design limits us to confer causality.   
5.3 Advantages, limitations and future recommendations  
5.3.1 Advantages 
This current study has several advantages which include the following; (i) it was the first study to 
make use of ABSI as a metric in a South African setting in relation  to metabolic status and body 
shape in this specific population of women, (ii) it investigated the pathophysiology of the MetS and 
cancer risk by including several factors (metabolic, growth and inflammatory factors, as well as sex 
hormone parameters) that may be involved in this pathophysiology, (iii) it included several 
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measurements of adiposity, (iv) it included a comprehensive sex hormone profile, and (v) it made use 
of a body shape classification method namely photoscopic somatotyping which is not often used.  
5.3.2 Limitations 
The inclusion of only women in this current study may be seen as a limitation, but considering the fact 
that this study also focused on female hormones, thus this cannot be considered as a limitation. 
As with many field studies, technical issues with data collection were encountered. For some 
volunteers, the BIA full body test revealed incorrect measurements, and even after repeating the 
measurements several times, the errors still remained. Possible reasons could include: the presence of 
prosthetic implants, the cold temperatures during the winter months, as well as the possibility that 
some of the electrode stickers did not stick properly to the specific skin areas of the participants. 
Secondly, due to the cross-sectional nature of this study, no inference to the total population or 
causality can be made. In addition, C-reactive protein is a non-specific marker of inflammation. 
Although this study had some limitations, it also added value to what is currently known regarding the 
MetS and body shapes in relation to body composition, metabolic and sex hormone parameters and 
cancer pathophysiology. This study also added value regarding the use of the new body shape index, 
ABSI. 
5.3.3 Future Recommendations 
For future investigation we propose to include additional inflammatory markers, such as IL-6 which 
could have been used to add value to this specific study. In addition, to rule out any active infection as 
a source of inflammation, oral temperature or a full white blood cell count might be necessary. More 
sensitive ELISA kits for CRP and IGF-1 in future studies should also be recommended to detect lower 
levels of both CRP and IGF-1. In addition, as an alternative we propose the use of WHR to classify 
body shape/fat distribution and to classify women as insulin resistant or not. We could not establish in 
what menstrual phase each of the women were, and thus could not establish if E2 levels were lower, 
within range or higher than the normal physiological levels for each individual. As an alternative we 
propose to include factors that could have an effect on sex hormone levels. For example a full 
menstrual history i.e. uses of contraception, date of last menstrual cycle, number of cycles or irregular 
cycles, as well as age, menopausal status, parity,  in future investigations. 
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Ethical approval from Stellenbosch University’s Health Research Ethics Committee I 
 
 


















Informed consent document  
PARTICIPANT INFORMATION LEAFLET AND CONSENT 
FORM 
 
TITLE OF THE RESEARCH PROJECT: 
Cancer risk during urbanisation: metabolic syndrome and cancer 
REFERENCE NUMBER: N13/04/052 
PRINCIPAL INVESTIGATOR: Dr Theo A Nell 
ADDRESS: 
Department of Physiological Sciences 
Mike de Vries Building 
Room 2007  
Stellenbosch University 
CONTACT NUMBER: 021 808 3147 
You are being invited to take part in a research project. Please take some time to read the information 
presented here, which will explain the details of this project. Please ask the study staff or doctor any 
questions about any part of this project that you do not fully understand. It is very important that you 
are fully satisfied that you clearly understand what this research entails and how you could be 
involved. Also, your participation is entirely voluntary and you are free to decline to participate. If 
you say no, this will not affect you negatively in any way whatsoever. You are also free to withdraw 
from the study at any point, even if you do agree to take part. 
This study has been approved by the Health Research Ethics Committee at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
Stellenbosch University  https://scholar.sun.ac.za
118 
 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the 
Medical Research Council Ethical Guidelines for Research. 
 
What is this research study all about? 
 This study will only be done in Western Cape Health districts. We will need approximately 
1000 patients. We are trying to gather information on laboratory tests, body composition and 
patient questionnaires profiles of people undergoing migration. By getting this information 
we would be able to assess the prevalence of the metabolic syndrome in different regions in 
the Western Cape and how this might increase risk of developing cancer. 
 More people are relocating to larger cities and with this their traditional habits change. One 
factor that plays an important role is nutritional changes. There are also changes in your 
body where some might become overweight.   
Your participation will help us look at the markers that tell researchers what factors are 
important to look at. Blood will be taken by a registered medical nurse. It will then be sent 
away to Pathcare (Stellenbosch) where metabolic-associated parameters will be measured. 
Other biochemical tests that will be done by Pathcare include insulin, glucose, lipids, and 
hormone measurements.  The remainder of your blood samples will be used to analyse 
omega-3 fats, CRP and IGF-1. 
The blood pressure and anthropometric evaluation, and life style questionnaire will be done 
at the clinic. 
Why have you been invited to participate? 
 We are trying to gather information on people that live in certain areas in the Western Cape 
provincial health districts. Your participation will help us understand what factors could lead 
to the development of certain cancers if people migrate from rural to urban areas.  There will 
also be questions asked about your diet at home and how active you are during the week.   
 By donating blood to our study you will be helping us to determine these profiles and how we 
can relate them to the current diagnostic tests to investigate the metabolic syndrome and 
development of cancer. 
What will your responsibilities be? 
 We will need to examine you as one of the selected patients. A blood sample will then be 
taken for laboratory tests. There will be a lifestyle questionnaire that you need to complete 
with the help of the researcher. A registered anthropometrist, Dr Theo Nell, will also perform 
anthropometric measurements to measure your waist circumference, hip circumference, the 
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back of your arm’s skin fold, height and weight. You will also be asked to lie on the 
examination bed where Dr. Nell will use a special machine that will tell us how much fat is in 
your body. This will only take a few minutes and does not hurt you. 
 
Will you benefit from taking part in this research? 
 Although there may not be any direct benefits to me/the participant by participating at 
this stage, future generations may benefit if the researchers succeed in finding out 
more about how migration could lead to increased number of people developing 
cancer. If you choose to know the results of your blood tests we will make these 
available. However, you would have to discuss this information with your 
usual/personal doctor, in order to assess your medical status.   
Are there any risks involved in your taking part in this research? 
There are no more than minimal medical or physiological risks associated with this study. 
 I/the participant may feel some pain associated with having blood drawn from a vein 
in my arm, and may experience some discomfort, bruising and/or slight bleeding at 
the site. The anthropometrical test will require you to take some of your clothes and 
shoes off, but there is no pain involved during this procedure. All measurements will 
be done in private and confidentiality is very important. 
 The machine that will be used to determine the fat in the body uses a very small 
electrical current that you will not feel. 
If you do not agree to take part, what alternatives do you have? 
 It is your decision to participate or not and nothing will be done from the researchers’ part 
or medical staff at the clinic/hospital to in any way to persuade you to take part. 
Who will have access to your medical records? 
 Only the principal researcher (Dr Theo Nell and other collaborators) will have access to 
your data and records.  All information will be treated with respect and utmost 
confidentiality.  Under no circumstances will your name or any form of identification be used 
in any publication, poster, lecture or thesis that results from this study.  Dr. Theo Nell will be 
the only authorised personnel who will have access to all your results from this study as well 
as the lifestyle questionnaire and anthropometric measurements. 
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What will happen in the unlikely event of some form injury occurring as a direct 
result of your taking part in this research study? 
 There are no risks involved that could lead to injury. Not applicable here. 
 
Will you be paid to take part in this study and are there any costs involved? 
 
 No, you will not be paid to take part in the study. There will be no costs involved for 
you, if you do take part. 
 
Would you like to know the results of your blood tests? 
 Please indicate by marking the correct box with an X 
           YES 
                       NO 
 
Is there anything else that you should know or do? 
 You can contact Dr Theo Nell on 021-808 3147 if you have any further queries or 
encounter any problems. 
 You can contact the Health Research Ethics Committee at 021-938 9207 if you 
have any concerns or complaints that have not been adequately addressed by your 
study doctor. 
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Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a research study 
entitled (Cancer risk during urbanization: metabolic syndrome and cancer). 
I declare that: 
 I have read or had read to me this information and consent form and it is written in a language 
with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately answered. 
 I understand that taking part in this study is voluntary and I have not been pressurised to take 
part. 
 I may choose to leave the study at any time and will not be penalised or prejudiced in any way. 
 I may be asked to leave the study before it has finished, if the study doctor or researcher feels it is 
in my best interests, or if I do not follow the study plan, as agreed to. 
 
Signed at (place) ......................…........…………….. On (date) …………....……….. 2015. 
 ...................................................................  ................................................................. 
Signature of participant Signature of witness 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 I explained the information in this document to ………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understands all aspects of the research, as discussed above 
 I did/did not use an interpreter.  (If an interpreter is used then the interpreter must sign the 
declaration below. 
Signed at (place) ......................…........…………….. On (date) …………....……….. 2015. 
 ...................................................................  ................................................................. 
Signature of investigator  Signature of witness 
 
Id Code: ___________________ 




Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
 I assisted the investigator (name) ………………………………………. to explain the 
information in this document to (name of participant) 
……………..…………………………….. Using the language medium of 
Afrikaans/Xhosa/Zulu/English. 
 We encouraged him/her to ask questions and took adequate time to answer them. 
 I conveyed a factually correct version of what was related to me. 
I am satisfied that the participant fully understands the content of this informed consent document and 
has had all his/her question satisfactorily answered. 
Signed at (place) ......................…........…………….. On (date) …………....……2015 
 
 ...................................................................  ................................................................. 











Id Code: ___________________ 











Next I am going to ask you about the time you spend doing different types of physical activity in a typical week. Please 
answer these questions even if you do not consider yourself to be a physically active person.  
Think first about the time you spend doing work.  Think of work as the things that you have to do such as paid or unpaid 
work, study/training, household chores, harvesting food/crops, fishing or hunting for food, seeking employment. [Insert 
other examples if needed].  In answering the following questions 'vigorous-intensity activities' are activities that require hard 
physical effort and cause large increases in breathing or heart rate, 'moderate-intensity activities' are activities that require 
moderate physical effort and cause small increases in breathing or heart rate. 
Questions Response Code 
Activity at work 
1 Does your work involve vigorous-intensity activity that 
causes large increases in breathing or heart rate like 
[carrying or lifting heavy loads, digging or construction 
work] for at least 10 minutes continuously?  
[INSERT EXAMPLES]  (USE SHOWCARD) 
Yes 1 
P1 
No 2     If No, go to P 4 
2 In a typical week, on how many days do you do 
vigorous-intensity activities as part of your work? Number of days └─┘ 
P2 
3 How much time do you spend doing vigorous-intensity 
activities at work on a typical day? 
Hours : minutes 
└─┴─┘: └─┴─┘ 
    hrs                mins 
P3  
(a-b) 
4 Does your work involve moderate-intensity activity that 
causes small increases in breathing or heart rate such as 
brisk walking [or carrying light loads] for at least 10 
minutes continuously?  
[INSERT EXAMPLES]   (USE SHOWCARD) 
Yes  1 
NO 2 
If No, go to P 7 
 
 P4 
 5 In a typical week, on how many days do you do 
moderate-intensity activities as part of your work? 
Number of days 
└─┘ P5 
 
Id Code: ___________________ 
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6 How much time do you spend doing moderate-intensity 
activities at work on a typical day? 
Hours : minutes 
└─┴─┘: └─┴─┘ 
    hrs                mins 
P6 
Travel to and from places 
The next questions exclude the physical activities at work that you have already mentioned. 
Now I would like to ask you about the usual way you travel to and from places.  For example to work, for shopping, to 
market, to place of worship. [insert other examples if needed] 
7 Do you walk or use a bicycle (pedal cycle) for at least 
10 minutes continuously to get to and from places? 
Yes 1 P7 
 No 2      If No, go to P 10 
8 In a typical week, on how many days do you walk or 
bicycle for at least 10 minutes continuously to get to 
and from places? 
Number of days 
└─┘ 
P8 
9 How much time do you spend walking or bicycling 
for travel on a typical day? 
Hours : minutes 
└─┴─┘: └─┴─┘ 




The next questions exclude the work and transport activities that you have already mentioned. 
Now I would like to ask you about sports, fitness and recreational activities (leisure), [insert relevant terms]. 
10 Do you do any vigorous-intensity sports, fitness or 
recreational (leisure) activities that cause large 
increases in breathing or heart rate like [running or 
football,] for at least 10 minutes continuously?  
[INSERT EXAMPLES]   (USE SHOWCARD) 
Yes   1  
P10 
 
No 2      If No, go  to P 13 
11 In a typical week, on how many days do you do 
vigorous-intensity sports, fitness or recreational 
(leisure) activities? 
Number of days 
└─┘ 
P11 
12 How much time do you spend doing vigorous-
intensity sports, fitness or recreational activities on a 
typical day? Hours : minutes 
└─┴─┘: └─┴─┘ 
    hrs                mins 
P12 
(a-b) 




Physical Activity (recreational activities) contd. 
Questions Response Code 
13 Do you do any moderate-intensity sports, fitness or 
recreational (leisure) activities that cause a small 
increase in breathing or heart rate such as brisk 
walking, (cycling, swimming, and volleyball) for at 
least 10 minutes continuously? 
[INSERT EXAMPLES]   (USE SHOWCARD) 
Yes   1 
P13 
No 2      If No, go to P16 
14 In a typical week, on how many days do you do 
moderate-intensity sports, fitness or recreational 
(leisure) activities? 
Number of days 
└─┘ 
P14 
15 How much time do you spend doing moderate-
intensity sports, fitness or recreational (leisure) 
activities on a typical day? Hours : minutes 
└─┴─┘: └─┴─┘ 




The following question is about sitting or reclining at work, at home, getting to and from places, or with friends including time 
spent [sitting at a desk, sitting with friends, travelling in car, bus, train, reading, playing cards or watching television], but do 
not include time spent sleeping. 
[INSERT EXAMPLES]   (USE SHOWCARD) 
16 How much time do you usually spend sitting or 
reclining on a typical day? 
Hours : minutes 
└─┴─┘: 
└─┴─┘ 





Id Code: ___________________ 



















Previous smoker or drinker: 
Yes: No 
 
If yes, how many and for how long: 
How many: How long: 
 
  
Current smoker or drinker: 
Yes: No 
 
If yes, how many and for how long: 
How many: How long: 
 
 
Id Code: ___________________ 
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Anthropometrical measurement sheet 






Body Mass (kg) 
 
Blood Pressure (mmHg) 







Waist Circumference (cm) 
 





















Id Code: ____________________ 







Bioelectrical impedance analysis (BIA) protocol-full test 
Pre-test recommendations for participants 
 No moderate or vigorous physical activity 12 hours prior to test. 
 No consumption of food or beverages (fasted for at least 2 hours prior to test). 
 No alcohol intake (12 hours prior to test). 
 Void the bladder prior to test. 
 The participant should not be diaphoretic (covered with sweat) or soaked in urine as the 
analyser measures this fluid as fat-free mass. 
Pre-test instructions 
 Make sure analyser battery is well charged. 
 Setup of the BIA analyser at room temperature, calibrate the analyser and cables. 
 Log participant variables prior to test (weight, height, age, gender and ethnicity). 
 Firstly, show the participant the BIA analyser and clearly explain how the analyser works. 
 Next, explain where you will place the respective electrode, and instruct the participant to 
remove his/her right shoe and sock. If, for some reason, the procedure must be done on the 
left side, then make a note of it, and subsequently (next visits) always use the left side. 
 Ask participant to remove any jewellery/money/electronic devises. 
 
Test Instructions 
 Instruct participant to get on to exam table (the exam table should be comfortable and free of 
drafts and electrical source heaters) and lay quietly with minimal movement during the test. 
 Have the participant lie on his/her back, arms by his/her sides and arms and thighs not 
touching. 




 Attach the electrodes as follows: 
 Wrist: Place the electrode labelled 2 at the proximal of the wrist (pisiform prominence). Make 
sure the top of the electrode is toward the shoulder with the tab facing away from the body. 
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 Hand: Place the electrode labelled 1 at the dorsal surfaces of the hand (near metacarpal 
phalangeal joint). The tab should be facing away from the body. 
 Ankle: Place the electrode labelled 4 on the ankle between medial and lateral malleoli bones. 
Make sure that the top of the electrode is toward the thigh with tab facing away from the 
body. 
 Foot: Place the electrode labelled 3 at just behind the middle toes above the knuckles (near 
metatarsophalangeal joint). 
 Attach the leads to the electrodes. 
 Start test, auto save test and write down test number. 
 
Electrode positioning for BIA full test: Channel 1: Electrode 1, Channel 2: Electrode 2, Channel 3: Electrode 3, 















Human C reactive protein  (CRP) ELISA protocol 
General considerations 
Kit stored between 2-8 °C. 
Reagent Preparation 
All kit reagents and samples were thawed and allowed to equilibrate at room temperature (18-25 °C) 
prior to assay.  
All reagents were prepared according to kit specifications (Cat ab181416). 
Reagent  Preparation 
1x Wash Buffer PT Dilute 10x wash buffer with deionized water. 
50 ml 1x Wash Buffer PT = 5 ml 10x wash buffer + 45 ml deionized water. 
Mix gently. 
Antibody cocktail  Dilute the capture and detector antibodies in antibody diluent. 
3ml antibody cocktail = 300 μl 10x capture antibody + 300 μl 10x detector antibody + 2.4 




Prepare standards prior to use. A standard curve was constructed by an eight-serial two-fold dilution 
series using the CRP human lyophilized recombinant protein supplied. 
1. Make up the 200 pg/ml stock standard solution. Reconstitute the CRP human protein sample 
by adding 200 μl of water and mix (room temperature for 5 minutes and mix again).  
2. Label 8 separate tubes from standard 1-8 and add 150 μl of the sample diluent in each tube. 
3.  Make standards up according to figure and table below.  
4. Standard 8 is blank (no protein). 


















1 Stock 150 150 2.000 1000 
2 Standard 1 150 150 1.000 500 
3 Standard 2 150 150 500 250 
4 Standard 3 150 150 250 125 
5 Standard 4 150 150 125 62.5 
6 Standard 5 150 150 62.5 31.25 
7 Standard 6 150 150 31.25 15.62 
8 (Blank) None 0 150 0 0 
 
Sample Preparation 
 Human serum sample dynamic dilution range: 8 000-512 000x, according to kit 
specifications. 
 Relevant literature was consulted to estimate the serum sample range for sample population. 
 Serum sample dilutions for this current study were 25 000x (see table below). 
 First, dilute serum samples with 1x wash buffer and then perform final dilution with sample 
diluent. 
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Volume of 1x 








1 Serum 10 240 0 neat 1:25 
2 Tube 1 10 390 0 1:25 1:1000 
3 Tube 2 10 0 240 1:1000 1:25 000 
 
Microplate preparation 
 Remove covering strip and add amount of plate strips needed for the assay. 
 Work out the plate layout i.e. standards, blanks, positive controls and samples (prior to assay). 
 
Assay procedure 
 Prepare all reagents, standards, samples and microplate according to kit specifications. 
 Add 50 µl of serum sample/control/standards in duplicate, followed by 50 µl of antibody 
cocktail to the assigned wells.  
 Seal the micro-titre plate and incubate at room temperature for 60 minutes on a plate shaker at 
400 rpm, followed by a wash step with wash buffer (three times 250 µl per well)  using a 
plate washer. 
 Invert the plate on tissue paper to remove all excess liquid.  
 Add 100 µl of TMB substrate to all wells, followed by a second incubation step, in the dark 
on a plate shaker at 400 rpm.  
 Add 100 µl of stop solution and incubate again for one minute on a plate shaker at 400 rpm.  
 The optical densities of the individual wells must be measured at 450 nm on an EL800 
universal microplate reader (BIO-Tek instruments, INC.) within 15 minutes after the reaction 
was stopped.  
 Analyse data 
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 The optical density is directly proportional to the CRP protein concentration of the participant 
sample. The concentration of all the participant samples was calculated by the formula 
produced by the standard curve. 



























Human insulin-like growth factor-1 (IGF-1) ELISA protocol 
General considerations 
Kit stored at -20 °C. 
Reagent Preparation 
All kit reagents and samples were thawed and allowed to equilibrate at to room temperature (18-25 
°C) prior to assay.  
All reagents were prepared according to kit specifications (Cat ab100545). 
Reagent  Preparation 
1x wash solution If the 20x wash concentrate contains crystals, thaw to room temperature and mix gently. 
400 ml of 1x wash solution= Dilute 20 ml 20x wash buffer concentrate with deionized/ 




Briefly spin down 1x biotinylated IGF-1 detection antibody vial before use. 
Add 100 μl of 1x assay diluent C into the vial to prepare a detection antibody concentrate 
(mix gently via pipetting). 
The detection antibody concentrate must be diluted 80x with 1x assay diluent prior to assay 
procedure. 




Briefly spin down 120x HRP-Streptavidin concentrate vial and pipette up n down to mix 
before use. 
HRP-Streptavidin concentrate must be diluted 120x with 1x assay diluent C prior to use. 
1x HRP-Streptavidin solution =Add 100 μl of 120x HRP-Streptavidin concentrate into + 12 








 Prepare standards prior to use.  
 Keep standard dilutions on ice while preparing. 
 Do not vortex the standards as it will destabilize the protein. 
A standard curve was constructed by a seven-serial two-fold dilution series, using IGF-1 human 
recombinant protein supplied by the kit. 
1. Spin down vial very briefly before preparing standards. Make sure powder is resolved when 
making standards. 
2. Make up the 100 ng/ml stock standard solution by adding 400 μl of 1x assay diluent C into the vial. 
3. Make sure powder is resolved when making standards, by gently inverting and flicking the tube 
several times and flick the tube a few times. Spin down. Repeat this 3-4 times. 
4. Label 6 separate tubes 1-6 and add 150 μl of the 100 ng/ml Stock standard solution to 350 μl of 
assay diluent in tube 1. Mix gently. 
5. Add 300 μl of assay diluent C into remaining tubes. 
6. Prepare standard 2 by adding 200 μl from tube 1 to tube 2 and mix. 
7. Prepare standard 3 by adding 200 μl from tube 2 to tube 3 and mix. 




















1 150 350 500 100 30 
2 200 300 500 30 12 
3 200 300 500 12 4.8 
4 200 300 500 4.8 1.92 
5 200 300 500 1.92 0.768 
6 200 300 500 0.768 0.307 
7 200 300 500 0.307 0.123 
8 (Blank) 0 300 300 0 0 
 
Sample Preparation 
 Serum samples should be diluted with 1x assay diluent. 
 Human serum sample dynamic dilution range: 2-20x according to the kit. 
 Relevant literature was consulted to estimate the serum sample range for the sample 
population. 
 Serum samples dilution for this current study was 20x: 100 μl of serum sample per well 
needed, thus 200 μl as samples are tested in duplicate.  
 Final sample volume is 250 μl in case of spills/pipetting errors. Thus, 12.5 μl sample plus 
237.5 μl sample diluent should be used for each sample dilution. 
 
Microplate Preparation 
 Work out the plate layout, i.e. standards, blanks, positive controls and samples (prior to 
assay). 
 Remove covering strip and add amount of plate strips needed for the assay. 





 Prepare all reagents, standards, samples and microplate are prepared to kit specifications. 
 Add 100 µl of each standard, serum sample or control (in duplicate) into the assigned wells, 
cover wells and incubate for 2.5 hours at room temperature with gentle shaking. 
 Discard solution and wash 4x with 1x wash buffer solution (300 μl).   
 Next invert the plate on tissue paper to remove all excess liquid.  
 Add 100 µl of 1x biotinylated IGF-1 detection antibody into the assigned wells. Incubate for 
60 minutes at room temperature with gentle shaking. 
 Discard solution and wash 4x with 1x wash buffer solution (300 μl).   
 Next invert the plate on tissue paper to remove all excess liquid.  
 Add 100 µl 1x HRP-Streptavidin solution to all wells, followed by an incubation step of 45 
minutes at room temperature with gentle shaking.  
 Discard solution and wash 4x with 1x wash buffer solution (300 μl).   
 Invert the plate on tissue paper to remove all excess liquid.  
 Add 100 µl of TMB one step substrate to each well and incubate for 30 minutes at room 
temperature in the dark with gentle shaking. 
 Add 50 μl stop solution to each well. 
 The optical densities of the individual wells must be measured at 450 nm on an EL800 
universal microplate reader (BIO-Tek instruments, INC. Weltevreden Park, South Africa) 
within 15 minutes after the reaction was stopped. 
 Analyse data 
 
 







Additional correlations for selected biochemical and anthropometric parameters   
Correlations 
Parameters 
ABSI & TG ABSI & LDL-c 
Fasting insulin & FM 
% 
r p r p r p 
MetSG -0.045 0.87 0.31 0.24 -0.38 0.08 
NMetSG 0.58 0.14 0.78 0.02 -0.29 0.19 
MetSA 0.55 0.02 0.32 0.18 -0.46 0.03 
























Lifestyle related risk factors results 
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